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Abstract 
Activation of the PI3K/AKT pathway protects the heart from ischaemia-reperfusion injury. 
Phosphatase and Tensin Homolog deleted on Chromosome10 (PTEN) is a negative regulator 
of this pathway. The hypothesis on which this thesis was based stated that inhibition of PTEN 
would confer protection against ischaemia-reperfusion injury. PTEN was reduced using: 1) a 
PTEN inhibitor, bpV(HOpic), 2) a mouse model of PTEN haploinsufficiency and 3) PTEN 
siRNA. The effects of PTEN reduction on ischaemia-reperfusion injury were investigated by 
using: 1) an isolated perfused heart model of ischaemia-reperfusion injury, 2) an isolated 
cardiomyocyte model of ROS induced mitochondria damage and 3) a cellular model of 
hypoxia-reoxygenation injury. No protection against ischaemia-reperfusion was observed in 
isolated perfused myocardium from C57BL/J6 mice, which were perfused with bpV(HOpic), or 
from PTEN
+/-mice. Likewise, no protection against ROS induced mitochondrial damage was 
observed in isolated cardiomyocytes from the PTEN
+/- mice. In these models an increase in 
AKT activity was recorded, however, this was not sufficient to confer cardioprotection. 
Similarly, H9c2 rat myoblast cells, silenced for PTEN expression using siRNA, were not 
protected against hypoxia-reoxygenation injury. Nevertheless, in isolated C57BL/J6 hearts 
perfused with bpV(HOpic) and in myocardium from PTEN
+/- mice, when the PI3K/AKT 
pathway was stimulated by the cardioprotective intervention of ischaemic preconditioning a 
reduced threshold for protection was achieved. To conclude, the level of PTEN inhibition 
achieved in this study was not sufficient to bestow protection against simulated ischaemia-
reperfusion injury. However, it appears that reductions in PTEN can increase the sensitivity 
towards cardioprotection.  Hilary Siddall 
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subjected to ischaemia reperfusion (I/R) control (perfused without 
ischaemia). 
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1  Chapter 1 – General Introduction 
1.1 Cardiovascular  disease 
In 2004 the World Health Organization (WHO) updated a study investigating the global 
burden of disease. It states that cardiovascular disease (CVD) is the leading cause of 
mortality worldwide. Astonishingly, 12% of all deaths can be attributed to ischaemic heart 
disease. Moreover, these figures are estimated to increase by 2015 
i(WHO). In addition to 
fatalities, possibly the most shocking information relates to heart disease as the leading 
cause of global burden. Therefore, medical and financial costs associated with CVD are also 
predicted to increase. Quality of life can be dramatically reduced, thus having a substantial 
impact on patient lifestyle (Allender et al., 2007) 
i(WHO).  
 
The number of known risk factors associated with the development of CVD are ever 
increasing and currently include: hypertension, hypercholesterolemia, increased low density 
lipoprotein (LDL), decreased high density lipoproteins (HDL), obesity, diabetes mellitus, 
smoking and physical inactivity (Smith and Kampine, 1990; Fuller et al., 2001; Allender et al., 
2007)
i(WHO). To limit the prevalence of CVD and these risk factors, personal accountability 
and prevention must be promoted. Furthermore, hereditary factors influence the development 
of CVD (Marion et al., 2002; Ishihara et al., 2003; Ferdinandy et al., 2007), some of which will 
be highlighted in the following chapters. Nonetheless, clinicians and scientists alike are 
striving to reduce this disease burden, in order to increase the quality of life and ultimately, to 
reduce the mortality subsequent to CVD.  
 
                                                 
i The world health organization. The global burden of disease. 2004 update. Geneva, World 
health organization, 2008 accessed on 24.11.2008 
http://www.who.int/healthinfo/global_burden_disease/2004_report_update 
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1.2 Myocardial  infarction 
Severe abrogation of blood supply (ischaemia) to a region of the heart can cause cell death, 
which is known as myocardial infarction (MI). This is detrimental and can induce tissue 
damage and consequentially the initiation of ischaemic heart disease (Smith and Kampine, 
1990). Periods of reduced blood supply to the heart can result in an energy demand that 
outweighs supply; thereby effecting function. Clinicians often observed this condition in 
patients who develop angina, which can be caused by the narrowing or obstruction of 
coronary arteries due to debris, such as a thrombus and/or atherosclerotic plaque formation, 
as illustrated in Figure 1.1. Ultimately, this ischaemic period initiates the process of tissue 
damage that is associated with MI. Reperfusion of the ischaemic area is required to prevent 
further tissue damage however, paradoxically, the act of reperfusing the ischaemic area can 
itself induce additional damage and can affect cardiac function thereafter (Smith and 
Kampine, 1990; Argaud et al., 2005a; Hausenloy et al., 2005; Ferdinandy et al., 2007). This 
damage is referred to as ischaemia-reperfusion or reperfusion-induced injury.  
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Figure 1.1:  The effects of myocardial infarction and the consequence of ischaemia-
reperfusion injury, on the myocardium and coronary system.   
Top =  http://images.medicinenet.com/images/illustrations/heart_attack.jpg, 
Bottom left    =  http://www.pbs.org/wgbh/nova/heart/troubled.html 
Bottom right = http://www.opt.indiana.edu/v543/labs/images/myo_infar1.jpg Hilary Siddall 
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Ischaemia-reperfusion injury can trigger cardiac stunning, arrhythmias, endothelial 
dysfunction and cell death (Smith and Kampine, 1990; Maddock et al., 2002; Ferdinandy et 
al., 2007). Further to promoting changes in life style, therapies for MI aim to decrease cardiac 
work load and minimise ischaemia-reperfusion injury. Current best practice for the treatment 
of patients suffering with a MI is to restore blood flow using thrombolytic therapy or to use 
surgical interventions, such as balloon catheter angioplasty or coronary artery bypass surgery 
(Smith and Kampine, 1990; Dauterman and Topol, 2002). While these interventions have 
proven successful, some are invasive and may result in further tissue damage and 
reoccurrence of MI later in life. Therefore, alternative strategies to enhance tissue viability 
post MI are required to help address this unmet clinical need (Dauterman and Topol, 2002; 
Ferdinandy et al., 2007). Much research is directed at investigating the cellular pathways 
involved in ischaemia-reperfusion injury and the cell death resulting in the formation of 
infarcted tissue. The period of ischaemia and the reperfusion of an ischaemic area, together, 
contribute to cell death and to the severity of myocardial injury (Headrick et al., 2001). 
 
1.2.1 Ischaemic  injury 
The myocardium is highly dependent on mitochondrial oxidative phosphorylation, also known 
as aerobic metabolism, for the production of ATP. With the onset of anoxia this form of 
metabolism cannot be sustained (Murry et al., 1986; Smith and Kampine, 1990; Ferdinandy 
et al., 2007). The remaining stores of ATP can only supply a few minutes of ventricular 
function. Consequentially, a switch to anaerobic glycolysis follows and lactate accumulates in 
the cardiomyocytes, resulting in low pH and acidic conditions (Smith and Kampine, 1990; 
Halestrap et al., 2004). 
 
The low pH alters metabolic signalling further; and also activates the sodium/hydrogen 
(Na
+/H
+) ion pump which acts to restore normal pH. Sodium (Na
+) accumulates in the cell Hilary Siddall 
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because the Na
+/K
+ ATPase is inactive, due to the lack of ATP, and thus Na
+ is no longer 
pumped out of the cell.  Additionally, the Na
+/Ca
2+ exchanger ceases to function normally and 
fails to pump calcium out of the cell. This is due to the high intracellular Na
2+ levels which 
causes the exchanger to switch into a reverse exchange mode, permitting the entry of 
calcium (Ca
2+) into the cell (Yellon and Baxter, 2000; Ferdinandy et al., 2007). Collectively, 
this overload of intracellular ions promotes swelling of the sarcoplasmic reticulum and the 
mitochondria (Halestrap et al., 2004). A proportion of cells become damaged, their 
membranes become permeable and as a result cellular enzymes are released. Lactate 
dehydrogenase (LDH) and creatine kinase (CK) are examples of such enzymes, they are 
predominantly cytoplasmic and their releases can be used as an indicator of necrotic cell 
death (van Nieuwenhoven et al., 1996). This type of cell death is described in section 1.3. 
Once such a chain of events occurs, signals for cell death in the affected area and the 
initiation of ischaemic injury commence, as described below in more detail (Smith and 
Kampine, 1990). To salvage remaining viable tissue, it is imperative to reperfuse the 
ischaemic myocardium as quickly as possible. 
 
1.2.2 Reperfusion  injury 
Rapid reperfusion of the ischaemic area is required to limit tissue damage and is necessary 
to reoxygenate and salvage remaining viable tissue. Conversely, reperfusion itself can cause 
additional damage; this phenomenon is termed lethal reperfusion-induced injury (Hausenloy 
et al., 2005; Argaud et al., 2005a; Ferdinandy et al., 2007). Such damage promotes further 
cell death, which contributes to an increase in irreversible tissue damage in the reperfused 
myocardium.  
 
Reperfusion of the ischaemic myocardium causes an enhanced generation of reactive 
oxygenation species (ROS), which induces cellular damage. Within the mitochondria, under Hilary Siddall 
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normoxic conditions, oxidative phosphorylation occurs freely. At the inner mitochondrial 
membrane a number of redox-reduction reactions occur along the electron transport chain to 
produce ATP (Gao et al., 2008a). This form of respiration will result in the low level 
generation of ROS, such as superoxide (O2
-) and hydrogen peroxide (H2O2) (Gao et al., 
2008a). Nevertheless, the cell is equipped with antioxidants, such as superoxide dismutase, 
glutathione peroxidase and catalase which can quickly convert the free radicals into H20 
(Becker, 2004; Zhao, 2004). However, during ischaemia these antioxidants cease to function 
due to restrictions in the levels of ATP and the level of free radicals intensifies. At reperfusion, 
the abrupt increase of oxygen in the ischaemic and acidic myocardium favours the production 
of the highly reactive, hydroperoxyl radical (
.HO2). Such elevated levels of ROS generation 
causes oxidative stress and induces severe cellular damage to lipids, proteins, 
deoxyribonucleic acid (DNA) and can cause apoptosis (Becker, 2004; Zhao, 2004). 
Moreover, reperfusion promotes a sudden increase in ATP synthesis which restores the level 
of ATP and reactivates the ion pumps, permitting further influxes of Na
+ and Ca
2+ into the cell. 
When mitochondria are overloaded with Ca
2+ ions the non specific mitochondrial permeability 
transition pore (mPTP) is thought to open, causing organelle disruption (Argaud et al., 2004). 
Consequently, further changes occur to the mitochondria, such as additional swelling, 
membrane instability and release of cytochrome c from the intramembrane space which 
contributes to mitochondrial membrane depolarisation. This makes the organelle unstable 
and initiates signalling for cell death (Halestrap et al., 2004), which are highlighted below. 
 
1.3  Cell death and myocardial ischaemia-reperfusion injury 
There are two well-defined mechanisms of cell death, known as apoptosis and necrosis, 
which are distinct from each other and are compared in Table 1.1. Intermediate forms can 
exist, bearing a mixture of features from each one (Kajstura et al., 1996; Crompton, 1999). 
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Table 1.1: Markers of necrosis and apoptosis induced cell death (Kajstura et al., 1996; 
Crompton, 1999). Adenosine triphosphate = ATP. 
 
Necrosis Apoptosis 
No ATP required.  ATP dependent. 
Influx of water, causing mitochondrial 
and cell swelling. 
Efflux of water, causing dehydration and 
cell shrinkage. 
Small nuclear structural changes.  Nuclear  break  down,  condensation  and 
fragmentation. 
Membrane rupture.  Membrane integrity maintained. 
Non functioning organelles released.  Formation of apoptotic bodies containing 
functional organelles. 
1.3.1 Necrosis 
Membrane disintegration causes the absorption of water, membrane rupture, release and 
destruction of cellular organelles. Subsequently, this attracts inflammatory cells to the area of 
necrosis which initiates inflammation and  further damage to surrounding tissue (Kajstura et 
al., 1996; Crompton, 1999). For example, in canine hearts, neutrophil accumulation occurs 
following ischaemia-reperfusion injury, which can be detected by the presence of 
myeloperoxidase activity (Corvera et al., 2003). Necrosis does not require energy and 
because of this it has been proposed that necrosis is the predominant type of cell death 
occurring during ischaemia, and that apoptosis occurs mainly during reperfusion when the 
energy supply is restored (Kajstura et al., 1996; Jeremias et al., 2000; Hamacher-Brady et al., 
2006b). This makes apoptosis a key research area in investigating novel therapies post 
ischaemia-reperfusion.  
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1.3.2 Apoptosis 
In contrast to necrosis, apoptosis is considered a mechanism of programmed cell death, for 
which energy is required. Cells undergoing apoptosis release water, shrink and undergo 
changes to membrane integrity. Thereafter, apoptotic bodies and membrane blebs form 
which engulf and preserve functional organelles. As described below, in section 1.3.4 other 
cells and mechanisms can preserve cellular organelles. In addition apoptosis can be 
identified by the presence of DNA condensation, fragmentation and breakdown of the nucleus 
(Kajstura et al., 1996; Crompton, 1999; Arbustini et al., 2008). 
 
The main effectors of apoptosis are a group of enzymes called caspases; which are cysteine 
containing proteases that specifically cleave proteins after aspartate residues. They are 
synthesised in a dormant prozymogen formation, but once stimulated, mature active 
fragments are generated (Nicholson et al., 1995). Importantly, a basal level of apoptosis is 
required for tissue development and cellular homeostasis (Kerr et al., 1972; Danial and 
Korsmeyer, 2004). However, enhanced apoptosis is observed in ischaemia-reperfusion injury 
and during cardiac remodelling (Hamacher-Brady et al., 2006b; Arbustini et al., 2008). 
Apoptotic cell death was first identified by Kerr, Wyllie and Currie early in the 1970s and can 
be initiated by two main mechanisms which are referred to as extrinsic and intrinsic pathways 
of cell death (Kerr et al., 1972; Wyllie et al., 1980). 
 
1.3.2.1   Extrinsic cell death pathways 
The extrinsic cell death pathway is activated by ‘death receptor’ ligands such as tumour 
necrosis factor alpha (TNFα) and Fas ligand (FasL), which bind to specific death receptors 
(Jeremias et al., 2000; Lee et al., 2003). Down stream stimulation of such receptors results in 
a number of proteolytic cleavages which activate initiator caspases, such as caspase 8 and 
10 (Kothakota et al., 1997; Li et al., 1998; Luo et al., 1998). The initiator caspases 8 and 10 Hilary Siddall 
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activate the executioner caspase 3. Caspase inhibition using z-VAD-fmk can prevent TNFα 
induced apoptosis (Li et al., 1998; Luo et al., 1998).  
 
TNFα and FasL- stimulated apoptosis can induce cleavage of structural proteins such as 
gelsolin, which can affect the actin cytoskeleton. This has been attributed to functional 
caspase 3, which also necessitates cleavage for function (Kothakota et al., 1997). The 
release of an active caspase 3 fragment can cleave Poly(ADP-ribose) polymerase (PARP); 
this cleavage prevents DNA repair and increases the level of apoptosis (Kothakota et al., 
1997). Following an apoptotic stimuli, the cleavage of PARP prevents DNA repair, which can 
be recorded by measuring DNA fragmentation (Nicholson et al., 1995; Li et al., 1997b; 
Communal et al., 2002). The incubation of purified myocyte microfilament proteins with 
caspase 3 can induce cleavage of structural proteins such as alpha actin and troponin c, and 
also of PARP. Over expression of the Fas receptor or addition of FasL to neonatal 
cardiomyocytes causes cell shrinkage and nuclear condensation, ultimately leading to 
apoptosis. This phenomenon can be assessed by positive staining for 4,6,diamidino-2-
phenylindole (DAPI), a nuclear morphology stain and terminal deoxynucleotidyl transferase 
dUTP nick end labelling (Tunel), a DNA cleavage marker (Jeremias et al., 2000; Lee et al., 
2003). Furthermore, compared to control hearts, mouse myocardium lacking functional Fas 
receptors showed a reduction in Tunel staining and a reduction in infarct size, following 
ischaemia-reperfusion (Lee et al., 2003). However, this observation is not unanimous (Tekin 
et al., 2006), highlighting the discrepancy in this area of study. 
 
1.3.2.2   Intrinsic cell death pathways 
Activation of intrinsic cell death pathways is usually independent of death receptors. The 
process can be regulated directly at the mitochondrial level involving a balanced interaction of 
many pro death and pro survival factors. Such factors include the Bcl family of proteins, which Hilary Siddall 
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contain a BH3 domain and are classified as either pro apoptotic (BH3 interacting domain death 
agonist (BID), BIM, Bcl-2-associated x protein (BAX) and Bcl-2 associated death promotor 
(BAD)) or anti apoptotic (Bcl2,BclxL) (Luo et al., 1998; Li et al., 1998; Chen et al., 2001; 
Kuwana et al., 2002). Their level of activity can depend on interactions from another protein 
family member; for example, the cleaved form of the pro apoptotic factor BID can activate 
BAX resulting in the formation of channels in the mitochondria membrane. These pores 
facilitate the release of large mitochondrial proteins up to 1500 Daltons, including cytochrome 
c (Luo et al., 1998; Kuwana et al., 2002). These proteins are up regulated in ischaemia-
reperfusion injury. Subsequent to simulated ischaemia-reperfusion injury in the HL-1 
myocardial cell line the expression of BAX is increased, causing cell death (Hamacher-Brady 
et al., 2006a). Consequentially, BID/BAX interactions at the mitochondrial membrane level 
can initiate apoptosis (Kuwana et al., 2002). Counteracting these events are the Bcl2/BclxL 
proteins which are anti apoptotic; over expression of BclxL  protein at the mitochondrial 
membrane level can prevent BID/BAX induced apoptosis by sequestering these pro apoptotic 
proteins (Kuwana et al., 2002; Chipuk et al., 2004). The change in balance between pro 
survival and pro death proteins at the level of the mitochondria depends also on the type of 
apoptotic stimuli such as free radicals, UV light or DNA damage. UV light can induce the 
tumour suppressor, p53, which is involved in cell cycle arrest and apoptosis (Chipuk et al., 
2004; Wang et al., 2005). 
 
The tumour suppressor p53 plays a role in apoptosis. During renal ischaemia and reperfusion 
p53 expression is increased and this is associated with activation of p21 and BAX induced 
cell death (Kelly et al., 2003). The proteins p21 and p53 promote G1 cell cycle arrest, halting 
the progression of the cell cycle (Katayose et al., 1995; Kelly et al., 2003). In the heart p53, 
has a role in the damage induced by ischaemia-reperfusion injury. Its contribution to cell 
death can be both due to its promotor dependent and independent activity (Chipuk et al., 
2004; Kelly et al., 2003; Zhao et al., 2001). As stated above, p53 stimulates cell cycle arrest Hilary Siddall 
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by up regulating cell cycle factors such as p21. In addition p53 can activate the apoptotic 
proteins BAX and indirectly effect caspase activity (Kelly et al., 2003; Ashkenazi, 2002). 
Pifithrin alpha (PFTα), a p53 inhibitor, can inhibit the apoptosis associated with ischaemia-
reperfusion injury (Kelly et al., 2003). Induction of cell death in the presence of nuclear import 
inhibition demonstrates that p53 can directly activate BAX, changing membrane permeability 
independent of its p53 promoter activity (Chipuk et al., 2004). Myocardium from p53 
heterozygous knockout mice exhibit less apoptosis and have a higher survival rate post MI 
(Matsusaka et al., 2006). Collectively, this implicates p53-induced apoptosis to ischaemia-
reperfusion injury and indicates that a reduction in apoptotic factors, such as p53, can 
facilitate survival.   
  
Moreover, once the mitochondrial membrane integrity has been compromised, cytochrome c 
is released where it can interact with Apaf3 and procaspase 9 forming a pro apoptotic 
complex. Procaspase 9 is activated in this complex and acts as an initiator caspase of the 
intrinsic death pathway, which can cleave (therefore activate) procaspase 3 (Kothakota et al., 
1997; Li et al., 1997b).  
 
1.3.2.3   Crosstalk between extrinsic and intrinsic death pathways 
Irrespective of the apoptotic trigger, the down stream signalling factors can converge. For 
example the activation of caspase 8 can initiate cleavage of BID. The over expression of BID 
in HeLa cells can cause an increase in apoptosis stimulated by TNFα. Furthermore, the 
cleaved form of BID can translocate from the cytosol to the mitochondrial membrane. This 
has been associated with the loss of mitochondrial membrane potential, cytochrome c 
release and consequentially cell shrinkage and nuclear fragmentation (Li et al., 1998; Luo et 
al., 1998). In contrast, some BH3 containing Bcl2 related proteins such as the pro survival 
protein Bcl2, can prevent such apoptosis. This shows that although activation of the extrinsic Hilary Siddall 
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pathway does not directly act in the mitochondria; it can activate the mechanisms within the 
intrinsic pathway (Arbustini et al., 2008). As shown in Figure 1.2.  
 
Figure 1.2: Intrinsic and extrinsic mechanisms of apoptosis and the cross talk that can 
occur between these pathways (Ashkenazi, 2002) including apoptotic protease 
activating factor 3 (APAF-1), Bcl-2 – associated x protein (BAX), BH3 interacting domain 
death agonist (BID), BCL, Fas – associated protein with death domain (FADD), FLIP, 
inhibitor of apoptosis (IAP), Second mitochondria-derived activator of caspase/ Diablo 
homolog (SMAC/DIABLO). Hilary Siddall 
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1.3.3  The Mitochondria and cell death 
Mitochondria are pivotal generators of cellular energy. Structurally they consist of an inner 
and an outer membrane that envelops an inter-membrane space. The inner membrane forms 
many folds known as cristae, which protrude into the mitochondrial matrix. In addition to 
generating ATP, mitochondria play a crucial role in maintaining a balance between cell 
survival and death (Crompton, 1999; Duchen et al., 2008). 
 
During apoptosis the mitochondrial structure is altered and its contents are released which 
executes the signalling involved in cell death. As described above the release of cytochrome 
c occurs. In addition second mitochondria-derived activator of caspase/ Diablo homolog 
(Smac/DIABLO), an apoptotic mitochondrial protein, is released from the mitochondrial inner 
membrane space where it inactivates inhibitors of apoptosis (IAP) (Adrain et al., 2001; Du et 
al., 2000). Such inhibitors include XIAP (X-linked inhibitor of apoptosis), which is highly 
expressed in cardiomyocytes and functions to prevent the activation of caspases (Potts et al., 
2005; Hamacher-Brady et al., 2006b). Smac/DIABLO release amplifies the signal for cell 
death. Furthermore, apoptosis inducing factors (AIF) and endonucleases released from the 
mitochondria can locate at the level of the nucleus to promote chromatin condensation and 
DNA fragmentation (Hamacher-Brady et al., 2006a; Hamacher-Brady et al., 2006b).  
 
Table 1.2 highlights some of the contributing factors crucial to cell survival. Pro death and pro 
survival signals contribute to mitochondrial stability by altering mitochondrial permeability, 
release of cytochrome c and mitochondrial membrane depolarisation (Kajstura et al., 1996; 
Crompton, 1999). The change in mitochondrial permeability has been attributed to the 
formation and opening of a non specific mitochondrial permeability transition pore (mPTP); 
which is a central factor in the disruption of mitochondria homeostasis (Hunter and Haworth, 
1979; Crompton et al., 1987). 
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Table 1.2: Contributors to the cellular pro and anti apoptotic status (Kajstura et al., 
1996; Crompton, 1999; Davidson et al., 2006). Bcl-2 associated death promoter (BAD), 
Bcl-2 associated x protein (BAX), BH3 interacting domain death agonist (BID), BCl2 like 
11 (BIM), mitochondrial permeability transition pore (mPTP) and p53 upregulated 
modulator of apoptosis (PUMA). 
Pro apoptosis  Anti apoptosis 
Pro death Bcl family proteins BID, BAD, 
BAX, BIM, PUMA 
Bcl pro survival protein; sequestered Pro 
death factors 
Caspase activation  Caspase inactivation 
Opening of mPTP and release of 
cytochrome c 
Delay to opening of mPTP and 
prevention of the release of cytochrome c
Presence and/or activation of detrimental 
pathways transcription factors p53, p21 
Prevention of nuclear condensation and 
DNA fragmentation.   
 
Opening of the mPTP is involved in cell death. Once the pore is formed the mitochondria are 
permeable to molecules up to 1500 Daltons. Solutes and water enter causing the organelle to 
swell, initiating damage (Hunter and Haworth, 1979; Crompton et al., 1987; Halestrap et al., 
1997; Hamacher-Brady et al., 2006b). Mitochondrial cristae projections unfold and, to an 
extent, can withstand some changes to the inner membrane. However, the outer membrane 
cannot adapt to such changes and quickly ruptures (Halestrap et al., 2004). Furthermore, the 
inner membrane becomes damaged, and oxidative phosphorylation becomes uncoupled. 
Consequentially, the normal activity of the mitochondria ceases; ATP is no longer produced 
and instead, becomes exhausted (Halestrap et al., 2004; Hamacher-Brady et al., 2006b).  
 
The structure of the mPTP 
The precise structure and mechanism of mPTP transition has not been completely elucidated 
(Halestrap, 2009). Previously, it was proposed that two adjacent adenine nucleotide 
translocase (ANT) proteins spanned the mitochondrial membrane and in the presence of ATP Hilary Siddall 
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and ADP they were capable of maintaining an impermeable barrier (Halestrap et al., 1997). It 
has also been suggested that a voltage dependent anion channel (VDAC), a mitochondrial 
outer membrane protein, is involved (Halestrap et al., 2004). Since these suggestions, the 
production of knockout models have demonstrated that these components are not essential 
for the formation of the mPTP (Kokoszka et al., 2004; Krauskopf et al., 2006; Baines et al., 
2007). However, the role of ANT is still debated, which may have a regulatory role in mPTP 
formation (Woodfield et al., 1998; Halestrap, 2009).  
 
Knockout models have implicated cyclophilin D, an inner membrane mitochondrial protein, in 
the formation of the mPTP (Woodfield et al., 1998; Baines et al., 2005). Interestingly, studies 
have indicated that cyclophilin D can bind to ANT proteins, which can change protein 
conformation to create a membrane channel (Woodfield et al., 1998). The binding of 
cyclophilin D is thought to be calcium dependent, however, exceptionally high levels of 
calcium open the pore independent of cyclophilin D (Halestrap et al., 1997). In addition, 
members of the Bcl2 family have been associated with the regulation of the mPTP (Halestrap 
et al., 2004). More recently, it has been proposed by Leung et al., 2008 that the mitochondrial 
phosphate carrier may be involved in the formation of the mPTP, where it can bind to 
cyclophilin D and ANT to promote pore opening (Leung et al., 2008; Halestrap, 2009). 
 
Opening of the mPTP 
The mPTP opening is enhanced by oxidative stress, Ca
2+ overload in the mitochondrial 
matrix, adenosine nucleotide reduction, increased phosphate and increased pH (Halestrap et 
al., 1997; Halestrap et al., 2004; Kim et al., 2006a). Atractyloside, which opens the mPTP 
causes the release of cytochrome c and induces cell death (Gao et al., 2006; Wang et al., 
2007a). 
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Pore opening is inhibited by binding of ATP, this has been associated with magnesium, low 
pH and adenine nucleotides (Halestrap et al., 1997). Pharmacological agents such as the 
immunosuppressant cyclosporine A (CsA) and sangliferin A can inhibit pore opening by 
preventing cyclophilin D binding to ANT (Halestrap et al., 1997; Woodfield et al., 1998). 
Additionally, the increase in mPTP opening and cell death associated with calcium overload 
can be prevented  by cyclosporine A (CsA) (Argaud et al., 2005a; Baines et al., 2005; Wang 
et al., 2007a). 
 
Myocardial cell death has been associated with opening of the mPTP, for example CsA and 
sangliferin A can prevent myocardial LDH release following ischaemia-reperfusion injury 
(Clarke et al., 2002; Halestrap et al., 2004). During ischaemic conditions the mPTP remains 
closed, however, the conditions following reperfusion favour mPTP opening (Clarke et al., 
2002; Halestrap et al., 2004). Inhibition of the mPTP opening subsequent to ischaemia-
reperfusion injury has a role in myocardial protection (Clarke et al., 2002; Argaud et al., 
2005a). In isolated rat hearts subjected to ischaemia-reperfusion, inhibition of the mPTP 
opening with CsA at reperfusion, conferred protection (Argaud et al., 2005a). Investigating 
mechanisms that prevent mPTP opening may lead to the development of drugs that can 
prevent cell death and ischaemia-reperfusion injury.   
 
1.3.4 Autophagy 
Recently, another form of cell death (autophagy) has been described. Similar to apoptosis, 
this pathway is associated with programmed cell death, however, it produces energy instead 
of utilising it (Hamacher-Brady et al., 2006b; Gurusamy et al., 2009). 
 
Broadly speaking, autophagy is executed when non-specific cytosolic proteins or organelles 
are engulfed in a membrane envelope. This forms an autophagosome which can fuse with Hilary Siddall 
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cellular lysosomes to create an autophagolysosome (Hamacher-Brady et al., 2007). The 
contents within this complex can be degraded by lysosmal hydrolases and in the process can 
produce ATP (Hamacher-Brady et al., 2006b; Hamacher-Brady et al., 2006a; Gurusamy et 
al., 2009). Cells subjected to stress, such as ischaemia and reperfusion, respond by 
increasing the number of autophagosomes, which, when it occurs to a limited degree, is 
thought to be a pro survival response (Gurusamy et al., 2009; Yitzhaki et al., 2009). In the 
HL-1 myocardial cell line, for example, over expression of Beclin1 (a component of the 
autophagesome) causes an increase in the volume and number of autophagosomes 
following simulated ischaemia-reperfusion. The authors of this work linked this to a reduction 
in the activation of BAX, conferring protection against ischaemia-reperfusion injury 
(Hamacher-Brady et al., 2006a). 
 
The mechanisms of cell death are diverse and include necrosis, apoptosis and autophagy 
(Lemasters et al., 1998). The role and the importance of each of these processes in 
ischaemia-reperfusion injury are still debated. There are suggestion that apoptosis, which 
requires energy, may not occur during ischaemia. Consequentially, it has been postulated 
that in ischaemia-reperfusion injury apoptosis predominantly occurs during reperfusion, when 
ATP has been restored (Kajstura et al., 1996; Jeremias et al., 2000; Toth et al., 2006). In 
contrast it has been proposed that apoptosis is not important in cardiomyocytes. For 
example, Taimor et al., 1999 preposed that isolated rat cardiomyocytes subjected to 18hr 
simulated hypoxia followed by 4hr reoxygenation undergo necrosis, however, this form of 
injury is not sufficient to cause apoptosis. In this study cells were considered necrotic if they 
fulfilled the criteria of 1) dual staining for annexinV and propidium iodide (PI), 2) LDH release 
and 3) non specific DNA degradation. Cells were considered apoptotic following the criteria of 
1) annexinV staining, 2) tunel staining and 3) DNA laddering. Importantly, the authors of this 
work were able to induced apoptosis in ischaemic cells by using an additional stress stimulus 
such as UV light or H202 (Taimor et al., 1999). Potts et al., 2005, showed that differentiated Hilary Siddall 
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cardiomyocytes are resistant to cytochrome c injections due to high levels of XIAP that 
prevent the activation of caspases (Potts et al., 2005).  Collectively, this highlights the 
controversy surrounding the contribution of apoptosis to ischaemia-reperfusion injury. 
Interestingly, there appears to be some cross talk between the signalling pathways involved 
in cell death (Li et al., 1998; Luo et al., 1998; Arbustini et al., 2008). It has been proposed that 
following ischaemia-reperfusion injury, necrosis and apoptosis occur and share a common 
end target to elicit cell death, by opening of the mPTP; the authors of this concept have 
termed such convergence of cell death as necrapoptosis (Kim et al., 2003). Nevertheless, 
whatever the form of cell death, strategies that focus on minimising such death may be 
important in reducing ischaemia-reperfusion injury. 
 
1.4 Cardioprotection 
The balance of pro survival and pro apoptotic cellular factors contributes to homeostasis. 
Therefore, survival from a cellular insult, such as ischaemia-reperfusion injury may be 
achieved by modulating these pathways in order to confer cardioprotection.  
  
1.4.1  Known survival pathways 
A network of cellular pathways contribute to cell growth and survival. Amongst these, the 
PI3K/AKT, ERK 1/2 , JAK/STAT, PKC, and p38 MAPK pathways are shown to promote 
survival in different models of myocardial ischaemia-reperfusion injury (Ping et al., 1999b; 
Ping et al., 1999a; Kuwahara et al., 2000; Gross et al., 2006). For example the cytokine, 
cardiotrophin-1 activates the PI3K/AKT pathway in ventricular cardiomyocytes and increases 
survival, which can be abolished in the presence of the PI3K/AKT inhibitor LY294008 
(Kuwahara et al., 2000). Furthermore, in isolated rat hearts subjected to ischaemia-
reperfusion, the presence of morphine conferred protection which has been attributed to an Hilary Siddall 
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increase in JAK/STAT3 phosphorylation and activation (Gross et al., 2006). Protection 
caused by the activation of this pathway can be abolished with the JAK/STAT inhibitor 
AG490, highlighting the role of STAT3 in survival (Gross et al., 2006). Additionally, inhibitors 
of p38 MAPK (SB203580), PKC (chelerythrine) and ERK1/2 (PD98059) used in models of 
survival can abolish cardioprotection (Mocanu et al., 2000; Hausenloy et al., 2004b). 
 
Conversely, other cellular pathways can promote cell death. Activation of angiotensin II type 1 
receptor, JNK, p53 and ROCK can be detrimental and can mediate ischaemia-reperfusion 
injury (Kelly et al., 2003; Ferrandi et al., 2004; Lange et al., 2007; Hamid et al., 2007). For 
example, phosphorylation and activation of the Rho kinase 1 (ROCK) substrate ezrin-radixin-
meosin (ERM) has been associated with myocardial ischaemia-reperfusion injury (Bao et al., 
2004; Hamid et al., 2007) and ROCK inhibitors, Fasudil and Y-27632 can protect against this 
injury (Bao et al., 2004; Hamid et al., 2007). Such inhibition in a mouse model of ischaemia-
reperfusion injury can decrease neutrophil accumulation and maintain the level of the pro 
survival factor Bcl2 (Bao et al., 2004). The PI3K inhibitor, wortmanin can abolish this 
protection, indicating that ROCK inhibits the PI3K/AKT pathway. Furthermore, in the 
presence of the nitric oxide synthase (NOS) inhibitor, nitro L-arginine methyl ester (L-NAME), 
the protective effects of ROCK inhibition were abolished (Hamid et al., 2007). This work 
indicates that the activity of NOS is important in cardioprotection and that ROCK is a 
reperfusion injury kinase which acts to down regulate PI3K/AKT and the down stream survival 
factor nitric oxide (NO) (Hamid et al., 2007). In addition, inhibitors of angiotensin receptor 
activation (ARB), JNK (AS601245) and p53 (pifithrin alpha) can confer cardioprotection 
against ischaemia-reperfusion injury (Mocanu and Yellon, 2003; Ferrandi et al., 2004; Liu et 
al., 2006; Lange et al., 2007).  
 
Reperfusion induced salvage kinase (RISK) pathway Hilary Siddall 
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The reperfusion injury salvage kinase (RISK) pathway encompasses PI3K/AKT and ERK 1/2 
signalling, and is considered an important signalling system involved in cardioprotection 
(Hausenloy and Yellon, 2004a). As shown in Figure 1.3 activation of either pathway can 
affect a number of the same substrates (Hausenloy and Yellon, 2004a; Hausenloy and 
Yellon, 2004b; Zhang et al., 2007). These two parallel pathways are not independent of each 
other; on the contrary there is a crosstalk between them. In isolated rat hearts perfusion with 
the PI3K inhibitor LY294008 can enhance phosphorylation and activation of ERK1/2. 
Similarly, perfusion with the ERK1/2 inhibitor PD98059 can enhance the phosphorylation and 
activation of AKT (Hausenloy et al., 2004b).  
 
Activation of the RISK pathway upon reperfusion of an ischaemic myocardium, can alter the 
balance of pro apoptotic and pro survival molecules, to promote cell survival. It is believed 
that protection is conferred down stream of the RISK pathway at the mitochondria and 
nuclear level. Survival is promoted when the activity of apoptotic proteins such as p53, 
caspases and members of the Bcl family, BIM, BAD, BAX are decreased (Gross and Gross, 
2006). In addition activation of RISK pathway activates pro survival factors such as AKT, 
murine double minute 2 (Mdm2), Bcl survival protein Bcl2/BclxL, endothelial nitric oxide 
synthase (eNOS), and 70 kDa ribosomal protein S6 kinase (p70S6K) to confer protection 
(Mocanu and Yellon, 2003; Hausenloy et al., 2004b; Gross and Gross, 2006). p70S6K 
activation plays a role in protein translation, cell cycle progression and has anti apoptotic 
effects (Jonassen et al., 2001; Jonassen et al., 2004). Inhibitors of these RISK associated 
survival factors can influence cardioprotection.  
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Figure 1.3: Reperfusion induced salvage kinase (RISK) pathway and the cell survival 
targets activated by PI3K/AKT and MEK/ERK. Red encodes pro apoptotic factors and 
green encodes pro survival factors (Hausenloy and Yellon, 2004b).  Including Bcl-2 
associated death promoter (BAD), BCl-2-associated x protein (BAX), endothelial nitric 
oxide synthase (eNOS), murine double minute 2 (MDM2), extra signal-regulated MAPK 
(MEK/ERK), 70 kDa ribosomal protein S6 kinase (p70S6K), Phosphatidylinositol 3 
kinase (PI3K). 
 
For example the p70S6K inhibitor, rapamycin abolished protection in the presence of RISK 
activation, suggesting that both PI3K/AKT and ERK1/2 can confer protection by activating 
70S6K (Hausenloy et al., 2004b). Perfusion of the NO donor SNAP, in isolated mouse hearts, 
conferred protection against ischaemia-reperfusion injury which additionally activates and 
opens mitochondrial KATP channels (Bell et al., 2003). The presence of the mitochondrial KATP Hilary Siddall 
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channel blocker, 5HD can prevent the cardioprotection associated with SNAP (Bell et al., 
2003; Hausenloy and Yellon, 2004a). 
 
Activation of the RISK pathway prior or subsequent to a lethal period of ischaemia promotes 
protection from ischaemia-reperfusion injury (Hausenloy et al., 2005). Cardioprotective 
agents such as bradykinin and insulin can activate the RISK pathway to promote 
cardioprotection (Jonassen et al., 2001; Bell and Yellon, 2003; Davidson et al., 2006). As 
described, the protective effects of the RISK pathway are attributed to many signalling 
molecules. However, research suggests that the end target of this pathway may be the mPTP 
(Hausenloy et al., 2004a; Davidson et al., 2006). Activation of the RISK pathway using 
insulin, delays the time to mPTP opening and has been coupled with protection. The PI3K 
inhibitor, LY294008 blocked this delay, highlighting the role of the RISK pathway and the 
inhibition of the mPTP, to the survival of cardiomyocytes (Davidson et al., 2006). Interestingly, 
the activation of the RISK pathway is associated with protection in other tissues, such as the 
brain, kidneys lung and liver (Kelly et al., 2003; Banga et al., 2005; Wu et al., 2006).  
 
1.4.1.1   PI3K/AKT pathway 
Phosphatidylinositol 3,4,5 phosphate kinase 
Phosphatidylinositol 3,4,5 phosphate kinase (PI3K) is a lipid kinase functioning down stream 
of G coupled protein receptors (GCPRs) and protein tyrosine/growth factor receptors 
(Stephens et al., 1993; Oudit et al., 2004). There are 3 classes of PI3K, known as class I,II 
and III (Kok et al., 2009). PI3K is important for cell growth, proliferation and survival. The 
majority of the research to date mainly focuses on type I, which in a heterodimeric enzyme 
and compromises an 110kDa catalytic domain and a 85kDa regulatory enzyme domain (Kok 
et al., 2009). Class 1A are classified according to the types of catalytic units and includes 
PI3Kα,β andδ and are coupled to protein tyrosine kinase/growth factor receptors. They are Hilary Siddall 
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thought to be involved in determining myocardial cell size. Class 1B includes catalytic unit γ 
(PI3Kγ), which is associated with GCPR and has a role in myocardial contractility (Stephens 
et al., 1993; Crackower et al., 2002; Hawkins and Stephens, 2007). In addition to the 
regulatory and a catalytic subunits PI3K class I contain a PH domain which localises the 
kinase to the membrane where it is active and has the capability to  phosphorylate 
phosphatidylinositol 4,5 phosphate (PIP2) (Hennessy et al., 2005; Hawkins and Stephens, 
2007). It is important to mention that the phosphorylation or dephosphorylation at different 
positions of the PIP2 inositol ring can influence cell signalling (Oudit et al., 2004).  
 
The product of PI3K is phosphatidylinositol 3,4,5 phosphate (PIP3) which acts as a lipid 
second messenger and is responsible for recruiting signalling kinases to the membrane 
(Kane and Weiss, 2003). PIP3 can attract and bind proteins containing PH domains. For 
example, PIP3 causes phosphoinositide-dependent kinase 1 (PDK1) phosphorylation and 
translocation to the membrane where in turn it is anchored, activated and can phosphorylate 
the pro survival protein AKT (Seo et al., 2005). Similarly, PDK2 can phosphorylate and 
activate AKT at the membrane level (Mao et al., 2008). Subsequently, phosphorylated AKT 
facilitates the activation of many additional pro survival factors, as described below.  
 
AKT 
The activation of the PI3K/AKT pathway results in the membrane recruitment of AKT which is 
central to controlling survival. AKT is a 57kDa ser/thr kinase. There are 3 isoforms including 
AKT1(α), AKT2(β) and AKT3(γ) (Sasaoka et al., 2004; Brognard et al., 2007). As shown in 
Figure 1.4, once AKT is phosphorylated, it becomes active influencing many factors that 
regulate growth, proliferation and survival (Vanhaesebroeck and Alessi, 2000). These include 
serum and glucocorticoid regulated kinase (SGK1) and p70S6K (Nakashima et al., 2000), 
p44/p42 mitogen activate protein kinase (p42/p44 MAPK), eNOS, Mdm2, IκB kinase (IKK), 
murine target of rapamycin / p70S6K (mTOR/p70S6K) (Kane and Weiss, 2003; Ijuin and Hilary Siddall 
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Takenawa, 2003; Jonassen et al., 2004; Zito et al., 2007). In addition activated AKT can 
phosphorylate and inactivate pro apoptotic targets such as apoptosis signal regulated kinase 
(ASK1) and glycogen synthase kinase 3 beta (GSK3β) (Al Khouri et al., 2005). Inhibition of 
GSK3β induces translocation of glucose transporter 4 (GLUT4) vesicles to the membrane. 
Primarily these responses have a role in glucose homoeostasis, however, they are also 
connected to a pro survival status (Mosser et al., 2001).  
 
There are 2 regulatory phosphorylation sites, one at amino acid threonine 308 (Thr308 – in 
the activation domain) and the second at serine 473 (Ser473 – in the regulatory domain) (Ma 
et al., 2008; Manning and Cantley, 2007). Prior phosphorylation at Thr308 is thought to be a 
requisite for Ser473 phosphorylation and it has been proposed that the phosphorylation of 
both Thr308 and Ser473 are required for maximal activation (Vanhaesebroeck and Alessi, 
2000; Carpten et al., 2007). However, the full mechanism of AKT activation is not completely 
elucidated. PIP levels can influence the activity of AKT for example D-3 phosphoinositides 
such as PI(3,4)P2 and PI(3,4,5)P3 can recruit and activate AKT at the membrane level 
(Vanhaesebroeck and Alessi, 2000; Kane and Weiss, 2003; Ma et al., 2008).  
 
The end effector of the PI3K/AKT pathway may be at the level of the mitochondria. 
Phosphorylated and activated AKT inhibits pro apoptotic factors such as caspases, BAD, 
BIM, BAX, and p53 (Li and Sato, 2001). In addition, it can increase the activity of the pro 
survival protein Bcl2, which sequesters and inhibits pro apoptotic signals (Luo et al., 1998; 
Chen et al., 2001). Furthermore, insulin activation by the PI3K/AKT pathway has been shown 
to delay the time to mPTP opening and reducing cell death in an eNOS dependent manner 
(Davidson et al., 2006).  
 
Biological roles of the PI3K/AKT pathway Hilary Siddall 
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The PI3K/AKT pathway is responsible for development, growth, proliferation, cell cycle 
progression, migration and survival, as shown in Figure 1.4. This pathway is activated by 
numerous factors that stimulate membrane receptors. For example, agents such as insulin, 
okadaic acid and Epidermal growth factor (EGF) activate the PI3K/AKT pathway resulting in 
phosphorylation of AKT at Thr308 and Ser473 which enhances AKT activity (Sasaoka et al., 
2004; Gao et al., 2005b; Brognard et al., 2007). Furthermore, PI3K/AKT is involved in 
vascular homeostasis and is important for glucose uptake (Ijuin and Takenawa, 2003). Insulin 
strongly activates the PI3K/AKT pathway, increasing the level of phosphorylated AKT and 
phosphorylated p70S6K, which induce GLUT4 translocation and 2-deoxyglucose uptake 
(Nakashima et al., 2000). In endothelial cells, incubation with HDL can activate the PI3K/AKT 
pathway increasing PIP3, phosphorylation of AKT and reducing caspase 3 activity and cell 
death (DeKroon et al., 2006), indicating that activation of AKT can prevent cell death. 
 
Numerous studies have demonstrated that the pharmacological activation of the PI3K/AKT 
pathway can promote myocardial protection and tissue salvage following periods of injury. 
Bell and Yellon, 2003, showed that mouse hearts were protected from ischaemia-reperfusion 
injury in the presence of bradykinin. This protection was attributed to the increase in 
phosphorylation and activation of AKT and eNOS because the effects were abolished in the 
presence of the PI3K inhibitor wortmanin (Bell and Yellon, 2003). In contrast, bradykinin failed 
to protect myocardium from eNOS knockout mice, even though phosphorylation of AKT was 
enhanced. This indicates that eNOS is required to confer protection downstream of the 
PI3K/AKT pathway (Bell and Yellon, 2003). There are numerous studies demonstrating that a 
large number of pharmacological agents which induce cardioprotection against ischaemia-
reperfusion injury can activate the PI3K/AKT pathway (Jonassen et al., 2001; Li and Sato, 
2001; Maddock et al., 2002; Clarke et al., 2002; Efthymiou et al., 2005).  
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Figure 1.4: Downstream signalling factors of activated AKT.  
http://www.cellsignal.com/reference/pathway/Akt_PKB.html on 17.03.2009 
 
In summary, activation of the PI3K/AKT pathway signals for cell survival, as shown in Figure 
1.4. This pathway is a central component of the RISK pathway and its enhanced activation 
can protect the myocardium from lethal ischaemia-reperfusion injury. This pro survival 
pathway can be activated by pharmacological agents and by ischaemic interventions such as 
pre and post conditioning, which is described in more detail below (Hausenloy et al., 2004b; 
Tsang et al., 2004).  Hilary Siddall 
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1.4.2 Ischaemic  preconditioning and cardioprotection 
Research investigating ischaemia-reperfusion injury and cell death in the heart reached a 
turning point when the pioneering research of Murry et al, 1986 was first published. This work 
has been referenced in over 3000 publications as the first to discover the paradoxical 
phenomenon of ischaemic preconditioning (IPC). Murry et al., 1986 discovered that four 
cycles of 5 minutes (min) ischaemia followed by 5 min of reperfusion conferred protection 
against a subsequent prolonged period of ischaemia; by significantly reducing infarct size in 
canine hearts (Murry et al., 1986). In 1997 the concept of IPC was validated in humans 
(Jenkins et al., 1997). Patients undergoing elective coronary artery bypass graft surgery for 
more than 3 vessels were included in an IPC study. Half the patients were subjected to 2 
additional 3 min ischaemic episodes immediately prior to revascularisation of the first artery. 
72h later the study was considered a success because these patients had significantly less 
serum troponin T (Jenkins et al., 1997). 
 
1.4.2.1   Ischaemic preconditioning, cell signalling and 
cardioprotection 
Over 5000 publications have investigated the mechanisms involved in IPC. Despite this, 
knowledge of the precise mechanisms involved in IPC induced protection remains 
incomplete. The signalling involved in IPC is complex, and implicates a number of known 
survival signalling pathways such as PI3K/AKT, ERK1/2, JAK/STAT, p38, and PKC. Classic 
ischaemic preconditioning, originally described by Murry et al, 1996 involves short sub lethal 
ischaemia-reperfusion periods prior to a lethal ischaemic injury. Paradoxically, this initiates 
redox signalling sufficient to generate ROS, which can act in combination with other effectors 
of IPC, to signalling survival (Baines et al., 1997). However, the ROS generated by this 
stimulus is not damaging unlike that generated by prolonged lethal ischaemia (Baines et al., 
1997). The minimal stress of the IPC stimulus can trigger the release of ligands such as Hilary Siddall 
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adenosine, opioids and bradykinin (Gross and Gross, 2006; Cohen and Downey, 2008). 
When these ligands bind to their GCPR, a signal for survival is promoted. For example 
perfusion of adenosine or an adenosine receptor agonist prior to lethal ischaemia confers a 
level of protection equal to that of IPC (Liu et al., 1991). Furthermore, in isolated rabbit hearts 
perfusion with the adenosine receptor blocker, 8-sulfophenyl theophylline (8SPT) can abolish 
the protection conferred by IPC (Liu et al., 1991). 
 
Down stream of GPCRs are cell signalling pathways such as JAK/STAT, p38, PKC, ERK and 
PI3K/AKT, activation of which have been associated with pro survival signalling and 
cardioprotection, as shown in Figure 1.5 (Ferdinandy et al., 2007). IPC has been associated 
with the activation of cell survival pathways, including the RISK pathway (Tsang et al., 2005; 
Hausenloy et al., 2005). The activation of the PI3K/AKT pathway is thought to be important 
for the protection obtained by IPC and increases in phosphorylated AKT levels can be 
detected in models of cell survival (Mocanu et al., 2002). Both PI3K and ERK pathways have 
been linked together and it has been shown that activation of these pathways is involved in 
the IPC protection (Hausenloy et al., 2004b; Tsang et al., 2005). 
 
Enhanced PI3K/AKT in IPC can also activate Mdm2 which binds and sequesters p53 to 
inhibit p53 activity and cell death (Mocanu and Yellon, 2003). In preconditioned rat hearts the 
expression of p53 is reduced and the level of p53 bound to Mdm2 is enhanced. Furthermore, 
perfusion with the p53 inhibitor pifithrin alpha, conferred myocardial protection against 
ischaemia-reperfusion injury however, the protection was not as powerful as IPC induced 
protection (Mocanu and Yellon, 2003). This indicates that other signalling molecules are also 
important in IPC-PI3K/AKT protection.  Additional signalling downstream of this is the 
activation of NOS and PKG, which have been implicated in the prevention of mPTP opening 
and calcium overload (Bell and Yellon, 2003; Ferdinandy et al., 2007). 
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Cardioprotection using IPC has been shown to trigger opening of the KATP  channels 
(Auchampach et al., 1992; Yao et al., 1993; Hausenloy et al., 2002), however, their role in 
IPC is still debated (Ferdinandy et al., 2007). It has been hypothesised that opening of the 
KATP channels is associated with a delay to mPTP opening however, the precise mechanism 
is unknown (Gross et al., 2008).  
 
Moreover, recently it has been observed that propagation of IPC signals between cells is 
required to convey protection throughout the heart; and gap junctions are thought to play a 
role in this signalling (Li et al., 2002). Connexin 43 is the major component of gap junction in 
the heart; IPC fails to protect the myocardium from connexin 43 knockout mice (Schwanke et 
al., 2002). Interestingly, connexin 43 has been located at the mitochondria, where it may have 
an additional role in cell survival (Rodriguez-Sinovas et al., 2006). In summary, this highlights 
the variety of signalling components and end effectors that have been associated with IPC. 
 
Pharmacological preconditioning and cardioprotective interventions 
Preconditioning can be induced pharmacologically without sub lethal ischaemia-reperfusion 
stimuli. The presence of pharmacological cardioprotective agents administered prior to lethal 
ischaemia or at the onset of the lethal reperfusion can confer protection against ischaemia-
reperfusion injury. Such agents are known as preconditioning and postconditioning mimetics, 
respectively. The concept of postconditioning is described in more detail below.  
 
As described above, activators of PI3K/AKT such as adenosine, bradykinin, opioids and also 
insulin (a tyrosine receptor ligand) confer protection against lethal ischaemia-reperfusion 
injury; mimicking IPC (Baines et al., 1999; Li and Sato, 2001; Maddock et al., 2002; Bell and 
Yellon, 2003; Gross and Gross, 2006). Other drugs targeting specific proteins can salvage 
tissue from ischaemia-reperfusion, for example, the presence of diazoxide, a mitochondrial 
KATP channel opener. In addition this cardioprotective agent can activate the PKC isoform Hilary Siddall 
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PKCε. Diazoxide is reported to instigate PKCε translocation from the cytosol to the 
mitochondria; where in the presence of hypoxia it can prevent Ca
2+ accumulation, membrane 
depolarisation and cytochrome c release (Kim et al., 2006b). Such observations are not 
recorded when cells containing a dominant negative form of PKCε are incubated in diazoxide 
(Kim et al., 2006b).  
 
1.4.2.2   Preconditioning and mitochondria 
As described in section 1.3 prevention of the mPTP opening confers protection against 
ischaemia-reperfusion injury. IPC induces a delay in Ca
2+ induced mPTP opening, 
mitochondrial rupture and cell death, as demonstrated in rabbit hearts and rat ventricular 
cardiomyocytes (Argaud et al., 2004; Davidson et al., 2006). Furthermore, a delay in the 
opening of the mPTP in rabbit hearts has been associated with the protection bestowed by 
IPC (Argaud et al., 2004; Argaud et al., 2008). In isolated rat hearts, perfusion with 
atractyloside, an mPTP opener, can abolish myocardial protection conferred with IPC and 
diazoxide (Hausenloy et al., 2002). Furthermore cyclophilin D (a component of the mPTP) 
knock out mice, are protected from lethal myocardial ischaemia-reperfusion injury. The mPTP 
is still able to form in these mice (Baines et al., 2005), however, IPC fails to protect the 
myocardium which already manifest small levels of infarction (Lim et al., 2007). Collectively, 
these observations suggest that IPC confers protection by inducing a delay in the mPTP 
opening and has a role in maintaining cell death and apoptosis. Additionally, autophagy has 
been shown to be important for IPC induced protection (Yitzhaki et al., 2009; Lemasters et 
al., 1998). Sub lethal periods of autophagy are proposed to be beneficial in maintaining ATP 
levels and preserving viable tissue, however, lethal periods of autophagy, as seen in lethal 
periods of ischaemia, can be detrimental (Sadoshima, 2008; Yitzhaki et al., 2009). 
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Figure 1.5: Signalling associated with ischaemic and pharmacological preconditioning 
(bradykinin is an example of a pharmacological preconditioning agent) (Ferdinandy et 
al., 2007). Including Bcl-2-associated death receptor (BAD), Bcl-2 associated x protein 
(BAX), cyclic guanosine monophosphate (cGMP), connexin 43 (cx43), epidermal 
growth factor receptor (EGFR), extracellular related kinase (ERK), glycogen synthase 
kinase 3 β (GSK3β), mitochondrial adenosine triphosphate sensitive potassium 
channels (mKATP), mitochondrial protein kinase C epsilon (mPKCε), mitochondrial 
permeability transition pore (mPTP), nitric oxide (NO), protein kinase G (PKG), reactive 
oxygen species (ROS), and sarcolemmal adenosine triphosphate sensitive potassium 
channels (SarcKATP). 
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1.4.3  Ischaemic postconditioning and cardioprotection 
In 2003, the phenomenon of postconditioning was first defined. Zhao et al., 2003 discovered 
that 3 cycles of 30 sec periods of ischaemia and reperfusion immediately following an 
extended period of ischaemia conferred cardioprotection against ischaemia-reperfusion injury 
(Zhao et al., 2003). This recent discovery has lead to much excitement. Clinically, it appears 
more practical and achievable to induce protection following an ischaemic episode due to the 
unpredictability of MI. Unlike IPC which would be limited to scheduled operations, post 
conditioning may be a more versatile therapy (Cleveland, Jr. et al., 1997; Loukogeorgakis et 
al., 2006). In 2005, postconditioning was successfully applied to human hearts (Staat et al., 
2005). Patients with acute MI, undergoing coronary angioplasty were subjected to control or 
post conditioning stimuli. Postconditioning was induced by subjecting the myocardium to an 
additional number of angioplasty balloon inflations and deflations, immediately following the 
initial rescue angioplasty balloon inflation/deflation. This resulted in a decrease in circulating 
creatine kinase in the postconditioned patients (Staat et al., 2005). The mechanisms involved 
in postconditioning are not completely understood. However, pathways similar to those 
involved in IPC have been implicated, the RISK pathway is one of them (Tsang et al., 2004; 
Hausenloy et al., 2005; Lim et al., 2007). For example, in rat myocardium subjected to 
postconditioning an increase in PI3K/AKT, phosphorylated p70S6K and eNOS can be 
recorded. The protection can be abolished with the PI3K inhibitors LY294002 and wortmanin 
(Tsang et al., 2004). Furthermore, postconditioning in rabbit myocardium has been attributed 
to a delay in the opening of the mPTP (Argaud et al., 2004; Argaud et al., 2005b; Lim et al., 
2007; Argaud et al., 2008). 
 
In summary, it appears that the activation of the RISK pathway, either prior to ischaemia or at 
reperfusion, is important in cardioprotection and that the PI3K/AKT pathway is a fundamental 
member of this salvage pathway. The development of novel therapies that enhance Hilary Siddall 
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protection following ischaemia-reperfusion may include mechanisms that up regulate and 
maintain the PI3K/AKT pathway in an activated state. 
1.4.4  Regulators of PI3K/AKT  
Unfortunately, unregulated activation of the PI3K/AKT pathway can promote excessive 
growth and hypertrophy in the myocardium (Liaw et al., 1997; Latronico et al., 2004; 
Hennessy et al., 2005).  To counterbalance this, the cells are equipped with a range of 
phosphatase enzymes which down regulate this pathway. The main negative regulator of this 
pathway is phosphatase and tensin homolog deleted on chromosome 10 (PTEN). Additionally 
phosphatases such as SRC homology 2 containing inositol 5 phosphatase 2 (SHIP2), PH 
domain leucine rich repeat protein phosphatase (PHLPP) and protein phosphatase 2A 
(PP2A) can down regulate AKT activity. Figure 1.6 displays some of the cellular mechanisms 
involved in negatively regulating PI3K and AKT activity. 
 
 Hilary Siddall 
 
58
Prosurvival
PI(3,4,5)
P3
PI3K
PI(4,5)
P2
PTEN
SHIP2
PI(3,4)
P2
pAKT
Proliferation Hypertrophy
PHLLP PP2A
Prosurvival
PI(3,4,5)
P3
PI3K PI3K
PI(4,5)
P2
PTEN
SHIP2
PI(3,4)
P2
pAKT pAKT
Proliferation Hypertrophy
PHLLP PP2A
 
 
Figure 1.6: Phosphatases that negatively regulate the PI3K/AKT pathway: the main 
regulator is Phosphatase and tensin homolog deleted on chromosome 10 (PTEN). In 
addition, SH containing inositol phosphatase 2 (SHIP2), PH domain leucine rich repeat 
protein phosphatase (PHLPP) and protein phosphatase 2A (PP2A) may also regulate 
this pathway. Phosphorylated AKT (pAKT) levels are indicative of AKT activity. 
Including phosphatidylinositol 3 kinase (PI3K), Phosphatidylinositol 2 phosphate 
(PIP2), and Phosphatidylinositol 3 phosphate (PIP3). 
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1.5 PTEN 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a lipid and protein 
phosphatase that was first identified in 1997 (Li et al., 1997a; Steck et al., 1997). It is the 
main negative regulator of the PI3K/AKT pathway. It dephosphorylates PI(3,4,5)P3 to 
produce PI(4,5)P2 (Maehama and Dixon, 1998b; Lee et al., 1999).  Its mutation is associated 
with the development of a hereditary disease called Cowden’s syndrome (Liaw et al., 1997). 
PTEN is a tumour suppressor and patients with this disease are predisposed to the 
development of multiple sporadic haematomas (Liaw et al., 1997). Since this discovery, over 
3700 research articles have been published with the aim to understand PTEN signalling and 
function. 
 
1.5.1 PTEN  structure 
The PTEN protein, presented in Figure 1.7, consists of 403 amino acids and has a molecular 
weight of 54kDa (Lee et al., 1999). As the name suggests, PTEN contains a homology 
sequence to tensin, which is a focal adhesion protein capable of binding to actins and is 
involved in maintaining normal cell shape (Li et al., 1997a; Steck et al., 1997; Lee et al., 1999; 
Chen et al., 2000).  
 
N terminus 
The N terminus of PTEN contains 179 residues, 6-15 encompass a PIP2 binding motif and 
work by Maehama et al., 2001 demonstrate that this is important for membrane binding 
(Maehama et al., 2001). Residues 15-185 contain what is known as the phosphatase catalytic 
domain which is pivotal for PTEN function (Lee et al., 1999). PTEN contains homology to 
general protein tyrosine phosphatases (PTP), but in contrast, the active site of PTEN is both 
wider and deeper than general PTP (Lee et al., 1999; Rosivatz et al., 2006). PTENs large 
active site facilitates sufficient binding to phosphatidylinositol 3,4,5 phosphate (PIP(3,4,5)P3) Hilary Siddall 
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(Myers et al., 1997; Maehama and Dixon, 1998b). Within this catalytic domain exists a 
cysteine (Cys124) residue fundamental for enzyme activity (Kwon et al., 2004).  
 
C terminus 
As described in more detail below, the core structure and activity of PTEN depend on its 
stability. This stability can be influenced by modifications to the C terminus, also termed the 
non catalytic domain of PTEN (Gil et al., 2006). The C terminus contains 166 residues, with a 
phospholipid C2 binding domain located at residues 185-350; and is critical for membrane 
binding (Lee et al., 1999). Within this region are loops that contain positive charges 
responsible for membrane binding independent of Ca
2+. This is different to PTPs which 
require Ca
2+ to promote a positive charge and membrane binding (Lee et al., 1999). In 
addition, there are nuclear inclusion and exclusion sequences in the C terminal domain, 
important for PTEN localisation and function, which are described in more detail below 
(Chung et al., 2005). Residues 350-403 are known as the PTEN stability motif and 
phosphorylation at this site can result in proteasomal degradation (Torres and Pulido, 2001). 
Finally, at the tail end of the C terminus resides as post synaptic density protein, drosophila 
disc large tumour suppressor and zonula occludens-1 protein (PDZ) binding domain. This is 
also important in PTEN stability and activity and is required to anchor the protein to 
membranes (Wu et al., 2000b). 
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Figure 1.7: Structure of PTEN, a 403 amino acid (aa) protein: displaying the N terminal 
catalytic domain, non catalytic C terminus, Phosphatidylinositol 2 phosphate (PIP2) 
and the Post synaptic density protein, Drosophila disc large tumour suppressor and 
Zonula occludens-1 protein (PDZ) domain (Lee et al., 1999; Wu et al., 2000b; Maehama 
et al., 2001; Gil et al., 2006).  
 
1.5.2 PTEN  function 
PTEN is an endogenous lipid and protein phosphatase (Lee et al., 1999). As a protein 
phosphatase, it is active at tyrosine, serine and threonine residues and as a lipid 
phosphatase it can dephosphorylate the second messenger phosphatidylinositol 3,4,5 
phosphate (PIP(3,4,5)P3) into phosphatidylinositol 4,5, phosphate (PI(4,5)P2) (Myers et al., 
1997; Maehama and Dixon, 1998a). PTEN is a 3’ PIP phosphatase because it removes 
phosphate groups specifically from the 3’ position of the inositol ring. In addition it can 
dephosphorylate phosphatidylinositol 3,4, phosphate (PI(3,4)P2), phosphatidylinositol 3,5, 
phosphate (PI(3,5)P2) and phosphatidylinositol 1,3,4,5 phosphate (PI(1,3,4,5)P4). However, 
in vivo these are secondary substrates to PI(3,4,5)P3 (Myers et al., 1997; Maehama and 
Dixon, 1998b; Lee et al., 1999; Campbell et al., 2003; Rosivatz et al., 2006). As shown in Hilary Siddall 
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Figure 1.8 PTEN negativity regulates the PI3K/AKT proliferation, growth and survival 
pathway, which is described further in section 1.5.5.  
 
Additionally, PTEN is reported to have a role in cell migration, embryonic development, cell 
adhesion and cell cycle (Mise-Omata et al., 2005; Hamada et al., 2005). For example 
functional PTEN can enhance the number of cells in the G1 cell arrest phase of the cell cycle. 
Whereas, inhibition of PTEN in human embryonic kidney cells 293 and mouse embryonic 
cells has been shown to increase AKT activity and decrease the number of cells in the G1 
phase (Okumura et al., 2006). Indicating that reduced PTEN can enhance the survival 
signalling. Functional PTEN can induce apoptosis and inhibition of PTEN can reduce the 
response to the apoptotic factor TNFα (Gil et al., 2006).  Hilary Siddall 
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Figure 1.8: Hypothesised role of PTEN: Receptor stimulation of the PI3K/AKT pathway 
in the absence (A) and presence (B) of PTEN. Including BCL-2-associated death 
promoter (BAD), endothelial nitric oxide synthase (eNOS), glycogen synthase kinase 
3β (GSK3β), murine double minute 2 (Mdm2), 70 kDa ribosomal protein S6 kinase 
(P70S6K), 3-phosphoinositide dependent protein kinase1 (PDK1), Phosphatidylinositol 
3 kinase (PI3K), Phosphatidylinositol 2 phosphate (PIP2), and Phosphatidylinositol 3 
phosphate (PIP3). Figure adapted from (Mocanu and Yellon, 2007).  Hilary Siddall 
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1.5.3 PTEN  localisation 
PTEN is constitutively expressed and is located predominately in the cytosol. When active it 
can be found at the lipid membrane (Lee et al., 1999). In addition PTEN has been observed 
in the endoplasmic reticulum and the nucleus (Gil et al., 2006; Lindsay et al., 2006). The 
localisation of PTEN within compartments of the cell is important to its function.  
 
1.5.3.1   PTEN localisation in the cytosol 
PTEN is implicated in cell motility, for which the cellular location is important. In leukocytes 
and HEK cells, chemoattractant factors can activate and control PTEN activity and 
localisation (Li et al., 2005). In resting leukocytes PTEN has been located in the cytoplasm. In 
contrast, in migrating cells PTEN co-localises with RhoA, towards the posterior of the cell at 
the plasma membrane. This facilitates an increase in PTEN activity whereas in the lateral and 
leading edge of the migrating cell PTEN was not present and the levels of PIP(3,4,5) were 
free to promote cell motility. Moreover, this group demonstrated that PTEN can be 
phosphorylated in vitro by Rho associated kinase 1 (ROCK1) the downstream effector of 
RhoA, and this contributes towards increasing PTEN activity (Li et al., 2005).  
 
1.5.3.2   PTEN localisation in the nucleus 
PTEN appears to have a role in the nucleus and this may involve regulating cell cycle and 
apoptosis. A nuclear pool of PI(3,4,5)P3 and PTEN has been identified, and a nuclear 
localisation sequence in the C terminus of PTEN has been discovered (Gimm et al., 2000; 
Chung et al., 2005; Lindsay et al., 2006). Lindsay Y, et al., 2006 demonstrate that PTEN is 
capable of dephosphorylating PI(3,4,5)P3 in the cytosolic fraction of the cell however. a 
proportion of PTEN in the endoplasmic reticulum and nucleus was unable to dephosphorylate Hilary Siddall 
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PI(3,4,5)P3 (Lindsay et al., 2006). Therefore PTEN may have a role in the nucleus 
independent of the PI3K/AKT pathway. 
 
In contrast, other groups have detected a nuclear pool of PTEN dependent on the expression 
of a PTEN nuclear localisation domain in the N terminus of the protein. In addition it has been 
suggested that a PTEN nuclear exclusion motif may be involved in its localisation. Normal 
expression of this motif appears to maintain cytosolic PTEN and mutations in this area have 
been associated with accumulation in the nucleus. Apoptotic stimuli such as doxorubicin or 
TNFα can induce PTEN accumulation in the nucleus (Gil et al., 2006). The authors of this 
work demonstrated that deletion of the PDZ membrane binding domain abolished the nuclear 
accumulation and PTEN protein remained in the cytoplasm (Gil et al., 2006). This may 
indicate that PTEN translocation to the nucleus may require membrane binding.  
 
Furthermore, monoubiquitination of PTEN can also induce its localisation in the nucleus. 
PTEN can be ubiquitinated by the E3 ligase NEDD4-1 which is involved in its degradation 
(Wang et al., 2007b). The monoubiquitinated PTEN is reported to be stable and capable of 
maintaining its tumour suppressor functions. However, further ubiquitination of PTEN results 
in re-accumulation in the cytosol where the polyubiquitinated PTEN is degraded (Trotman et 
al., 2007). 
 
An additional role for PTEN in the nucleus has been proposed, and this is to promote nuclear 
and chromosomal stability. Nuclear PTEN has been co-localised with the centromeres. 
Disruption of PTEN or mutations in the C terminal region can induce double stranded breaks 
of centromere and DNA. Therefore, the authors of this work suggested that nuclear PTEN 
plays a role in chromosomal integrity and DNA repair (Shen et al., 2007).  
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Nuclear PTEN level can be increased by depletion of ATP, while the restoration of ATP can 
reverse nuclear localisation of PTEN (Lobo et al., 2008). The complete mechanisms and 
consequence of PTEN nuclear accumulation remains unknown, however, it is evident that 
PTEN localisation can influence its role in the cell. The cellular localisation of PTEN is 
highlighted in Figure 1.9. To summarise, PTEN is abundant in the cytosol, however, it 
appears active when located at the membrane, and conditionally, in the nucleus.  
 
 
 
Figure 1.9: The role of PTEN in the nucleus and cytoplasm (Baker, 2007). Including 
centromere protein C (CENP-C), neural precurser cell expressed developmental down 
regulated (NEDD4-1), Phosphatidylinositol 3 kinase  (PI3K), Phosphatidylinositol 2 
phosphate (PIP2), and Phosphatidylinositol 3 phosphate (PIP3), phosphatase and 
tensin homolog deleted on chromosome 10 (PTEN) and ubiquitination (Ub) signalling. Hilary Siddall 
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1.5.4 PTEN  regulation 
Reversible inhibition of PTEN may have a major impact in the treatment for apoptotic related 
diseases, because inhibition of PTEN can enhance the signalling of the PIP3/PI3K/AKT 
survival pathway (Schmid et al., 2004; Wu et al., 2006). The potential methods for 
manipulating PTEN level and function are described below.  
 
1.5.4.1   Transcriptional regulation of PTEN 
As described below in more detail and displayed in Figure 1.10 changes in the transcription 
and translation of PTEN can regulate its expression.  
 
1.5.4.1.1  Positive transcriptional regulators 
Factors that positively regulate the transcription of PTEN can enhance PTEN protein 
expression such factors include agents such as dimethyl sulfoxide (DMSO) and cellular 
proteins such as peroxisome proliferators-activated receptors (PPARγ) and p53. In HL60 
cells, the addition of  0.5 – 1.5% DMSO increased PTEN expression, in a dose dependent 
manner (Lee et al., 2005). Additionally, there is a proposed PPARγ binding site on the PTEN 
promoter. In the MCF-7 breast cancer cell line, rosiglitazone (a PPAR activator) and 
lovastatin (a HMG CoA reductase inhibitor) activate PPARγ and increase PTEN mRNA 
expression, in a time and dose dependent manner. This increase was associated with 
reduced phosphorylation of AKT and an increased number of cells in G1 cell cycle arrest 
(Teresi et al., 2006). 
 
Mensah,  et al., 2005 were the first to demonstrate changes in PTEN whilst studying 
ischaemia-reperfusion injury. In a rat model of myocardial ischaemia-reperfusion injury acute 
atorvastatin treatment (1 and 3days) can induce protection. However, this protection was Hilary Siddall 
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abolished with chronic atorvastatin treatment (1 and 3 weeks) (Mensah et al., 2005). The 
authors of this work attributed the loss of protection in chronic atorvastatin treatment to an 
increase in PTEN protein expression. Such stimulation may be due to the up regulation of 
PPARγ however, the involvement of such mechanisms were not investigated in this study.  
 
Furthermore, there is a p53 dependent binding element in the PTEN promoter region and p53 
can cause the inducible activation of PTEN  (Stambolic et al., 2001). PTEN regulation is 
sensitive to changes in p53 levels. In fibroblasts the presence of pifithrin alpha (PFTα), a p53 
inhibitor, induces a decrease in the PTEN protein levels (Wang et al., 2005). Collectively, 
these studies are important and they imply that PTEN can be regulated acutely and 
manipulated pharmacologically.  
 
 
1.5.4.1.2 Negative  transcriptional  regulation 
Negative transcriptional regulation of PTEN results in a reduction of PTEN protein expression 
and/or function. The micro RNA 21 (MiRNA-21) has been linked to the degradation of PTEN. 
MiRNA’s are endogenous oligonucleotides that are responsible for silencing protein 
expression, targeting specific mRNA sequences for degradation (Haghikia and Hilfiker-
Kleiner, 2009). Interestingly, fibroblasts extracted from hearts subjected to ischaemia-
reperfusion have enhanced distribution of MiRNA-21, which are thought to be responsible for 
reduction of PTEN protein level (Roy et al., 2009).  
 
Mutations in the genetic coding of PTEN can also reduce expression and function. For 
example, PI(4,5)P2 can bind and activate PTEN. However, mutations in the N terminus which 
codes for PI(4,5)P2 binding site can disrupt PTEN activity (Campbell et al., 2003). Similarly, 
PTEN activity is highly influenced by membrane localisation. Over expression of PTEN can 
reduce insulin stimulated GLUT4 translocation. However, mutations in regions coding for Hilary Siddall 
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PTEN membrane binding can abolish this effect (Mosser et al., 2001). PTEN mutations have 
been associated with diverse human pathology; the physiological relevance of PTEN 
mutations and inhibition are described below, in section 1.6.  
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Figure 1.10: Factors that regulate the transcriptional activity of phosphatase and tensin 
homolog deleted on chromosome 10 (PTEN) and total PTEN expression. DMSO = 
dimethyl sulfoxide, PPAR = peroxisome proliferators-activated receptors, MiRNA-21 = 
Micro ribonucleic acid-21. 
 
1.5.4.2   Post translational modifications of PTEN 
The activity of PTEN can be altered by factors that modify translated PTEN protein. Factors 
effecting post translation modifications of PTEN are displayed in Figure 1.11 and described 
below.  Hilary Siddall 
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1.5.4.2.1 Positive  post  translational modifications of PTEN 
Factors that induce post translational regulators of PTEN induce modifications that enhance 
PTEN activity. As displayed in Figure 1.11 modifications increasing activity can include PTEN 
membrane binding and PTEN-ROCK1 interactions (Wu et al., 2000b; Li et al., 2005). 
 
PTEN membrane binding 
Wu Y, et al., 2000 have demonstrated that PTEN can bind to ‘membrane-associated 
guanylate kinase with inverted orientation’ (MAGI3). This interaction has been shown to 
facilitate PTEN binding and localisation at the membrane. It is thought that MAGI3, which 
contains a PDZ domain, binds to the PDZ binding domain in the C terminus of PTEN, acting 
as a scaffold for PTEN function. The author of this research demonstrated that PTEN-MAGI3-
membrane binding is associated with a decrease in AKT activity and enhanced PTEN activity 
(Wu et al., 2000b). Mutations in the PDZ domain of PTEN prevents this effect, indicating that 
membrane binding is important for PTEN function (Wu et al., 2000b).  
 
ROCK enhanced expression. 
The kinase, ROCK1, can phosphorylate PTEN at Ser229-Thr223 and Thr319-Thr321, which 
increases PTEN activity. In leukocytes, RhoA and ROCK1 have been shown to up regulate 
PTEN activity. ROCK1 is involved in enhancing apoptosis and plays a role in ischaemia-
reperfusion injury (Chang et al., 2006; Hamid et al., 2007). In patients with heart failure an 
increased expression of active ROCK1 has been observed in myocardial tissue. Similarly, in 
a mouse model of cardiomyopathy enhanced ROCK1 has been observed in parallel to an 
increase in PTEN activity and a decrease in AKT activity (Chang et al., 2006). Furthermore, 
ROCK1 has been attributed to the phosphorylation and activation of PTEN in migrating 
leuokocytes (Li et al., 2005).  
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Cytomegalovirus 
Viral infections have also been shown to modify PTEN activity. For example incubation of 
human aortic endothelial cells with the human cytomegalovirus has been associated with 
activation of PTEN and endothelial dysfunction. This is indicated by a decreased activity of 
AKT and eNOS following insulin stimulation. Furthermore, human cytomegalovirus has been 
shown to increase PTEN mRNA and total protein levels. In addition PTEN dephosphorylation 
at Ser380 and Thr382/383 has been observed, and these effects were dependent on p38 
MAPK. Therefore this study indicates that PTEN activity can be enhanced by 
dephosphorylation of PTEN at Ser380,Thr382/383 (Shen et al., 2006). 
 
Additional regulators effecting the activity of PTEN 
Recently, it has been communicated that components of the NOTCH signalling pathway can 
increase the activity and protein expression of PTEN. For example, transcription factor hairy 
and enhancer of split 1 (HES-1) and the promoter CBF-1 (also known as recombination 
signal binding protein for immunoglobulin kappa J region (RBBJ)) can enhance PTEN activity. 
(Palomero et al., 2008; Whelan et al., 2007; Chappell et al., 2005). An additional factor that 
positively influences PTEN is s-nitrosylation (Zhang et al., 2007; Pei et al., 2009). However, 
the precise effect of s-nitrosylation appears complex, as it is noted to cause either PTEN 
activation or PTEN inhibition. These opposite effects may be dependent on the order and 
position of the nitrosylation which may contribute to either activity or inactivity. See figure 
6.24. 
 
1.5.4.2.2 Negative  post  translational modifications of PTEN 
Negative post translational regulators of PTEN induce changes that reduce PTEN activity. 
Such modifications include phosphorylation, oxidation, acetylation and ubiquitination Hilary Siddall 
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(protesomal degradation), as displayed in Figure 1.11 (Torres and Pulido, 2001; Wu et al., 
2003; Meuillet et al., 2004). 
 
Phosphorylation and endogenous inhibitors of PTEN 
Initial experiments investigating PTEN phosphorylation indicate that Ser380, Thr382 and 
Thr383 phosphorylation reduces PTEN activity. In these original studies, active PTEN was 
readily degraded and unstable (Torres and Pulido, 2001; Valiente et al., 2005). Subsequently, 
a flourish of experiments investigating the phosphorylation and activity of PTEN have been 
published.  
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Figure 1.11: Post translational modifications that effect PTEN function. Casein kinase II 
(CK2), Cytomegalovirus (CMV), membrane-associated guanylate kinase with inverted 
orientation (MAGI), neural precursor cell expressed developmental down regulated 
(NEDD4-1), nerve growth factor (NGF), p300/CBP associated factor (PCAF), 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and reactive 
oxygen species (ROS). 
 
A number of endogenous intracellular factors and enzymes such as casein kinase II (CK2), 
caspase 3, nerve growth factor (NGF), the tumour suppressor LKB1 and the mitochondrial 
protein DJ-1 have been shown to regulate PTEN: some of which are described below. 
 
Casein kinase II 
Casein kinase II (CK2) can phosphorylate the C terminus of PTEN, decreasing PTEN stability 
and increasing its protesomal degradation (Torres and Pulido, 2001). Similarly, in pancreatic Hilary Siddall 
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and hypothalamic cells stimulated with the cardioprotective adipocytokine leptin, the level of 
CK2 activity is increased and is associated with reduced PTEN function (Ning et al., 2006; 
Smith et al., 2006). This finding was attributed to the activation of CK2 by leptin which, in turn 
phosphorylated and destabilised PTEN (Ning et al., 2006). 
 
Furthermore, in HEK293 cells casein kinase I (CKI), CK2 and GSK3B were shown to 
phosphorylate the C terminus of PTEN in the presence of insulin like growth factor 1 (IGF1) 
(Al Khouri et al., 2005). The authors of this work demonstrate that CKI and CK2 can 
phosphorylate PTEN at Ser385 and Ser370, whereas GSK3β only phosphorylated Ser362 
and Thr366 (Al Khouri et al., 2005). Moreover a synergistic effect between these enzymes 
was demonstrated. The physiological relevance of these phosphorylation events were 
explained as a decrease in PTEN activity, measured by an increase in phosphorylated AKT 
at Ser473 and consequentially a decrease in GSK3β phosphorylation at Ser21/9. These 
phenomena appear to be dependent on Thr366 phosphorylation, as IGFα, in cells null for 
Thr366 phosphorylation, was unable to stimulate the increase in AKT phosphorylation (Al 
Khouri et al., 2005).  
 
Additionally, in gliblastoma cells, phosphorylation of PTEN at Thr366 has been associated 
with protein destabilisation. Mutations in this region prevented the phosphorylation of Thr366 
and enhanced PTEN stability, the phosphatase activity remained unaffected (Maccario et al., 
2007).  
 
Caspase 3 
The apoptotic factor, caspase 3 can negatively regulate PTEN. In HEK293 cells the apoptotic 
ligand, TNFα causes caspase 3 binding to PTEN which facilitates caspases 3 cleavage at the 
C terminal domain of PTEN. This cleavage can abolish PTEN binding to MAGI, which is 
important for PTEN activity (Wu et al., 2000a; Wu et al., 2000b; Torres et al., 2003). Torres J, Hilary Siddall 
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et al., 2003 indicate that the cleaved PTEN is non functional, unstable and is rapidly 
degraded (Torres et al., 2003). Conversely, PTEN phosphorylation by CK2 protects PTEN 
from caspase 3 cleavage (Torres et al., 2003). Nonetheless, as described above CK2 
phosphorylation of PTEN promotes the occurrence of ubiqitination and proteosomal 
degradation of PTEN (Torres and Pulido, 2001).  
 
Nerve growth factor 
Nerve growth factor (NGF) reduces PTEN level in hippocampal neurons. This PTEN inhibition 
was attributed to the activation of CK2 (by NGF) which in turn was shown to phosphorylate 
PTEN at Ser380. This phosphorylation was associated with a decrease in PTEN activity as 
indicated by an increase in phosphorylation of AKT (at Ser473 phosphorylation site), 
phosphorylation of GSK3β and axon elongation (Arevalo and Rodriguez-Tebar, 2006).  
 
LKB1 
LKB1 is a protein kinase, up regulated in many cancers, which can regulate PTEN activity 
(Shaw et al., 2005). A study looking at the activity of LKB1 showed that this kinase binds to 
PTEN. In addition LKB1, normally located in the nucleus, translocates to the cytoplasm where 
it interacts with PTEN. LKB1 can phosphorylate PTEN at the C terminal, between 
phosphorylation sites Ser360-Ser385, leading to the onset of tumours (Mehenni et al., 2005). 
 
Mitochondrial proteins 
A mitochondrial protein called DJ-1 can negatively regulate PTEN. Mutations of this protein 
are associated with the early onset of Parkinson’s disease. It is thought to act as a sensor of 
oxidative stress. Reduced expression of DJ in NIH-3T3 cells results in decreased AKT 
phosphorylation. Furthermore the over expression of DJ-1 can enhance AKT activity and cell 
viability (Kim et al., 2005).The precise mechanism of this negative regulation is unknown. 
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Oxidation and inhibition of PTEN 
Oxidation of PTEN has been associated with loss of activity. A cysteine (Cys124) residue 
within the phosphatase catalytic domain is fundamental for PTEN activity. Cys124 can be 
oxidised by H2O2 forming a disulfide bridge with Cys71 and rendering the enzyme inactive 
however, this effect is reversible  (Lee et al., 2002).  
 
In a redox engineered cell line expressing increased levels of mitochondrial manganese 
superoxide dismutase, enhanced levels of H2O2 was produced, which increased PTEN 
oxidation. Consequentially, it was demonstrated that PTEN activity was decreased and AKT 
activity increased. This effect was abolished when PTEN was over expressed (Connor et al., 
2005). Moreover, peptide growth factors such as platelet derived growth factor (PDGF) or 
EGF can inhibit PTEN by producing H2O2 which reversibly oxidises PTEN at Cys124. The 
over expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1 
amplified PIP3 levels and further enhanced the increase in AKT activity (Kwon et al., 2004). 
In addition, insulin stimulation in neuroblastoma cells was shown to induce ROS formation 
which inhibited PTEN activity. The PI3K activity in these cells remained the same however, 
the level of phosphorylated AKT was enhanced in the presence of insulin. The authors of this 
work attributed this effect to the production of ROS and the inhibition of PTEN, because no 
increase in phosphorylated AKT using insulin was observed in cells that lacked the ability to 
generate ROS (Seo et al., 2005).  
 
Redox reduced PTEN has been associated with normal regulation of PTEN function (Lee et 
al., 2002). Thioredoxin-1, a redox protein and electron donor, can affect PTEN activity. 
Peptide growth factors can stimulate H2O2 production and subsequently, oxidise PTEN. 
Mutagenesis studies reveal that thioredoxin 1 can form a disulfide bond at the Cys32 in the 
active site of PTEN, Moreover, thioredoxin 1 can bind to PTEN at the C2 domain where it can 
abolish membrane binding and prevent lipid phosphatase activity (Meuillet et al., 2004). Hilary Siddall 
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Interestingly, peroxidase peroxiedoxin (Prdx1) can bind to PTEN and protect it from becoming 
oxidised and inhibited, thereby maintaining PTEN stability (Cao et al., 2009). 
 
The synthetic analogue of vitamin K, menadione (2-methyl-1,4-nahthoquinone), can inhibit 
protein tyrosine phosphatases and has been reported to affect PTEN. Menadione can induce 
oxidative stress. In CHO cells it reduces PTEN phosphatase activity and increases 
phosphorylation of AKT at Ser473 and Thr308 (Yoshikawa et al., 2007).  
 
Acetylation and inhibition of PTEN 
Lysine residues (Lys125 and Lys128) located in the PTEN phosphatase catalytic domain can 
be acetylated and in turn, can affect PTEN function. The presence of EGF in HEK293 cells 
that over express the histone acetyltransferase, (p300/CBP associated factor (PCAF)) can 
induce PCAF-PTEN binding and PTEN acetylation (Okumura et al., 2006). PTEN acetylation 
has been associated with a reduction in lipid phosphatase activity, an increase in AKT 
phosphorylation (Ser473) and a reduction in the number of cells in G1 phase of cell cycle 
(Okumura et al., 2006). 
 
Ubiquitination and inhibition of PTEN 
PTEN can be ubiquitinated by the E3 ligase NEDD4-1. This ubiquitination is involved in PTEN 
degradation and causes tumourgenosis. Deletion of NEDD4-1 increases PTEN protein level 
and activity (Wang et al., 2007b). Monoubiquitination of PTEN can induce localisation in the 
nucleus where it retains activity as a stable tumour suppressor (Wang et al., 2007b). It has 
been suggested that mutations in a lysine residue prevent monoubiquitination and nuclear 
localisation. In patients suffering with Cowden syndrome mutations in a PTEN lysine residue 
have been observed. These patients have catalytically active PTEN, whilst expressing 
reduced nuclear PTEN content, although they still develop tumours (Trotman et al., 2007). 
These data underline that nuclear PTEN is important for function and that monoubiquitination Hilary Siddall 
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of PTEN is required for this activity. In contrast polyubiquitinated PTEN induces PTEN 
instability and degradation (Baker, 2007; Trotman et al., 2007).  Recently, it has been shown 
that in mouse fibroblasts XIAP, an antiapoptotic factor, can associate with PTEN. This 
association was shown to cause polyubiquitination, nuclear exclusion, and protein reduction 
of PTEN, mirrored by an increase in AKT activity (Van Themsche et al., 2009). The authors of 
this work propose that XIAP is an E3 ubiquitin ligase for PTEN, which acts to inhibit and 
reduce PTEN activity.    
 
Chemical inhibitors of PTEN 
Vanadium compounds, which are tyrosine phosphatase inhibitors, are reported to affect 
PTEN phosphatase activity (Schmid et al., 2004). Incubation with bisperoxo(5-hyroxypyridine-
2carboxy) oxovanadate (bpV(HOpic), in NIH3T3 cells, can increase AKT phosphorylation. 
This compound was demonstrated to have 100 fold specificity for PTEN inhibition compared 
to general tyrosine phosphatase inhibition (Schmid et al., 2004). Additionally, in Sprague-
Dawley rats i.p injections of orthovanadate conferred protection in the brain following 
ischaemia-reperfusion injury in addition to down regulating PTEN activity. PTEN and AKT 
phosphorylation were increased and the activity of ASK1, a pro apoptotic substrate of AKT, 
was decreased (Wu et al., 2006). However, the mechanism by which PTEN phosphorylation 
is induced by the vanadium compounds is unclear. 
 
Zinc can also inhibit PTEN, by signalling for its inactivation and protesomal degradation. In 
human airway epithelial cells, zinc can decrease PTEN activity in a dose and time dependent 
manner. This effect is abolished in the presence of a proteasome inhibitor. The authors of this 
work assessed the decrease in PTEN phosphatase activity by measuring changes in 
phosphorylated AKT levels (Wu et al., 2003). 
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Additional factors that appear to inhibit PTEN activity, include the activation of the c-Jun N 
terminal kinases (JNK) and NFκB (Zhang et al., 2007; Kim et al., 2004). In summary, PTEN 
function can be modified by altering synthesis, catabolism or activity. Processes by which 
PTEN function can be altered include protein localisation, membrane binding, 
phosphorylation, oxidation, acetylation, nitrosylation and ubiquitination (protesomal 
degradation) (Torres and Pulido, 2001; Wu et al., 2003; Meuillet et al., 2004). The following 
sections highlight why a reversible inhibition of PTEN may be clinically desirable when 
targeting ischaemia-reperfusion injury.  
 
1.5.5 PTEN/PI3K/AKT  pathway and cell survival 
PTEN knockout models and conditional tissue specific PTEN deletion models have been 
produced. The published data relating to these models is described over the next sections. 
Figure 1.9 represents the role of PTEN when the PI3K/AKT pathway is stimulated. PTEN is 
thoroughly researched as a tumour suppressor; mutations have been associated with 
proliferative diseases such as Cowden syndrome. In this disease patients suffer multiple 
sporadic haematomas (Pilarski and Eng, 2004). Mice with PTEN deletions (PTEN 
haploinsufficient mice heterozygous for PTEN
+/-) exhibit multiple organ neoplasms, enhanced 
cell proliferation and defective apoptotic abilities. Homozygous littermates (PTEN
-/-) do not 
survive gestation further than embryonic day E6.5 (Podsypanina et al., 1999).  
 
PTEN is negatively involved in growth and development. For example PTEN can regulate 
axon cell growth. In hippocampal neurons the presence of nerve growth factor (NGF) can 
induce cell elongation and growth. The authors of this work attributed this to the activation of 
CK2, which phosphorylates PTEN at Ser380 and decreases PTEN activity; as indicated by 
increased phosphorylation of AKT and GSK3β (Arevalo and Rodriguez-Tebar, 2006). 
Moreover the authors demonstrate that the presence of 0.2µM dipotassium bisperoxo Hilary Siddall 
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(pyridine-2-carboxyl) oxovanadate (bpV(pic)), a PTEN inhibitor, can increase phosphorylation 
of AKT and GSK3β to promote axon elongation and growth (Arevalo and Rodriguez-Tebar, 
2006).  
 
PTEN can delay proliferation and wound repair. In lung epithelial cells PTEN inhibitors 
bpV(pic) and dipotassium bisperoxo (1,10-phenanthroline) oxovanadate, (bpV(phen)), 
increased phosphorylation of AKT and promoted time to wound healing (Lai et al., 2007). 
Similarly PTEN siRNA and dominant negative PTEN transfection, used to limit PTEN activity, 
also decreased the time to wound healing (Lai et al., 2007). Interestingly, PTEN inhibition can 
be used as a tool to study survival, proliferation and growth. The pharmaceutical company, 
Semafore Pharmaceuticals are currently investigating PTEN inhibition as a way of targeting 
the side effects of chemo therapy (Hennessy et al., 2005).  
 
However, recently PTEN has been associated with pro survival. For example the localisation 
of nuclear PTEN has been associated with chromosomal stability and PTEN inhibition has 
been associated with double stranded DNA breaks (Puc and Parsons, 2005; Shen et al., 
2007). Similarly, PTEN has also been associated with mitochondrial pro survival proteins 
such the Ser/Thr kinase PTEN induced kinase 1 (PINK1). This kinase is highly expressed in 
heart, skeletal muscle and testis (Unoki and Nakamura, 2001).  
 
1.5.5.1   PTEN Induced Kinase 1 (PINK1) 
PINK1 was originally discovered in PTEN deficient cancer cells as a gene transcriptionally 
activated by the re-expression of PTEN protein (Unoki and Nakamura, 2001). Therefore, 
PINK1 was hypothesised to be a potential tumour suppressor linked to the PTEN pathway. 
However, when the authors of this work expressed PINK1 in tumour cells surprisingly, tumour 
cell growth was not inhibited (Unoki and Nakamura, 2001).  Hilary Siddall 
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Disruption of PINK1 has been associated with degenerative diseases and cell death. 
Mutations in this kinase have been discovered in patients suffering with autosomal recessive, 
early onset Parkinson’s disease (Valente et al., 2004; Wang et al., 2007a). Silencing PINK1 
using siRNA induces apoptosis in dopaminergic cells and incubation with pesticide rotenone, 
a complex I inhibitor, further increased cell death (Deng et al., 2005).  
 
PINK1 is reported to have a molecular weight of 65Kda and to contain a mitochondrial 
targeting motif (Wang et al., 2007a). It is mainly observed in the mitochondria where it is 
rapidly processed, however a proportion of total PINK1 is also found in the cytosol (Valente et 
al., 2004; Wang et al., 2007a; Lin and Kang, 2008a). PINK1 has been associated with 
protection against neuronal oxidative stress (Deng et al., 2005; Pridgeon et al., 2007) and 
apoptosis (Valente et al., 2004). In HEK293 cells the effects of inducing apoptosis, using the 
proteosome inhibitor MG132, was prevented by over expressing PINK1. In these cells the 
release of cytochrome c and caspase 3 cleavage were minimal. (Wang et al., 2007a). 
Additionally, these cells were protected from atractyloside-induced mPTP opening and cell 
death. These phenomena were abolished in cells transfected with mitochondrial resistant 
PINK1. Therefore, the authors of this work suggested that the protective effects of PINK1 
were dependent on PINK1 localisation in the mitochondria  (Wang et al., 2007a).  
 
Additionally, PINK1 has a role in the survival of neurons: reduced levels can lead to 
enhanced oxidative stress and changes in mitochondria morphology which can decrease 
neuronal viability (Wood-Kaczmar et al., 2008). Collectively, as shown in Figure 1.12 it 
appears that PINK1 is required for mitochondrial function and morphology, in addition to 
cellular survival post oxidative stress. Hilary Siddall 
 
82
PINK1
P
PINK1
HtrA2
PINK1
P
TRAP1
PARKIN Bcl2
Mitochondria Cytoplasm
PINK1 enables Parkin to 
activate IKK complex and AKT 
and maintains Bcl-2 inhibition 
of cytochrome c release.
PINK1 phosphorylates
chaperone TRAP1 and protease 
HtrA2 preventing neurotoxin 
induced apoptosis, generation of 
ROS and cytochrome c release.
PARKIN
P
AKT
IKK complex 
activation
NFκB
PINK1 PINK1
P P
PINK1 PINK1
HtrA2
PINK1
P P
TRAP1
PARKIN Bcl2
Mitochondria Cytoplasm
PINK1 enables Parkin to 
activate IKK complex and AKT 
and maintains Bcl-2 inhibition 
of cytochrome c release.
PINK1 phosphorylates
chaperone TRAP1 and protease 
HtrA2 preventing neurotoxin 
induced apoptosis, generation of 
ROS and cytochrome c release.
PARKIN
P P
AKT
IKK complex 
activation
NFκB NFκB
 
Figure 1.12: Suggested neuroprotective mechanisms of PINK1, adapted by Mills et al., 
2008; p=phophorylated protein. Including, HtrA serine peptidase 2 (HtrA2), IκB kinase 
(IKK), nuclear factor kappa light chain enhancer of activated B cells (NFκβ), PTEN 
induced kinase 1 (PINK1), reactive oxygen species (ROS) and TNF – related activated 
protein (TRAP). 
 
1.5.6  PTEN/PI3K/AKT pathway and the role in cardiovascular system 
1.5.6.1   PTEN and cardiovascular physiology 
PTEN is an important regulator of cell homeostasis and indeed plays a role in controlling 
vascular cell function, growth and development. In mice with endothelial specific knock down 
of PTEN (Tie2CrePten
flox/+) an increase in tumourgenesis can be observed. When stimulated 
with growth factors, VEGF release is enhanced and an increased rate of proliferation, Hilary Siddall 
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migration and angiogenesis is observed (Hamada et al., 2005). These mice do not survive 
past embryonic day 11.5 and die due to cardiac failure and bleeding. The authors of this work 
suggest that this is due to impaired recruitment of cardiomyocytes into the endocardium, and 
smooth muscles cells into the vasculature, during development (Hamada et al., 2005). 
Therefore PTEN is important in controlling vascular development and is involved in regulating 
cell migration and angiogenesis.   
 
Furthermore, PTEN is important in the normal physiology of the heart, as shown in Figure 
1.13. Characterisation of mice with targeted deletions of PTEN in smooth muscle cells, 
reveals the importance of PTEN in the vasculature and cardiac cells. In these mice an 
increase in phosphorylated AKT is recorded in the heart and blood vessels: moreover, 
hyperplasia (an increase in smooth muscle cell number) and vascular remodelling was 
documented. Furthermore, an increase in heart weight and right ventricular hypertrophy was 
observed in the myocardium from these mice (Nemenoff et al., 2008). Similarly, mice with 
targeted PTEN deletions in cardiomyocytes develop cardiac hypertrophy and exhibit reduced 
cardiac contractility. Myocardial phosphorylated AKT and phosphorylated GSKβ levels were 
increased (Crackower et al., 2002).  
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Figure 1.13: The effects of PTEN deletion on cardiac physiology in mouse myocardium. 
1) Heart size (a) and heart sections (stained with trichrome for the detection of 
interstitial fibrosis) (b) from mckCRE-PTEN
∆/+ heterozygous littermates and mckCRE-
PTEN
∆/∆ homozygous mutants (LV = left ventricle and RV = right ventricle). Hypertrophy 
is recorded when compared to control (Crackower et al., 2002). 2) Cross sections from 
control (mckCRE-PTEN
+/+) and PTEN knockout (mckCRE-PTEN
flox/flox) myocardium 
subjected to sham (a) or aortic banding (AB), to achieve pressure overload (b). 
Paradoxically, reduced ventricular distortion in response to pressure overload is 
observed in the PTEN mutants (Oudit et al., 2008). 
 
PTEN can maintain normal cardiac contractility. In mice with targeted deletion of PTEN in 
skeletal muscle, an increase in cardiac L-Type calcium currents has been observed. Blockers 
of these channel are used as anti arrhythmic drugs, indicating that PTEN has a role in Hilary Siddall 
 
85
regulating normal cardiac contraction (Sun et al., 2006). The evidence from these studies 
suggests that growth and survival pathways are enhanced when PTEN is inhibited and that 
PTEN functions to control normal cell development, growth and function of the myocardium 
and vasculature.  
 
1.5.6.2   Diabetes 
PTEN is linked to CVD, diabetes and cardiovascular metabolic syndrome. In diabetes 
suppression of the PI3K/AKT pathway can be observed (Kushner et al., 2005). As described, 
PTEN can negatively regulate the PI3K/AKT pathway and plays a role in glucose uptake. 
Over expression of PTEN can reduce insulin stimulated GLUT4 translocation and 
phosphorylation of AKT and p70S6K (Mosser et al., 2001; Nakashima et al., 2000).  
 
In  isolated diabetic Goto Kakazaki rat hearts the expression of PTEN protein is higher than in 
the non diabetic control (Mocanu et al., 2006). This indicates that Goto Kakazaki rats have 
desensitised insulin signalling pathway in conjunction with increased PTEN level. In addition, 
they display a higher threshold to IPC and consequentially are more difficult to protect against 
ischaemia-reperfusion injury (Tsang et al., 2005). Moreover, a Japanese study of patients 
with type 2 diabetes detected 3 different mutations in the PTEN gene (Ishihara et al., 2003). 
 
Interestingly, muscle specific deletion of PTEN in mice on a high fat diet evade the 
development of diabetes and insulin resistance (Wijesekara et al., 2005). Similar prevention 
studies were performed in diabetic db/db and ob/ob mice with intra peritoneal injections (i.p) 
of PTEN antisense, which reduced PTEN mRNA and protein expression in liver and fat cells. 
Consequentially, these mice displayed normalised blood glucose levels with an increased 
sensitivity to insulin and increased levels of phosphorylated AKT (Butler et al., 2002). Hilary Siddall 
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Collectively, these experiments indicate that PTEN prevents glucose uptake and implicates 
PTEN in the patho-physiology of diabetes.  
 
1.5.6.3   The physiological relevance of PTEN inhibition 
As described above, PI3K/AKT is one of the most important intracellular signalling pathways 
responsible for increasing cell survival and repair (Manning and Cantley, 2007) Activation of 
this pathway is associated with reduced myocardial infarction following ischaemia-reperfusion 
injury (Hausenloy et al., 2005). However, if activated chronically, PI3K/AKT has pro 
hypertrophic and pro oncogenic consequences and therefore this signalling kinase cascade is 
tightly controlled. The most important down regulator of this pathway is PTEN, which 
dephosphorylates PI(3,4,5)P3 preventing AKT activation (Maehama and Dixon, 1998b). 
Potentially, this may have a negative impact upon myocardial survival following an ischaemic 
episode (Mocanu et al., 2006; Mocanu and Yellon, 2007). 
 
PTEN targeted deletions in muscle have been generated (mckCRE-PTEN
flox/flox) and have 
been used to study the effects of PTEN reduction on the myocardium. As described, these 
hearts exhibit reduced contractility and increased heart size (Crackower et al., 2002). 
However, supplementary studies in these animals demonstrate a reduction in detrimental 
vascular cell remodelling subsequent to aortic banding. Such salvage was associated with a 
reduction in pathological hypertrophy, fibrosis, and apoptosis and was attributed to reduced 
phosphorylated JNK and p38 levels. Conversely, no difference in the detrimental remodelling 
effects of angiotensin II were observed in this model (Oudit et al., 2008). Collectively, this 
indicates that enhanced PI3K/AKT (as a consequence of PTEN inhibition) can be beneficial in 
a biomechanical model of cell stress and that PTEN may have a role on vascular remodelling 
and long term heart failure. 
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PTEN is involved in apoptosis (Stambolic et al., 1998) and its inhibition may have a role in 
IPC. Recently work by Cai and Semenza, has implicated PTEN inhibition to IPC induced 
myocardial protection. The group demonstrated that PTEN is oxidised and inhibited, as a 
consequence of IPC (Cai and Semenza, 2005). Hypoxia inducible factor 1alpha (HIF1α) 
signalling may be involved in the oxidation and inhibition of PTEN. In mice hearts with HIF1α 
targeted deletions, IPC induced protection was abolished, and is thought to be due to the lack 
of ROS and PTEN oxidisation (Cai et al., 2008a). Interestingly the presence of the GPCR 
agonist adenosine, used as an IPC mimetic, was sufficient to confer protection in these mice 
(Cai et al., 2008a). This may implicate that divergent mechanisms are involved in 
cardioprotection induced by IPC compared to protection induced pharmacologically. PTEN 
inhibition may have a protective function in CVD and ischaemia-reperfusion injury.  
 
1.6  Additional negative regulators of the PI3K/AKT pathway 
As outlined above and shown in Figure 1.6 PTEN is the main regulator of the PI3K/AKT 
pathway. However there are other phosphatases that negatively regulate this pathway, such 
negative regulators are described in more detail below. 
 
1.6.1  SH containing inositol phosphatase 2 (SHIP2) 
The SH containing inositol phosphatase 2 (SHIP2) protein is a lipid phosphatase that 
negatively regulates the PI3K/AKT pathway (Chi et al., 2004). It has a predicted molecular 
weight of 142kDa and is highly expressed in heart, skeletal, placental and insulin sensitive 
tissues (Pesesse et al., 1997).  
 
SHIP2 appears to have an important role in the PI3K/AKT signalling by regulating the 
PI(3,4,5)P3 to PI(3,4)P2 ratio. Over expression of SHIP2 can result in a decrease of Hilary Siddall 
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phosphorylation of AKT (Sasaoka et al., 2004). Increased SHIP2 activity is associated with 
enhanced plasma membrane localisation facilitating a decrease in PIP3 production and 
reduced phosphorylation of AKT (DeKroon et al., 2006). SHIP2 has a role in proliferation and 
growth (Pesesse et al., 1997). The activity of this phosphatase is to convert PI(3,4.5)P3 into 
PI(3,4)P2 (Chi et al., 2004). Insulin stimulation in cells over expressing SHIP2 indicates that 
this phosphatase has a role negatively regulating PI3K/AKT activity (Marion et al., 2002). 
Unlike PTEN, the inhibition of SHIP2 has not been associated with formation of cancers, 
however the reason for this is unknown (Lazar and Saltiel, 2006).  
 
SHIP2 appears to have an important role in regulating insulin signalling. In patients with type 
2 diabetes genetic mutations have been observed and correlated with enhanced SHIP2 
mRNA and protein expression (Marion et al., 2002). In diabetic Goto-Katizaki rats, mutations 
in the SHIP2 gene have been recorded (Marion et al., 2002). Additionally, the development of 
insulin resistance in C57BL/J6 mice subjected to a high fat diet provokes increases in SHIP2 
protein expression in skeletal and fat tissue (Hori et al., 2002). Furthermore, db/db diabetic 
mice develop an increase in SHIP2 protein expression in skeletal and fat tissue. There is a 
diminished response to insulin treatment in these mice and less PI3K/AKT and PKC activity is 
recorded compared to control mice (Hori et al., 2002). 
 
1.6.2  PH domain leucine rich repeat protein phosphatase (PHLPP)  
PH domain leucine rich repeat protein phosphatase (PHLPP) is a ubiquitously expressed 
phosphatase, with the highest levels detected in the brain. It has a molecular weight of 
140Kda and contains a PH domain, leucine rich repeat motif, PP2C domain and PDZ binding 
region (Gao et al., 2005b).   
 
PHLPP functions as negative regulator of the PI3K/AKT pathway and it can directly bind to 
AKT. Over expression studies demonstrate that PHLPP dephosphorylates AKT at Ser473 but Hilary Siddall 
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not the Thr308, consequentially increasing apoptosis (Gao et al., 2005b). This data suggests 
that PHLPP is a key protein phosphatase acting at the AKT Ser473 phosphorylation site. The 
above authors showed that, by deleting the PDZ domain of PHLPP, the dephosphorylation of 
AKT is abolished, indicating that PHLPP is active at the plasma membrane (Gao et al., 
2005b). In addition PHLPP can dephosphorylate PKC, for which the PHLPP PH domain is 
required, indicating the structure of PHLPP can influence its activity (Gao et al., 2008b).  
 
In tumour cell lines, a reduction in PHLPP protein expression and increased AKT activity can 
be observed. Over expression of PHLPP in mice exhibiting tumour formation display a 68% 
reduction in tumour size (Gao et al., 2005b). Collectively, this indicates that PHLPP is a 
protein phosphatase involved in dephosphorylating AKT, suppressing tumour growth and 
inducing apoptosis (Gao et al., 2005b).  
1.6.3  Protein phosphatase 2A 
Protein phosphatase 2A (PP2A) is involved in regulating AKT, functioning as a negative 
regulator of the PI3K/AKT pathway. This phosphatase directly inactivates AKT in the cytosolic 
and membrane fractions of the cell and is involved in cell death and apoptosis. The PP2A 
inhibitor okadaic acid can reduce phosphatase activity and consequentially increase 
phosphorylation of AKT at Ser473 and Thr308 and reduce cell death (Resjo et al., 2002; Liu 
et al., 2003).  
 
In addition PP2A can bind and dephosphorylate the pro survival protein Bcl2, preventing its 
anti apoptotic activity. (for a review on PP2A and apoptosis see Garcia et al, 2003). There is 
evidence to suggest that PP2A inhibition is protective against ischaemia-reperfusion injury. In 
an isolated rat heart model of ischaemia-reperfusion injury the presence of the PP2A inhibitor 
okadaic acid reduced PP2A activity to bestow cardioprotection. In addition, the authors of this 
work demonstrate that, in the ageing rat heart (which are not protected by IPC), there is Hilary Siddall 
 
90
enhanced PP2A activity (Fenton et al., 2005). This indicates that PP2A has a role in cell 
death, negatively regulating PI3K/AKT signalling. 
 
1.7 Summary 
Activation of the prosurvival PI3K/AKT pathway can reduce apoptosis and protect against 
myocardial ischaemia-reperfusion injury (Hausenloy et al., 2005; Davidson et al., 2006). The 
main regulator of this pathway is PTEN, a lipid phosphatase that dephosphorylates 
PI(3,4,5)P3 into PI(4,5)P2 and limits AKT activation (Maehama and Dixon, 1998b; Lee et al., 
1999). Inhibition of this phosphatase can enhance the PI3K/AKT pathway (Butler et al., 2002; 
Arevalo and Rodriguez-Tebar, 2006). Reduction of PTEN function may have a role in tissue 
salvage following an acute injury such as that observed in myocardial ischaemia-reperfusion 
injury. However, studying the reversible inactivation of PTEN would be required in order to 
avoid chronic PI3K/AKT activation. In this thesis methods to decrease myocardial PTEN were 
investigated to explore the effects of reduced PTEN on ischaemia-reperfusion injury. Hilary Siddall 
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1.8 Hypothesis 
That PTEN reduction would be cardioprotective against ischaemia-reperfusion injury; 
by enhancing the PI3K/AKT prosurvival pathways and decreasing the extent of cell 
death. Aim: To investigate the role of PTEN down regulation in cardioprotection. 
 
In order to investigate the hypothesis above the following methods were used: 
1)  Chemical inhibition of PTEN (bpV(HOpic 
2)  ) and SF1773). 
3)  Biochemical modulators of p53 (pifithrin alpha). 
4)  Genetic modifications of PTEN (congenital haploinsufficient PTEN
+/- mouse). 
5)  Genetic modifications of PTEN (small interfering RNA induced PTEN knockdown in 
H9c2 cells). 
The experimental models used were: 
1)  An isolated perfused mouse heart model of global ischaemia-reperfusion injury. 
2)  A cellular model of reactive oxygen species induced mitochondrial damage. 
3)  A cellular model of hypoxia-reoxygenation injury. 
The end points measured were:  
1)  Cell death, measuring infarct size developed in the ischaemic-reperfused 
myocardium, and time to mPTP opening and caspase 3 cleavage in the cellular 
models of simulated ischaemia-reperfusion injury. 
2) The myocardial protein expression of kinases and phosphatases implicated in 
ischaemia-reperfusion injury, using Western blot technique. Hilary Siddall 
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2  Chapter 2 – General methods 
2.1  Overview of experimental Models 
We investigated the consequence of reducing PTEN level upon myocardial ischaemia- 
reperfusion injury. We used a variety of experimental models, which are outlined in this 
section and are described in more detail in the remaining sections of this chapter. Within each 
experimental chapter we described the specific protocols used, relevant to the investigation. 
All chemicals and reagents were purchased from Sigma Aldrich, UK unless otherwise stated.  
 
2.1.1 Animal  strains 
All investigations using animals were carried out under the Home Office guidelines for the 
Animals (Scientific Procedure) Act 1986. Male NIH-Swiss White mice (10-15 weeks, 20-30g) 
(Charles River, UK) and male C57BL/J6 mice (10-15 weeks, 20-30g) (Charles River, UK) 
were used. In addition PTEN haploinsufficient mice (PTEN
+/-), donated by Dr D Alessi 
(Dundee University) with the permission of Raymon Parson (the original producer of these 
mice as described by Podsypanina et al., 1999), were bred in house. 
 
2.1.2  Whole organ models used to investigate the effect of reduced PTEN 
level on myocardial ischaemia-reperfusion injury 
We used a Langendorff model of isolated perfused mouse hearts to investigate infarct size 
resulting from ischaemia-reperfusion injury. In parallel with infarct measurements, Western 
blot techniques were used to monitor levels of pro and anti apoptotic markers. In these 
studies we used myocardium (perfused with chemical inhibitors of PTEN) from C57BL/J6 and 
isolated hearts from the PTEN
+/- mouse strain. Hilary Siddall 
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We attempted to reduce PTEN levels using pharmacological and molecular mechanisms. 
Targeting the molecular reduction of PTEN, we aimed to inhibit the transcription of PTEN by 
reducing p53 levels, as described in chapter 5. The p53 inhibition studies were performed in 
NIH-Swiss White mice.  
 
2.1.3 Cell models used to investigate the effects of reduced PTEN level 
on simulated ischaemia-reperfusion injury  
We used two cellular models of simulated ischaemia-reperfusion injury, outlined below, to 
study the effects of reduced PTEN on myocardial cell damage.  
 
1)  Isolated primary myocytes from PTEN
+/- mice and their littermate controls were used 
to investigate their sensitivity to ROS induced mitochondrial damage. This was done 
by measuring the time to mitochondrial permeability transition pore opening, using 
confocal microscopy.   
 
2)  H9c2 rat myoblast cells were subjected to simulated ischaemia-reperfusion injury 
using a model of hypoxia-reoxygenation. PTEN protein expression was silenced using 
siRNA. Western blot analysis was used to investigate changes in caspase 3 cleavage 
subsequent to simulated ischaemia-reperfusion to assess the cell damage.  
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2.2  Langendorff model of isolated perfused hearts  
2.2.1  The concept of the isolated perfused heart 
In the early 1900s Oscar Langendorff was one of the first to study and develop the model of 
isolated retrograde perfused myocardium (Zimmer, 1998; Skrzypiec-Spring et al., 2007). A 
simplified representation of the equipment and principle of the model is shown in Figure 2.1. 
This technique maintains cardiac activity and permits analysis of isolated hearts. Perfusion 
buffer flows to the heart, through a cannula placed in the ascending aorta. The pressure of 
the retrograde perfusion causes the aortic valves to close, forcing perfusion buffer into the 
coronary system, mimicking the conditions during diastole. The cardiac chambers are mainly 
empty through out perfusion whilst the buffer finally flows off the coronary sinus in the right 
atrium. This method can be used to maintain the cardiac activity for several hours. In this 
study we used a standard Langendorff ML870B2 perfusion apparatus (AD Instruments, UK) 
modified for perfusion of mouse hearts. We used a system of constant perfusion pressure 
where, changes in flow rate indicated changes in coronary vessel resistance. This 
measurement can be used as an indicator of vasoconstriction or vasodilatation. 
Haemodynamic recordings were converted to electronic data through a PowerLab system 
and monitored using MacLab Chart 4.3 software. (AD Instruments, UK) Figure 2.2 and Figure 
2.3 show the apparatus set up and Figure 2.4 represents a typical Chart 4.3 tracing, when 
perfusing an isolated murine myocardium. More importantly, this method can be used to 
study the effects of ischaemia-reperfusion injury on isolated functional whole hearts. The 
details of the methods used to study this are described below. We performed optimisation 
experiments for the Langendorff perfusion of mouse hearts, which are described in chapter 3.  
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Figure 2.1: Schematic representation of a Langendorff experimental system used to 
study isolated perfused heart preperations, including a photo of Oscar Langendorff. 
O2 (oxygen), CO2 (carbon dioxide) and ECG (electrocardiogram). 
http://www.med.uio.no/imb/fysiol/valen/pictures/Langendorff.gif  
 
2.2.2  Preparation of hearts for isolated Langendorff perfusion 
Mice were injected with 500U of heparin, i.p, 10 min prior to culling by cervical dislocation. 
The hearts were then removed and placed in ice cold perfusion buffer. As a consequence of 
the low temperature, hearts stopped beating. This temporary hypoxia eased the cannulation 
process but also, more importantly, reduced the metabolic processes and the amount of 
protease activity, and therefore, minimised cell damage. The myocardium was trimmed to 
expose the aorta which was cannulated with a 22 gauge murine cannula (ADinstruments,UK), 
secured with a 5/0 silk tie (Syneture,USA) and attached to the Langendorff apparatus, making 
sure to avoid air bubbles. Hearts were then retrogradedly perfused at a constant perfusion Hilary Siddall 
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pressure of 80-100 mmHg which matches the physiological pressures required to adequately 
supply the mouse coronary arteries. The perfusion buffer used was an oxygenated (bubbled 
with 95%O2/5% CO2 to pH 7.3-7.4) Krebs-Henseleit buffer containing 118mM NaCl, 25mM 
NaHCO3, 11mM Glucose, 4.7mM KCl, 1.22mM MgSO4.7H2O,1.21mM KH2PO4 and 1.84mM 
CaCl2.2H2O. 
 
A.
B.
C.
D.
E.
 
Figure 2.2: The perfusion system used for studying isolated mouse hearts: A) 
dissection area, B) cannulation area, C) perfusion apparatus, D) PowerLab electronics 
and E) computer used for data acquisition. 
 Hilary Siddall 
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1) 2)
A)
B)
C)
B) A)
C)
 
Figure 2.3: 1) Isolated mouse heart, mounted on the perfusion apparatus: pressure 
transducer used to measure A) perfusion pressure and B) left ventricular pressure and 
C) the heated water reservoir used to warm the perfusion buffer. 2) Closer image of the 
isolated mouse heart on the perfusion apparatus: A) cannulated heart, B) balloon 
inserted into the left ventricle of the heart to measure ventricular pressure and C) 
heated glass water jacket to surround the heart.  
 
2.2.3  Measuring heart function in the Langendorff perfused myocardium 
Haemodynamic parameters were measured to ensure fully functional hearts were used in all 
experiments and only healthy hearts were included. To minimise experimental error and to 
eliminate false positive or negative results, strict inclusion/exclusion criteria were set and 
adhered to, shown in Table 2.1.  
 
Coronary flow was recorded by measuring the volume of perfusion buffer per minute required 
to maintain the set perfusion pressure. This closed circuit included a pressure transducer, 
attached to a fluid filled tube which was connected to the Langendorff apparatus (just above Hilary Siddall 
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the heart attachment point), which provided a feedback into a pump controller 
(ADInstruments,UK). This adjusts flow of perfusion buffer to achieve the fixed perfusion 
pressure, which was set between 80-100mmHg.  
 
The status of the heart, was measured using a pressure transducer connected to a water 
filled balloon (roughly 4 mm x 3mm) inserted in the left ventricle and inflated to 5 –10 mmHg. 
The balloon detects the left ventricular end diastolic pressure (LVEDP) and left ventricular 
peak pressure (LVPP, the maximum pressure in systole). Left ventricular developed pressure 
(LVDP) is a measure of the force of contraction which was calculated by subtracting LVEDP 
from LVPP. Heart rate (HR) was calculated based on the number of systole-diastole cycles 
per minute. The rate pressure product (RPP) is an arbitrary measurement of heart function, 
which was obtained by multiplying HR by LVEP.  
 
The temperature of the circulating perfusion buffer was adjusted in order to maintain the 
myocardium at 37±0.5°C. A desk lamp and a heated glass water jacket were additionally 
used to assist in controlling any smaller temperature fluctuations of the heart. The 
temperature was measured by placing a thermometer probe (T type) connected to a thermo 
pod and coupler (AD Instruments,UK) at the heart.  
 
These haemodynamic parameters were recorded during a stabilisation period to ensure the 
hearts were functioning well. Any hearts with parameters which did not fit within the inclusion 
criteria, listed in Table 2.1 were excluded. A representation of a Chart 4.3 tracing during 
stabilisation is shown in Figure 2.4.  
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Table 2.1: Inclusion criteria for isolated hearts undergoing Langendorff perfusion. 
(BPM = beats per minute).  
Measurement Inclusion  criteria 
Time from extracting the heart to perfusion  ≤ 5 min 
Coronary flow  1.0 - 6.0 ml/min 
Heart rate  ≥ 300 BPM 
Temperature  37.0 ± 0.5 °C 
 
 
Figure 2.4 Typical Chart 4.3 tracing obtained during the stabilisation period of an 
isolated perfused mouse heart.  BPM = beats per minute. 
 Hilary Siddall 
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2.2.4 Ischaemia-reperfusion  protocols in the isolated heart. 
The standard protocol used for studying ischaemia-reperfusion injury in isolated perfused 
hearts is shown below and described in more detail in the following respective chapters. 
Myocardial injury was determined at the end of the protocol by measuring infarct size which is 
described below.  
 
The control ischaemia-reperfusion protocol consisted of 30 min stabilisation followed by 35 
min global ischaemia and 30 min reperfusion, as shown in Figure 2.5. Global ischaemia was 
achieved by interrupting the flow of perfusion of buffer, which was completely switched off. 
Sudden cooling of the heart during this time was avoided by submerging the heart in 
perfusion buffer (submersion buffer) at 37±0.5
oC.  
 
=  infarct measurement (I/R%) using TTC staining
35min global 
ischaemia
30min 
reperfusion
30min stabilisation
=  infarct measurement (I/R%) using TTC staining
35min global 
ischaemia
30min 
reperfusion
30min stabilisation
 
Figure 2.5: Langendorff control ischaemia-reperfusion protocol. Infarct size was 
measured as the percentage of infarction to risk area (I/R%), at the end of the 
reperfusion period, using triphenyltetrazolium chloride (TTC) (white areas represents 
the infarct and red areas the viable myocardium).  
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2.2.5  Ischaemia-reperfusion injury: analysis of infarct size 
At the end of the reperfusion period, hearts were taken off the perfusion apparatus and 
perfused, through the aortic cannula, with 1% pre-warmed triphenyltetrazolium chloride (TTC) 
which acts as a viability dye. Hearts were subsequently immersed in TTC and incubated at 
37
oC for 10 min, after which they were weighed and frozen at -20
oC for 24h. Whilst still 
frozen, hearts were sliced from base to apex at a thickness of ≈1mm. The slices were fixed in 
10% formalin for 12h to define the stain borders. 
 
The TTC is a redox indicator and can stain areas of viable myocardium red. This is because 
viable cells (with intact membranes) retain the dye where it can react with dehydrogenases 
and NADPH. In the presence of oxygen these enzymes can reduce TTC, causing a 
conversion into a red colour (Klein et al., 1981). Areas of tissue containing non 
viable/infarcted cells have lost their dehydrogenases, due to wash out in reperfusion, and are 
unable to retain or convert the dye and therefore emerge unstained and white in appearance. 
Examples of a mouse myocardium subjected to ischaemia-reperfusion and stained for 
infarction with TTC is shown in Figure 2.5 and 2.6.  
 
Heart slices were then photographed on a perspex mounting block using a digital EsKape 
(Eskape, NY, USA) fixed camera. NIH Image 1.63 software was used to calculate the 
infarcted areas and the results were expressed as a % of the whole heart at risk of damage 
induced by ischaemia-reperfusion injury (I/R%) and presented as means ± standard error of 
the mean (SEM). A t-test or a one way ANOVA test were used to assess the differences 
between groups, as described in the statistics section further in this chapter. The results were 
considered significantly different when p≤ 0.05. 
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Figure 2.6: Mouse myocardium subjected to: A) global ischaemia-reperfusion only and 
B) global ischaemia-reperfusion with ischaemic preconditioning as a cardioprotective 
stimulus, following triphenyltetrazolium chloride staining. Viable myocardium was 
stained red however; the infarcted tissue does not retain the dye and remains white.   
 
2.3  Ischaemia-reperfusion injury and pharmacological inhibitors of 
PTEN 
We used the PTEN inhibitors bisperoxo(5-hyroxypyridine-2carboxy) oxovanadate 
(bpV(HOpic)) and SF1773, a small peptide donated from Semafore Pharmacuticals, USA to 
reduce PTEN function. Secondly, we aimed to inhibit p53, using pifithrin alpha (PFTα) a p53 
inhibitor purchased from Calbiochem, UK, as a potential tool to down regulate PTEN; as 
described in Chapter 5. The PTEN inhibitors bpV(HOpic) and SF1773 were diluted in water, 
the p53 inhibitor PFTα was diluted in 0.1%DMSO/0.9%saline and the pharmacological 
cardioprotective positive control (orthovanadate) was diluted in water. The chemical 
structures of these molecules are shown below in Figure 2.7.  
B: Myocardial protection   A: Ischaemia-Reperfusion injury  Hilary Siddall 
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Figure 2.7: Chemical structure of: A) orthovanadate (Na3VO4), B) the PTEN inhibitor 
bpV(HOpic) (K2[VO(O2)2)C6H4NO3], C) the PTEN inhibitor SF1773 (C20H13NO4S) and D) 
the p53 inhibitor pifithrin alpha (C16H18N2OS.HBr).  
 
2.4 PTEN:  haploinsufficient  mice 
2.4.1 Breeding 
A breeding rota within UCL Biological Services was established; PTEN 
+/+ and PTEN 
+/- mice 
were crossed, using male PTEN
+/- as the preferred haploinsufficient carrier. Female PTEN 
+/- 
can breed but only for a few months as they suffer endometrial tumours, and each litter 
contains fewer pups until they cease producing litters. The PTEN
-/- pups are not recorded 
alive beyond embryonic day 6.5; the PTEN
+/- survive gestation, although they develop early 
B.  A. 
D.  C. Hilary Siddall 
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onset of sporadic tumours (Podsypanina et al., 1999). Male animals are used in 
investigations between the ages of 10-15 weeks, unless otherwise stated.  
 
2.4.2  Genotyping PTEN haploinsufficient mice 
2.4.2.1   DNA extraction 
DNA was extracted from mouse tail tip (0.5cm long) or ear punches and processed using 
Qiagen DNeasy kit (Qiagen, UK), according to the manufacturer’s instructions.  Tissues were 
lysed overnight at 55
oC in a proteinase K lysis buffer (40mAU/mg protein). This enzyme is a 
serine protease which facilitates protein degradation to reveal nucleic acids. Samples were 
then incubated in an ethanol-lysis buffer and added to individual spin columns, which allowed 
the DNA to bind the silica gel membrane as a consequence of the differences in electron 
charges. The membranes were then washed twice by centrifugation with optimized buffer, 
which prepares the column for removal of the DNA. The elution buffer/DNA absorbance ratio 
at A260/A280 (1.8-2.0) is an indicator of good DNA purity. 
 
2.4.2.2   DNA amplification and visualisation 
Polymerase chain reaction (PCR) was used to amplify the DNA. This technique facilitates the 
exponential amplification of DNA and enables further analysis of the DNA extract. The PCR 
protocol was originally provided by Gail Fraser from the University of Dundee and the settings 
were adapted to the Hatter Laboratory.  The primer sequences were as follows. PTEN Wild 
type - 5’ GTC TCT GGT CCT TAC TTC C 3’, PTEN common   - 5’TTG CAC AGT ATC CTT 
TTG AAG 3’, PTEN neo/NEW - 5’ACG AGA CTA GTG AGA CGT GC 3’. 0.5µM primers 
(MWG, Germany), 2.5mM MgCl, 0.2mM dNTPs mix and 1unit Taq Polymerase (all from 
Promega, UK) were mixed with approx 10ng DNA, and run on a thermocycler under the 
conditions shown in Table 2.2. The amplified DNA was analysed on a 2% agarose gel with Hilary Siddall 
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ethidium bromide, which intercalates between nucleic acid bases and fluoresces orange 
when exposed to UV light. The PCR amplification products reveals either a wild type 
phenotype (from littermate control PTEN
+/+) or a haploinsufficient phenotype (from PTEN
+/-); 
consisting of one band running to 240bp or two bands running to 240bp and 320bp, 
respectively.  
 
Table 2.2: PTEN PCR conditions. 
 
Step Temp  (
oC) Time  (min) 
1 94  5 
2  94  0.5 (Separates dsDNA) 
3  55  0.5 (Annealing of primers) 
4  72  2 (DNA synthesis) 
5  Cycle steps 2-4  34 cycles (Amplification) 
6 72  7 
7 4  Finish 
 
 
2.5  PTEN ELISA (activity assay) 
2.5.1  The concept of the ELISA assay 
The PTEN activity assay was purchased from Echelon Biosciences Incorporated, USA and 
has been successfully used to detect PTEN phosphatase activity (Eickholt et al., 2007; 
Papakonstanti et al., 2007). The assay used was based on an Enzyme-Link ImmunoSorbant 
Assay (ELISA), which utilizes several antigen antibody binding reactions to quantify a protein 
of interest. Antibodies that are enzyme tagged can be used to assess the amount of target 
protein present in a sample. These enzymes are used to produce a detectable signal, which Hilary Siddall 
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can be measured either using a substrate that will emit a colour or fluorescence. A 
description of the assay used to detect PTEN phosphatase activity is outlined in Figure 2.8.  
 
 
 
Figure 2.8: Steps involved in the PTEN ELISA assay, used for detecting PTEN 
phosphatase activity. 1) phosphatidylinositol 3 phosphate (PI(3,4,5)P3) was pre coated 
on the ELISA substrate plate. (Echelon, USA) 2) Myocardial tissue homogenates were 
incubated on the substrate plate. 3) Antibodies that recognised phosphatidylinositol 2 
phosphate (PIP(4,5)P2) were then added. 4) A secondary antibody, which reacts with 
the PIP(4,5)P2 detection antibody, tagged with horseradish peroxidase (HRP) was 
added. 5) A tetra methyl benzidine (TMB) chromogenic reagent was then added. 6) The 
TMB reagent reacts with HRP to create a blue colour, which is proportional to the 
amount of PIP(4,5)P2. 7) sulfuric acid (H2SO4 was added to each well to stabilise and 
stop the reaction. The intensity of the blue colour could be measured at 450nm on an 
absorbance spectrophotometer. 
 
PI(4,5)P2 
PI(3,4,5)P3  Sample containing 
PTEN enzyme 
PI(4,5)P2 detector 
Secondary HRP detector 
TMB 
1  3 4 5  6 
1 
7 8  2 
H2SO4 450nm  BlankHilary Siddall 
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2.5.2 Enzyme  preparation 
Myocardium samples were collected and homogenised as described in the Western blot 
protocol, below. According to the manufacturer’s instructions, PTEN samples were diluted in 
PTEN enzyme reaction buffer (10mM HEPES, 150mM NaCl including 10mM dithiothreitol 
(DTT) added just prior to use). Samples were incubated on a substrate plate (pre-coated with 
PI(3,4,5)P3), in replicates of 3. Wells pre-coated in various concentrations of PI(4,5)P2 were 
provided with the assay and used as the standard curve. 10nM of the PTEN Enzyme 
(Echelon,USA) was purchased as a positive control. The sample wells were then incubated at 
37
oC for 1hr. Sample wells were then washed 3x with 300ul TBS-Tween 20 ((Tris buffered 
saline (TBS)10mM Tris, 150mM NaCl, pH7.4) + 0.05% Tween 20). 
 
2.5.3 Detection of PTEN activity by measuring conversion of PI(3,4,5)P3 
into PI(4,5)P2 
 
Detection of converted PI(4,5)P2 was initiated by the addition of the PI(4,5)P2 detector, 
provided with the assay. The PI(4,5)P2 detector was prepared in TBS-goat serum (TBS + 1% 
goat serum (Gibco/Invitrogen, UK). The reaction was incubated at RT for 1hr. Reaction wells 
were then washed 3x with 300ul TBS-Tween 20. The detector-PI(4,5)P2 reaction was then 
identified by the addition of a Horse Radish Peroxidase (HRP) conjugate solution, prepared in 
TBS-goat serum and incubated at RT for 1hr. Reaction wells were then washed 3x with 300ul 
TBS-Tween 20. Tetra methyl benzidine (TMB), a chromogenic substrate of HRP, was added 
to each well and incubated in the dark at RT for 15-30 min. In the presence of hydrogen 
peroxide, HRP oxidises TMB causing the emission of a blue colour. When sufficient colour 
was developed the assay reaction was terminated by adding a sulphuric stopping solution 
(0.5M sulphuric acid). This final oxidisation step of the TMB by the peroxide solution turns the 
reaction yellow. The absorbance of the samples were then measured, using a 96 well plate Hilary Siddall 
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absorbance reader (Dynex technologies, USA with a Revelation software platform) at 450nm 
wavelength. The average absorbance values were calculated and used as an indicator of 
PI(3,4,5)P3 conversion into PI(4,5)P2 which was therefore, indicative of PTEN phosphatase 
activity. An example of the expected standard curve was supplied with the assay protocol and 
is shown below in Figure 2.9. 
     
Figure 2.9: Expected phosphatidylinositol 2 phosphate (PI(4,5)P2) standard curve, 
provided in the Echelon PTEN ELISA assay kit. 
 
2.6  Simulated ischaemia-reperfusion injury in an isolated 
cardiomyocyte cell model  
We used a cellular model of ROS induced mitochondrial damage to determine the response 
of the mitochondria in isolated cardiomyocytes, to this aspect of simulated ischaemia-
reperfusion injury. Ischaemia-reperfusion injury has been linked to the opening of the mPTP, 
therefore we use a cellular model to mimic this phenomenon  (Halestrap et al., 2004). To 
investigate this primary adult cardiomyocytes were isolated from the myocardium of PTEN
+/- 
mice and cells were loaded with the cationic dye, tetra methyl rhodamine methyl (TMRM) 
which is highly selective for normally functioning mitochondria due to its negative charge. A 
Confocal microscope was used to excite TMRM using a HeNe (Helium/Neon) 543nm laser. Hilary Siddall 
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When used at relatively high concentrations of 3µM, the fluorescence of the dye, highly 
concentrated within the mitochondria, is quenched. Upon mPTP opening the dye is released 
into the cytosol, the effective concentration in the larger volume is decreased, and detected 
as an increase in fluorescence. The excitation of the TMRM dye in the mitochondria 
generates ROS (predominantly superoxide, O2
-) that induces mPTP opening and 
mitochondrial depolarisation (Zorov et al., 2000; Davidson et al., 2006). We measured the 
time to depolarisation as an indicator of ROS induced mitochondrial damage and cell death. 
This protocol is an established method that has been validated within the Hatter 
Cardiovascular Institute and is described in more detail below (Hausenloy et al., 2003; 
Davidson et al., 2006; Lim et al., 2008).  
 
2.6.1  Isolation of ventricular cardiomyocytes 
Mice were injected (i.p) with 500U of Heparin (CP Pharmacuticals,Wrexham, UK) 30 min prior 
to anaesthetic, which consisted of  a 0.01ml/g i.p injection of a Ketamine (10mg/ml)/Xylazine 
(2mg/ml)/Atropine (0.06mg/ml) reagent. The heart was excised and immediately placed in ice 
cold calcium free perfusion buffer. The heart was trimmed and the aorta was rapidly 
cannulated with a 22 gauge murine cannula (ADinstruments, Oxford, UK) and secured with a 
5/0 surgical silk tie. (Syneture Technologies,USA). The heart was attached to the Langendorff 
perfusion apparatus where it was perfused retrogradely at 3mls/min, with pre warmed (37
oC) 
oxygenated (95%O2/5%CO2) calcium free perfusion buffer for 4 min. Calcium free perfusion 
buffer consisted of 113mM NaCl, 4.7mM KCL, 0.6mM KH2PO4, 0.6mM Na2HPO4, 1.2mM 
MgSO4.7H2O, 12mM NaHCO3, 10mMKHCO3, 30mM Taurine, 10mM HEPES, 11mM Glucose 
and 10mM 2,3-Butanedione monoxime (BDM). The reagent, BDM, is used in the buffer to 
inhibit myocardial contraction during isolation. Time from heart excision to perfusion on the rig 
was within 3 min. The heart was then perfused with pre-warmed oxygenated digestion buffer 
for 10 min. Digestion buffer consisted of 220U/ml of type 2 Collagenase (Worthington,UK), Hilary Siddall 
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which breaks down the collagen connections in the heart and 55U/ml Hyaluronidase, which 
breaks down hyaluronic acid and is used to assist digestion by permeablising the cell 
membrane. These enzymes were dissolved in the calcium free perfusion buffer 
supplemented with 12.5µM CaCl2.  
 
Following the initial 10 min digestion step the ventricles were collected in 3-5mls of digestion 
buffer and torn apart for additional tissue disruption. The tissue was digested further by 
incubating the mixture with 95%O2/5%CO2 in a shaking incubator (170rev/min) at 37
oC for 5 
min. A second and final digestion step was performed by adding 5mls fresh digestion buffer 
followed by 10 min incubation with 95%O2/5%CO2 in a shaking incubator at 37
oC. The 
following extraction steps were performed under sterile conditions. The ventricular cell 
suspension was transferred to a fresh tube and 5% foetal bovine serum (FBS) 
(Gibco/Invitrogen,UK) was added. The ventricular cells were centrifuged at a 600 relative 
centrifugal force (RCF)  for 3 min to separate the larger, myocyte pellet. The smaller 
fibroblasts and remaining connective tissue in the supernatant were discarded. The myocyte 
cell pellet was re-suspended in a low calcium buffer, which consisted of the calcium free 
perfusion buffer supplemented with 12.5µM CaCl2. Small volumes of calcium was re-
introduced to the myocyte suspension every 4 min to gradually reach a final concentration of 
1mM. The cells were then centrifuged at 600 relative centrifugal force (RCF) for 3 min and re-
suspended in 1-2mls plating media which consisted of Medium-199 (Sigma,UK) 
supplemented with 2mg/ml Bovine Serum Albumin (BSA) (VWR, Lutterworth, UK) 0.66mg/ml 
Creatine, 0.662mg/ml Taurine, 0.322mg/ml Carnitine, 50U/ml Penicillin (Gibco/Invitrogen,UK) 
and 5µg/ml Streptomycin  (Gibco/Invitrogen,UK) and 25µM blebbistatin a cell cycle and 
myosin II inhibitor. (Calbiochem, Nottingham,UK) The cell suspension was then added to a 
glass cover slip, 22mm diameter (VWR, Lutterworth, UK) pre-coated with laminin (1mg/ml) to 
aid cell adhesion. Cells were left to adhere for 1hr in the cell culture incubator (New Bruswick 
Scientific, Hertfordshire,UK)  at 37
oC, 95%O2/5%CO2 and 90% humidity. Each cover slip was Hilary Siddall 
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washed with plating media and the adhered cardiomyocytes were supplemented with 1ml of 
fresh plating media. The morphology of a typical myocyte isolation preparation is shown 
below in Figure 2.10.      
 
 
Figure 2.10: Typical morphology of isolated murine myocytes, viewed under light 
microscope. 
 
2.6.2  Preparations of the cells for imaging mitochondria 
The cover slip containing the isolated cardiomyocytes was removed from the plating media 
and gently blotted dry. The cover slip was then inserted into the confocal metal ring, as 
shown in Figure 2.11. Cells were covered with a 3µM solution of TMRM (Sigma,UK) diluted in 
imaging buffer (which consisted of low calcium perfusion buffer without BDM and 
supplemented  with 10mM HEPES pH 7.4 to maintain pH and 1.2mM CaCl2). The cells were Hilary Siddall 
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incubated with the dye for 15 min at room temperature. The TMRM containing media was 
removed and cells were incubated at RT for 5 min in either imaging buffer alone or CsA 
(0.4µM, diluted in imaging buffer) used as a positive control. Using microscope oil as an 
interface between the objective and cover slip the cells were mounted onto the confocal 
microscope ready for visualisation of the mitochondria.  
 
C. A. B.
 
 
Figure 2.11: Metal rings (A,B) used to secure (C) cover slips, which are coated with 
myocytes, prior to viewing on the confocal microscope. 
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2.6.3  Visualising the mitochondria and measuring time to reactive 
oxygen species induced depolarisation.  
Marvin Minsky was the founder of 3D microscopic imaging, using multiple fluorescent 
labelling, of living cells and tissues. The use of confocal microscopy has continued to expand 
(Paddock, 2000). We used pinhole confocal microscopy for fluorescent imaging of 
mitochondria. The cells on the cover slip were secured in the microscope chambers, as 
shown in Figure 2.11, and were mounted on the stage of a confocal microscope DMI3000B 
(Lecia Microsystems, Germany,) equipped with s 40x optical objective (numerical aperture 
was equal to 1.25) with immersion oil (Type F immersion oil, Leica, Germany). The Leica 
application suite for Advanced Fluorescence (LAS AF) was the software linking the confocal 
laser (Leica TCS SP5) to the microscope. The settings used to image the cells are described 
below and an example of the system set up is shown in Figures 2.12. 
 
 Hilary Siddall 
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C.
 
Figure 2.12: The equipment required for the Leica Application Suite, used for 
investigating time to cardiomyocyte depolarisation: A) confocal microscope, B) laser 
scan head and C) software and data acquisition point.   
 
The TMRM dye is a positively charged lipophilic cation which will accumulate at high negative 
charge, as in the mitochondria. This fluorophore can be excited with a 543nm wavelength to 
emit a fluorescent signal which was collected using a long pass filter above 560nm. However, 
when used in a high concentration, the dye accumulates within the mitochondria and the 
fluorescence is quenched. When the dye is excited the contrast in fluorescence from 
quenched and non quenched TMRM provides an outline of the mitochondria in-situ. An 
example of the TMRM staining and imaging of the mitochondria is shown in Figure 2.13.  
Following ischaemia-reperfusion the mPTP opens which can initiate signals for cell death 
(Crompton, 1999). Reoxygenation of an ischaemic area can signal the formation of the mPTP Hilary Siddall 
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to facilitate pore opening, rapid equilibration of ions across the membrane and a collapse of 
the mitochondrial membrane potential. This is an indicator of imminent cell death (Griffiths 
and Halestrap, 1995; Crompton, 1999). The excitation of the TMRM dye in the mitochondria 
can generate ROS (Zorov et al., 2000), which has been reported to induce the mPTP opening 
and mitochondrial depolarisation (Smith et al., 2006; Davidson et al., 2006). We used 
confocal microscopy and TMRM-generated ROS in isolated ventricular myocytes as a model 
of the injury that occurs at the mitochondria during reperfusion. The laser beam path settings 
on the Lecia Application Suite were as follows. 
 
Confocal images were acquired using xyt (x, y, time) mode at a scan rate of 400Hz, with a 
pinhole size of 67.91µM and a zoom of 1 with a line average of 2 and a frame average of 1. 
This provided a 512x512 format image with an actual size of 387.50µM x 387.50µM (pixel 
size of 758.32nmx758.32nm). The HeNe laser used to excite the TMRM was set to 60% 
power, sufficient to generate ROS from the loaded TMRM. The image gain was set to 338V. 
Sequential images were acquired at 2.633s intervals until depolarisation occurred. An 
example of the images indicating mitochondrial depolarisation is shown in Figure 2.13. The 
TMRM dye showed individual mitochondria are located in a structured formation striated 
along the cell. Closer images were not collected at the time of this study and any attempts to 
zoom in on the original images collected during these experiments substituted resolution for 
magnification. Therefore, no further images are displayed in this thesis. Results are 
expressed as time to TMRM release and mitochondrial depolarisation. 
 
The time from commencement of TMRM excitation until the time of depolarisation was 
recorded. Cyclosporine A (CsA), known to bind cyclophilin D, thus preventing the formation of 
the mPTP, and delaying pore formation, opening and mitochondrial depolarisation (Griffiths 
and Halestrap, 1995) and was used as a positive control. The time to depolarisation in 
isolated cardiomyocytes from PTEN
+/+ and PTEN
+/- was compared with and without CsA.  Hilary Siddall 
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Figure 2.13: Fluorescent imagining of an isolated cardiomyocyte loaded with Tetra 
methyl rhodamine methyl dye. Frames 1-4 display the change in intensity as the dye is 
released from the mitochondria into the cytoplasm to indicate mitochondrial 
depolarisation.  
 
2.7  Protein analysis using Western blot analysis 
The protocol for Western blot analysis was originally described by W.N Burnette in 1981 and 
combines molecular and immunological technologies to analyse the expression of proteins 
(Burnette, 1981). Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) 
is used to separate proteins according to their molecular weight. Antibodies are used to 
visualise the levels of total protein expression or phosphorylation, specific to the protein of 
interest. The western blot protocols used in the Hatter Cardiovascular Institute have been 
validated and subsequently published (Mocanu et al., 2002; Bell and Yellon, 2003; Tsang et 
al., 2005), as described below. Western blot analysis enables a qualitative investigation of 
proteins separated by gel electrophoresis. Proteins are identified by their transfer to a 
membrane, which facilitates immuno-identification and analysis of specific proteins. An 
outline of the method used is shown in Figure 2.14. 
 
1 3 24  Hilary Siddall 
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Figure 2.14: A schematic presentation of the sodium disulphide poly acrylamide gel 
electrophoresis and Western blot techniques. 1) Sample proteins are loaded onto an 
acrylamide gel and separated by electrophoresis. 2) Proteins are transferred to a 
membrane. 3) The membrane is blocked with milk proteins. 4) Primary antibody to 
protein of interest binds the protein located on the membrane. 5) Secondary antibody 
conjugated to horse radish peroxidase (HRP), binds to primary antibody. 6) 
Electrochemiluminescence (ECL) reagent reacts with HRP and emits a light signal that 
is correlated to the amount of protein of interest.  
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2.7.1  SDS-PAGE sample collection 
2.7.1.1   Myocardial models 
The protocols used to collect myocardial samples for Western blot analysis are described in 
more detail in the relevant experimental chapters. The ventricular tissue of all hearts was 
collected by rapidly trimming the aorta and atrial appendages. The remaining tissue was 
immediately snap frozen in liquid nitrogen and stored at -80
oC.  
 
2.7.1.2   Cell models 
Cell samples collected for Western blot analysis were prepared as follows. At the end of the 
experiment, cells were washed on ice with ice cold PBS. The washing buffer was removed 
and the cells were homogenised in whole cell lysis buffer (1 part suspension buffer (0.1M 
NaCl, 10mM Tris, 1mM (pH 8.0) EDTA, 2mM Sodium Pyrophosphate, 2mM NaF, 2mM B-
glyerophosphate, protease cocktail and 0.5mM AEBSF) and 1 part sample buffer (l00mM Tris 
(pH 6.8), 200mM DTT, 2% SDS, 0.2% Bromophenol blue and 20% Glycerol). The cells were 
scraped from the surface of the cell culture plate with a pipette tip to ensure maximal whole 
cell lysis; samples were stored at -80
oC. 
 
2.7.2 Protein  extraction 
2.7.2.1   Myocardial models 
Cytoplasmic proteins were extracted from heart samples that were previously snap frozen in 
liquid nitrogen. Samples were homogenised in ice cold suspension buffer, on ice. 
Homogenates were centrifuged for 10 min at 12900 RCF at 4
oC. Small aliquots of extracted 
protein were quantified using a bicinchoninic acid assay (BCA) (Sigma, UK); This is a Hilary Siddall 
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colorimetric assay where peptide bonds in the protein samples reduce Cu
2+, present in the 
BCA reagent, to form Cu
1+. The bicinchoninic acid in the BCA reagent then chelates the Cu1
+, 
(a temperature sensitive reaction aided by cysteine, tyrosine and tryptophan amino acids in 
the protein samples producing a change in colour, from light green to purple. This change in 
optical density can be measured by an absorbance reader at a wavelength of 562nm, and is 
proportional to the level of protein in each sample. A BSA protein standard curve was created 
with each BCA assay. The extracted remaining protein, in suspension buffer, was then diluted 
at a 1:1 ratio in SDS sample buffer and heated to 95
oC for 10 min to ensure protein 
denaturation. 
 
2.7.2.2   Cell models 
Equal volumes of whole cell lysates (already collected in the cell lysis buffer) were heated at 
95
oC for 10 min and were loaded directly to the acrylamide gel ready for protein separation by 
SDS-PAGE.  
 
2.7.3 SDS-PAGE 
2.7.3.1   Preparing and running PAGE 
The SDS in the sample buffer is an anionic detergent which denatures proteins and provides 
a uniform charge across the samples. Therefore, when a current is applied the proteins 
loaded in the gel migrate according to their molecular weight and resistance in that matrix. A 
polyacrylamide gel is used to separate the proteins and is prepared by the polymerisation of 
acrylamide and bis-acrylamide. The polymerisation is initiated by the addition of ammonium 
persulfate (APS) and tetramethylethylenediamine (TEMED). This reaction releases free 
radicals causing the acrylamide to cross link and solidify which creates pores of equal size in Hilary Siddall 
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a 3D gel matrix. We used a 12.5% running gel (consisting of 12.5% acrylamide, 0.4M Tris, 
0.1% SDS, 0.1% TEMED and 0.05% APS) and a 5% stacking gel (consisting of 5% 
acrylamide, 0.125M Tris, 0.1% SDS, 0.2% TEMED, 0.1% APS and 0.02% bromophenol blue) 
30µg protein was loaded per lane with one lane per gel assigned for a standard precision plus 
protein marker (BioRad, UK). This protein marker is used for quality control when running and 
transferring the gel. In addition, the protein weight marker (containing bands of known 
molecular weight) can be used as a reference point for the identification of proteins of 
interest, based on molecular weight. Gels were run in 1x running buffer (10x = 144.2g glycine, 
10g SDS, 30.3g Tris in a litre of dH20) at 200V until the bromophenol reached the bottom and 
good separation of the protein marker occurred.  
 
2.7.3.2   Protein transfer 
To prepare the proteins for visualisation they were transferred from the acrylamide gel to 
Western blot transfer paper, Hybond electrochemiluminescence (ECL) (GE Health Care, UK). 
The nitrocellulose transfer paper and Whatman blotting paper were pre-soaked in 1x transfer 
buffer (10% 10x transfer buffer (10x transfer buffer = Glycine 144.2g, Tris 30.3g, in 1litre 
distilled water) 20% MeOH and 70% water. The gel and the membrane were sandwiched 
together between the Whatman paper. Air bubbles were removed, the cassette closed, 
loaded into the tank according to the direction of the protein transfer and immersed in transfer 
buffer. The protein transfer was set to run at 140mA overnight. When an electric current is 
applied to this set up the negatively charged proteins in the gel move towards the positive 
electrode and are caught on the nitrocelluose membrane. As a consequence, at the end of 
the protein transfer period a mirror image of the gel is formed.  Hilary Siddall 
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2.7.4 Protein  detection 
Detection of the proteins on the Western blot membrane is based on immunological 
reactions, as shown in Figure 2.14, and requires antibody-antigen binding to localise proteins 
of interest (similar to an ELISA reaction). To visualise the proteins, membranes were probed 
with the antibody of interest which were identified using a chemiluminescence reaction. The 
membrane was incubated in 5% blocking buffer (5% marvel milk in 1x Tris buffered saline 
(TBS) containing 0. 1%Tween20 (TBS-Tween20) (10x TBS = Tris base 24.2g, NaCl 80.0g 
pH7.6) at RT for 1hr. The role of the blocking buffer was to cover up the remaining areas of 
the membrane with protein and therefore, to reduce non specific binding of the antibody of 
interest to the membrane. Thereafter, the membrane was rinsed 3 times with 1xTBS-
Tween20. A primary antibody with specificity to an epitope on the protein of interest was 
diluted according to the manufacturer’s instructions. Primary antibodies were diluted in 5% 
BSA made up in TBS-Tween20 and incubated with the membrane for a minimum of 2h at RT. 
The primary antibodies used were as follows: total AKT, phosphorylated AKT (for Ser473 and 
Thr308 phosphorylation sites), total PTEN, phosphorylated PTEN (for Ser/Thr 380/382&383 
phosphorylation sites), total p53 and caspase 3 were all from Cell Signalling technologies, 
UK. SHIP2 and PHLPP were from Bethyl laboratories,USA and PINK1 was obtained from 
Abcam, UK. Additionally, antibodies used for analysis of equal protein loading, such as Beta 
Actin, alpha Tubulin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), were all 
from AbCam, UK and were used to normalise for any loading discrepancies. The primary 
antibodies were then washed off 3 times in 1xTBS-Tween20 and the secondary antibody 
(HRP linked) was prepared in 5% blocking buffer and incubated with the membrane for 1hr at 
RT according to the manufacturer’s recommendations. After the final wash an ECL reagent 
(GE Healthcare,UK) was used to start the chemiluminescences reaction. The membranes 
were incubated in ECL reagent for 5 min before exposure to ECL Hyperfilm (GE Health care, 
UK). The ECL is a chemiluminescent reagent which contains peroxide acid, luminal and 
phenol. When this reagent is added to the membrane HRP, bound to the secondary antibody Hilary Siddall 
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which is attached to the protein of interest on the membrane, induces an oxidative reaction in 
the ECL reagent. Therefore, the emission of light correlates to the amount of HRP-
primary/secondary antibody conjugate and this is indicative of the expression of the protein of 
interest bound to the membrane.  
 
The Hyperfilm-autoradiography paper, which is sensitive to blue light (emission of light at 
428nm wavelength), was exposed to the luminescence reaction. The paper was then 
incubated in developer (which catalysed the area of light sensitivity) followed by fixer solution 
(which stopped the reaction and dissolves the light sensitive coating). This reaction exposes 
a black band on the autoradiography paper and is an indicator of location and quantity of the 
protein of interest. These bands were scanned into the computer for densitometry analysis 
using NIH Image.3.63. The relative density of the scanned bands were compared and 
expressed in arbitrary units (A.U) or as percentage change from control. 
 
Membranes requiring re-probing were washed and striped of antigen antibody reactions by 
submersing the membrane in Restore Plus Western blot stripping buffer (Thermo Scientific, 
USA). Membranes were stripped for 10 min at RT with gentle agitation. Membranes were 
washed 3 times before re-blocking and probing for additional proteins or house keeping 
proteins to normalise for lane loading. 
 
2.8  Studies using H9c2 cells silenced for PTEN protein expression 
with small interfering RNA technology 
2.8.1  Cell culture of H9C2 cells 
H9c2 cells are an adherent rat cardiac cell line with myoblast morphology. These cells were 
originally sourced from the European Collection of Cell Cultures (ECACC) ECACC number Hilary Siddall 
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88092904 (Kimes and Brandt, 1976) and were obtained within UCL. An example of the cell 
morphology is shown in Figure 2.15.  Cells were cultured in sterile conditions and were grown 
in culture media and maintained in a New Bruswick Scientific incubator at 37
oC in 
95%O2/5%CO2 with 90% humidity. H9c2 cell culture media was MEM (minimum essential 
media with Earles salts and 2mM glutamine) (Invitrogen-Gibco,UK) culture media 
supplemented with 10% FBS (Invitrogen, Gibco), 50U/ml Penicillin (Gibco/Invitrogen,UK) and 
5µg/ml Streptomycin  (Gibco/Invitrogen,UK). Cells were sub-cultured when they grew to a 
confluence of 70-80%. This was achieved by covering cells in 0.25 % Trypsin/EDTA 
(Invitrogen/Gibco, UK) for 2 min at 37
oC, to detach the cells from the surface of the culture 
plate. Cells were then seeded at a 1 in 10 dilution, in a fresh 75 cm
2 growth culture flask 
(Orange Scientific, Belgium), this was performed twice a week. Growth of cells in clusters, 
groups or to confluence was avoided, as under these circumstances, H9c2 cells can 
differentiate into myotubules.  
 
Figure 2.15: Typical morphology of the myoblast H9c2 cell line. Hilary Siddall 
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2.8.2  SiRNA knockdown of PTEN protein 
In 2006 Fire and Mello won the Nobel Prize in Physiology and Medicine for their contributions 
to the discovery of RNA interference (Couzin, 2006). The discovery that double stranded 
RNA can suppress gene activity has led to much excitement and as a consequence the 
technology is evolving. An overview of the method is illustrated in Figure 2.16. The technique 
facilitates the manipulation of the cells’ natural transcriptional and translational mechanisms 
to silence the expression of the specific protein of interest. The addition of double stranded 
RNA with specificity to a target transcript prevents the translation of that protein whilst the 
genome itself remains unaltered  (Caplen et al., 2001).  
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Figure 2.16: Principle of small interfering RNA (siRNA) induced silencing of target 
proteins. The siRNA complexes that are specific for the target protein, are recognised 
within the cell by a RNA-induced silencing complex (RISC). The cell attaches a 
degradation flag on anything that is bound to the siRNA, such as the protein 
transcripts for the target protein. This destroys the mRNA for the target and prevents 
protein synthesis. (RNA = ribonucleic acid, mRNA = messenger RNA) 
 
The process of siRNA protein silencing was not previously established within the Hatter 
Institute. Therefore, we had to perform a number of optimisation studies to verify that it was 
GCCUC 
CGGAG  mRNA 
2. The activated RISC complex promotes siRNA specific 
sequence recognition with cellular mRNA and flags the 
mRNA for degradation. 
GCCUC  RISC 
1. Specific cleaved ends on the siRNAs are recognised and bound by 
an endogenous RNA induced silencing complex (RISC). 
3. The cell degrades the flagged mRNA preventing 
subsequent protein synthesis. 
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possible to knock down the expression of specific proteins in H9c2 cells. These experiments 
are described in more detail in chapter 7. An overview of the methods used in to study PTEN 
silencing with siRNA is described below.  
 
Cells were sub-cultured; counted using a haemocytometer and seeded at 4,000cells/3.8cm
2 
(in 12 well plates) (Sigma, UK). Immediately after seeding, cells were gently placed in the 
incubator (avoiding vortexing and pooling of cells) and left to adhere for 6-8h. Once they were 
adherent and their usual morphology had returned, cells were transfected with either reagent 
control or reagent-siRNA primers complex. The reagent-siRNA complex targeted either non 
coding scrambled primers (control), GAPDH or PTEN protein. All siRNA primers were 
purchased from Ambion. The sequences are shown in Table 2.3. GAPDH siRNA was used in 
the initial optimisation experiments and every experiment included a scrambled siRNA 
control. The Silencer
® pre-designed PTEN primers were purchased from Ambion with a 
guarantee 1 out of 3 purchased siRNA primers would knockdown PTEN protein with 80% 
efficiency. The extent of the protein knock down was verified before routine use, by Western 
blot technique. 
 
To transfect cells, the growth media was replaced with fresh culture media and transfection 
reagent was added to each well. The X-tremeGene siRNA transfection reagent, a multi lipid 
component, was used. A reagent-siRNA complex was generated at a 3:1 ratio of reagent (ul) 
to siRNA (ng), in 1/10
th of the final well volume in serum and antibiotic free culture medium. 
This reagent-siRNA complex is required for membrane penetration and transfer of siRNA 
across cell membranes. Cells were transfected overnight for approximately 12h, after which 
the medium containing the transfection complex was replaced with fresh growth medium. We 
observed that the time for PTEN protein turnover (time for remaining PTEN to be degraded) 
within these transfection conditions was 60-72h, following which the medium was removed Hilary Siddall 
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and the cells were prepared for protein analysis (as described in the Western blot protocol) or 
induction of hypoxia-reoxygenation.  
 
Table 2.3: The sequence of oligonucleotides for the siRNA primers used in this study. 
GAPDH = Glyceraldehyde 3-phosphate dehydrogenase, PTEN Phosphatase and tensin 
homolog deleted on chromosome 10 and siRNA = small interfering ribonucleic acid. 
siRNA target  Anti-sense (5’-3’) 
•  Scrambled Silencer® control siRNA  CCGUAUCGUAAGCAGUACUTT 
•  GAPDH Silencer® control siRNA  AAAGUUGUCAUGGAUGACCTT 
•  PTEN primer 1, Silencer® pre-designed 
to exon 2 
ACAUCAUCAAUAUUGUUCCTG 
•  PTEN primer 2, Silencer® pre-designed 
to exon 5 
UGAUAAGUUCUAGCUGUGGTG 
•  PTEN primer 3, Silencer® pre-designed 
to exon 5. 
CAAGAUCUUCACAAAAGGGTT 
 
2.8.3 Hypoxia-reoxygenation 
An appropriate protocol for the induction of cell death using hypoxia-reoxygenation (duration 
of hypoxic buffer) in H9c2 cells was established, based upon past protocols and published 
techniques used at the Hatter Institute. We reinstated the methods for hypoxia and 
reoxygenation (duration and hypoxic buffer) (Smith et al., 2007; Lim et al., 2008). The 
hypoxia-reoxygenation protocol used in this thesis is described below. 
 
Two culture plates were prepared in parallel (normoxia and hypoxia plates) and for each 
treatment and cells were seeded in replicates of 2 or more wells. After the 60 h transfection 
protocol, described above, cells were serum starved overnight: by replacing growth media Hilary Siddall 
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with serum free media. 12 h later media was removed and cells were either maintained in 
normoxia or incubated in hypoxic conditions, as described below. 
 
2.8.3.1   Maintaining normoxia 
Cell medium, was replaced with normoxic buffer (Table 2.4) and cells were placed in the 
standard cell culture incubator, as previously described, for 24h. 
 
2.8.3.2   Induction of hypoxia 
Cell media was replaced with hypoxic buffer (Table 2.4), which was designed to mimic 
ischaemic conditions. It contains no glucose, elevated potassium levels, lactate and is pH 6.7, 
reflecting the acidic conditions caused by the accumulation of lactate from increased 
glycolytic metabolism. The cells were placed in the hypoxic chamber (as shown in Figure 
2.17) and maintained at 37
oC for 24h. The hypoxic chamber was designed and made in 
house. It is temperature protected and contains two one-way gas valves which enable the 
entry of nitrogen into the chamber and facilitates the displacement of oxygen. Thus re-entry of 
gases into the chamber is prevented providing a low oxygen environment. 
  Hilary Siddall 
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Figure 2.17: The hypoxic chamber used in the hypoxia-reoxygenation experiments: A) 
heating chamber, B) one way, gas inlet valve, C) one way, gas outlet valve and D) 
temperature sensor. 
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Table 2.4: The components of the normoxic and hypoxic buffer. These buffers are 
abased on a modified KREBS-Ringer N-2-hydroxyethylpiperazine N-2ethanesulfonic 
acid (HEPES) buffer (Rakhit et al., 2001).  
Normoxic Buffer  Hypoxic Buffer 
Compound 
 
[Final] (mM)  Compound 
 
[Final] (mM) 
• KH2PO4  1mM  • KH2PO4  1mM 
• NaHCO3  10mM  • NaHCO3  10mM 
• MgCl2.6H20  1.2mM  • MgCl2.6H20  1.2mM 
• NaHEPES  25mM  • NaHEPES  25mM 
• NaCl  98mM  • NaCl  74mM 
• KCl  3mM  • KCl  16mM 
• D-glucose  10mM    
• Na-Pyruvate  2mM  • NaLactate  20mM 
• Bubble 
95%O2/5%CO2 
  • Bubble  Nitrogen   
• pH  7.4    • pH  7.4   
• CaCl2  1.2mM  • CaCl2  1.2mM 
   • De-oxy  glucose  5mM 
 
2.8.3.3   Reoxygenation 
Following 24hr incubation the cells were reoxygenated for 4hr. Normoxic or hypoxic buffer 
was removed and gently replaced with  MEM growth media lacking FBS and containing 
propidium iodide (PI) at 10µg/ml (Molecular Probes, UK). Insulin (10µg/ml), known to prevent 
the injury induced by hypoxia-reoxygenation (Davidson et al., 2006) was used as a positive 
control. Reoxygenation buffer was used as a control for insulin. At the end of reoxygenation 
the medium was removed and cells were collected for Western blot analysis. 
 Hilary Siddall 
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2.8.3.4   Analysis of cell viability 
We performed experiments to determine the best method to asses H9c2 cell viability 
following hypoxia-reoxygenation. Firstly we investigated the detection of PI, which is a 
membrane impermeable dye however, when the cell membrane is permeable, as in necrosis 
or late stage apoptosis, the dye can enter the cell and bind to DNA (Jonassen et al., 2004). 
Fluorescence from the dye can be excited using a mercury lamp which causes the emission 
of a red fluorescence which can be recorded as an indicator of cell death.  
 
Secondly, we investigated the changes in lactate dehydrogenase (LDH) release as an 
indictor of cell death. When the cell plasma membrane is permeabilised, enzymes such as 
lactate dehydrogenase (LDH) and creatine kinase are released and can be used as an 
indicator of cell damage (Jonassen et al., 2004). The CytoTox 96 Non-radioactive cytotoxicity 
assay (Promega, UK), was used in an attempt to measure cell viability in a secondary cell 
viability model. After reoxygenation, cell medium was collected and assayed following the 
manufacturer’s instructions. Following a number of enzymatic reaction steps this assay 
measures the activity of LDH in samples. Firstly, lactate and NAD(+) in samples are 
converted by LDH into NADPH and pyruvate. Next, tetrazolium salts ((2-p(iodophynyl)-3-(p-
nitrophynyl)-5-phenyltetrazolium chloride, present in the assay substrate mix, react with 
NAD(+) to create a red formazan product. In doing so this creates a change in optical density 
that can be measured at 490nm, which is symptomatic of LDH activity. This is a marker of 
LDL release and therefore can be used as an indicator of cell and viability (WROBLEWSKI 
and LADUE, 1955).  
 
The results are presented as a ratio of released LDH in comparison to the total LDH extracted 
from remaining viable and adherent cells. Further optimisation experiments to detect LDH 
were required and are described in more detail in chapter 7. Cell suspension and cell lysate Hilary Siddall 
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samples were incubated in the assay lysis buffer for 60 min followed by the addition of assay 
substrate mix. Isolated LDH (provided as a positive control in the assay) at 1.6units/ml, 
3.2units/ml and 6.4units/ml was used as a positive control. Changes in the colour were 
measured by reading the absorbance at 490nm.  
 
Finally, we investigated the detection and changes in expression of cleaved caspase 3. The 
cleavage of caspase 3 is a determining step of apoptosis and therefore can be used as an 
indicator of cell damage (Kothakota et al., 1997). This was performed by assessing the 
expression of caspase 3 in whole cell lysates, collected after reoxygenation; as described in 
the Western blot protocol above. Antibodies detecting total and cleaved caspase 3, from Cell 
Signalling Technologies, UK) were used and the ratio of cleaved caspase 3 compared to the 
total caspase 3, was used as an indicator of cell death.  
 
2.9 Statistics 
For comparisons between two groups an unpaired t-test was used.  For comparison between 
more than two groups a One Way ANOVA, using GraphPad Prism4 (GraphPad software inc, 
California, USA), was used; to analyse between groups the Bonferroni’s multiple comparison 
post hoc test was used. Results were considered significant when p ≤ 0.05.  All results were 
displayed as group means ± standard error (SE) and the test used was specified in the 
legend of the appropriate graph. 
 
 Hilary Siddall 
 
133
3  Chapter 3 - Characterisation of the isolated perfused 
mouse heart model of global ischaemia-reperfusion 
injury. 
3.1 Background  and  aims 
The Langendorff model can be used for studying ischaemia-reperfusion injury in isolated 
perfused hearts, as described in chapter 2, section 2, and has previously been used within 
the Hatter Institute (Sumeray et al., 2000; Simpkin et al., 2007). However, optimisation 
experiments were performed to validate and further characterise the model of ischaemia-
reperfusion injury in isolated mouse hearts. It was predicted that future experiments may 
require varying degrees of ischaemia-reperfusion. 
 
Additionally, in advance of investigating the effects of PTEN inhibition on cardioprotection in 
isolated perfused mouse hearts, a positive control was required. For this purpose ischaemic 
preconditioning (IPC), which is initiated by inducing sub-lethal ischaemia and reperfusion 
cycles prior to a lethal ischaemic event, was selected. IPC is considered the most powerful 
protective mechanism against infarction (Murry et al., 1986; Yellon and Downey, 2003).  
 
3.2  Experimental protocols, methods and hypothesis 
The Langendorff perfusion apparatus was used to study the effects of ischaemia-reperfusion 
on isolated perfused mouse hearts, as described in chapter 2, section 2. Infarct size was 
assessed as an end point. To validate this model the effects of submersion buffer, mouse 
strain, duration of ischaemia and reperfusion, and various IPC protocols on myocardial 
infarction was investigated. Hilary Siddall 
 
134
3.2.1  Infarction and ischaemic buffer 
NIH Swiss white mice were used for the initial Langendorff characterisation studies. The level 
of infarction induced by 30 min stabilisation followed by 35 min ischaemia and 30 min 
reperfusion, was compared in the presence of either oxygenated (n=22) or non oxygenated 
(n=6) submersion buffer, as shown in Figure 3.1. It was hypothesised that the myocardium 
incubated in non oxygenated submersion buffer would incur a greater level of infarction 
following ischaemia-reperfusion. 
 
35min global
ischaemia
30min 
reperfusion
Stabilisation
= Infarct measurement (I/R%) using TTC staining
= Ischaemia
A. 
Oxygenated 
ischaemic
buffer
B. 
Non oxygenated 
ischaemic
buffer
35min global
ischaemia
30min 
reperfusion
Stabilisation
= Infarct measurement (I/R%) using TTC staining
= Ischaemia
A. 
Oxygenated 
ischaemic
buffer
B. 
Non oxygenated 
ischaemic
buffer
 
Figure 3.1: Langendorff perfusion protocols used to investigate ischaemia-reperfusion 
injury. In the presence of A) oxygenated submersion buffer or B) non oxygenated 
submersion buffer. I/R% = percentage of infarction to risk area TTC = 
triphenyltetrazolium chloride. 
 
3.2.2  Infarction in different murine strains 
The response to ischaemia-reperfusion injury in myocardium from the NIH Swiss White 
(n=28) and C57BL/J6 mice (n=17) was compared. The standard protocol of 30 min Hilary Siddall 
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stabilisation followed by 35 min ischaemia and 30min reperfusion, as shown in Figure 3.1 
was used.  
 
3.2.3  Infarction and duration of ischaemia and reperfusion 
The infarction developed in C57BL/J6 myocardium, as a consequence of increasing durations 
of ischaemia (25, 35, 45, 55 min n=5, 17, 5 and 6, respectively) and reperfusion (30 and 120 
min, n = 17 and 6, respectively) was investigated.  
 
Sham hearts perfused without ischaemia, time matched to the control protocol, were also 
collected to establish any basal damage caused by the balloon and/or by the manoeuvres 
required by the hanging of the heart on the perfusion apparatus. (sham control for 30 and 120 
min reperfusion, n = 4 and 4, respectively).   
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Figure 3.2: Langendorff perfusion protocols used to ischaemia-reperfusion injury: 
following different durations of A) ischaemia and B) reperfusion periods. I/R% = 
percentage of infarction to risk area TTC = triphenyltetrazolium chloride. 
 
Various IPC protocols (listed below and shown in Figure 3.3) applied prior to the lethal 
ischaemia-reperfusion protocol, of 35 min ischaemia and 30 min reperfusion, were 
investigated in isolated perfused C57BL/J6 mouse hearts.   
 
1)  1 cycle of 5 min ischaemia followed by 15min reperfusion (n=3). 
2)  2 cycles of 10 min ischaemia followed by 10min reperfusion (n=3). 
3)  1, 2, or 4 cycles of 5 min ischaemia followed by 5 min reperfusion (n=2,2 and 3, 
respectively). Hilary Siddall 
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Figure 3.3: Different IPC protocols tested to investigate cardioprotection in isolated 
C57BL/J6 mouse hearts. I/R% = percentage of infarction to risk area TTC = 
triphenyltetrazolium chloride. 
 
The best IPC protocol was selected based on results from these characterisation studies and 
previously established findings in the Hatter Cardiovascular Institute. In order to match the 
ischaemia-reperfused control hearts with the IPC hearts the stabilisation duration in control 
hearts was extended from 30 to 55 min, (n=5) as shown in Figure 3.4.  
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Figure 3.4: The selected IPC protocol used to investigate protection in isolated 
C57BL/J6 mouse hearts:  A) IPC protocol and B) time matched control protocol. I/R% = 
percentage of infarction to risk area TTC = triphenyltetrazolium chloride. 
 
3.3 Results 
3.3.1  Infarction and the submersion buffer 
Myocardium from NIH Swiss white mice were subjected to ischaemia-reperfusion, which 
consisted of 30 min stabilisation followed by 35 min global ischaemia and 30 min reperfusion, 
(30/35/30). Unexpectedly, the level of infarction incurred was small, 19.03 ± 1.83%. It was 
hypothesised that the presence of oxygenated submersion buffer surrounding the heart 
during ischaemia may provide protection due to the passive diffusion of the oxygen into the 
tissue. As shown in Figure 3.5 this hypothesis was not confirmed because no significant 
differences were observed when ischaemia-reperfusion injury was investigated in hearts Hilary Siddall 
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submerged in oxygenated (19.03 ± 1.83%) compared to non oxygenated submersion buffer 
(16.82 ± 1.07%).  
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Figure 3.5: Percentage of infarction developed in the risk area (I/R%) in the NIH Swiss 
White mouse myocardium submersed in normothermic oxygenated (n=22) and non 
oxygenated (n=6) buffer during ischaemia. There was no statistical differences 
between groups, assessed using the Student’s paired t-test. 
 
 
3.3.2  Infarction in different murine species  
In an attempt to explain the small infarct size in Swiss White mice, it was hypothesised that 
there may be different susceptibilities to myocardial ischaemia-reperfusion injury in different 
strains of mice. To investigate this, the level of infarction was compared using the control 
ischaemia-reperfusion protocol (30 min / 35 min / 30 min) in the myocardium from Swiss 
White and C57BL/J6 mice. As shown in Figure 3.6 the mean infarct size observed in 
C57BL/J6 myocardium was significantly higher than in NIH Swiss White myocardium (39.33 ± 
3.47%, vs. 18.55 ± 1.43%,p<0.005). Hilary Siddall 
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Figure 3.6: Percentage of infarction developed in the risk area (I/R%) in Swiss White 
mouse myocardium (n=28) and C57BL/J6 mouse myocardium n= 17. Statistical 
differences were assessed using the Student’s paired t-test, (*=p<0.005). 
 
3.3.3  Infarction and the duration of ischaemia and reperfusion 
Further optimisation experiments were performed using the C57BL/J6 mouse model in which 
the hearts were subjected to various durations of ischaemia and reperfusion. The results, 
shown in Figure 3.7 indicate that, as the ischaemic time increases, infarct size is amplified. 
For example 25 min of ischaemia induced 28.29 ± 8.2% infarction. Increasing the ischaemic 
time, from 25min to 35 or 45 min was associated with an augmented infarct size to 39.33 ± 
3.47% and 50.28 ± 2.71%, respectively. Furhter on when the ischaemic time was increased 
to 55 min an even greater infarct size was recorded; 54.92 ± 3.85%, p<0.05. The greatest 
injury occurred at 55 min ischaemia, alternatively the effect of 35 min ischaemia (39.33 ± 
3.47%) appeared to be positioned in the linear part of the ischaemic effect response. 
Therefore, 30 min stabilisation and 35 min, ischaemia followed by 30 min reperfusion may Hilary Siddall 
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offer the most manipulative protocol for studying infarct size, whereby detection of changes in 
ischaemia-reperfusion injury may be more evident. 
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Figure 3.7:  Percentage of infarction developed in the risk area (I/R%) in C57BL/J6 
myocardium, stabilised for 30 min and subjected to varying durations of global 
ischaemia, (25min (n=5), 35min (n=17), 45min (n=5) and 55 min (n=6)) followed by 30 
min reperfusion. Statistical differences were assessed using One Way ANOVA, 
(*=p<0.05, 25min to 55mins ischaemia).  
 
In addition to investigating a range of ischaemic durations the effects of various periods of 
reperfusion on ischaemia-reperfusion injury were also explored. Figure 3.8 demonstrates the 
level of infarction following increasing durations of reperfusion, while stabilisation and 
ischaemia time remained fixed at 30 and 35 min respectively. The results indicate there is a 
significant increase in infarct size (61.72±3.26%, p<0.001) at 120 min reperfusion. 
Interestingly, in the sham (perfusion without ischaemia-reperfusion) hearts developed 
6.4±1.56% infarction after 95min perfusion. This duration is equal with an experimental 
protocol of 30 min stabilisation, 35 min ischaemia and 30 min reperfusion. In comparison, Hilary Siddall 
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when the length of time on the perfusion apparatus was extended to 185 min (equating with 
30 min stabilisation, 35 min ischaemia and 120 min reperfusion).  
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Figure 3.8: (A) Percentage of infarction developed in the risk area (I/R%) subsequent to 
30 min stabilisation and 35 min ischaemia followed by either 30 min (n=17) or 120 min 
(n=6) reperfusion and (B) percentage of infarction developed in the risk area (I/R%) in 
sham (perfusion without ischaemia-reperfusion) hearts perfused for either 95 min (n=4) 
or 185 min perfusion (n=4). Statistical differences between 30min and 120min in group 
A and B were assessed using One Way ANOVA, *=p<0.001.  
 
Heart rate, developed pressure, coronary flow rate and temperature were permenatly 
recorded throughout experimental protocols. Figure 3.9 represents an example of the 
haemodynamic recordings, collected during every experiment. Collected data was used to 
ensure that the hearts were functioning and that the recordings were within the 
inclusion/exclusion criteria throughout the experiments. However, our aim was not to 
investigate changes in heart function, we measured infarct size as an end point of the Hilary Siddall 
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experiments. Therefore, the haemodynamic recordings will not be presented further in this 
thesis. For investigating function as an end point there is a more reliable and consistant 
model of isolated perfused hearts, namely the “working heart model” which was not used in 
this study. 
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Figure 3.9: Example of haemodynamic measurements during experiments protocols of 
30 min stabilisation and 35 min ischaemia followed by either 30 min (30/35/30, n=17) or 
120 min (30/35/120, n=6) reperfusion. Data from sham (perfusion without ischaemia-
reperfusion) hearts perfused for either 95 min (95min Sham, n=4) or 185 min perfusion 
(185min Sham, n=4) are also included. A) heart rate in beats per minute (BPM), B) 
developed pressure in mmHg, C) flow rate in ml/min and D) temperature in degrees 
celsius (
oC). 
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3.3.4  Infarction and the ischaemic preconditioning protocol 
The optimum number of preconditioning cycles required to protect the C57BL/J6 mouse 
myocardium, subjected to our protocol of 30 min ischaemia and 35 min reperfusion was 
investigated. Figure 3.10 and Figure 3.11 show the results of the IPC optimisation 
experiments. Historically, in the Hatter Institute, IPC in the mouse myocardium was induced 
using 4 cycles of 5 min ischaemia followed by 5 min reperfusion (Bell and Yellon, 2001). 
Other laboratories have induced protection with alternative protocols, for example 3 cycles of 
5 min ischaemia (Lange et al., 2007). Conversely, 1 cycle of 5 min ischaemia and 15 min 
reperfusion has been used to initiate cardioprotection (Turcato et al., 2006). However, as 
shown in Figure 3.10 the alternative protocols investigated did not facilitate protection in our 
C57BL/J6 mouse model. In our hands, as presented in Figure 3.9, 4 cycles of 5 min 
ischaemia followed by 5 min reperfusion were required to confer protection in the C57BL/J6 
myocardium. Infarction was reduced from 50.4± 4.6% in control to 38.2 ± 3.3% in the 
presence of 4 cycles of IPC stimulus (consisting of 5 min ischaemia and 5 min reperfusion) 
prior to lethal ischaemia.  
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Figure 3.10:  Percentage of infarction developed in the risk area (I/R%) in C57BL/J6 
myocardium in control and following different ischaemic preconditioning (IPC) 
protocols, (1x 5+15 min ischaemia-reperfusion (n=3), 2x 10+10 min ischaemia-
reperfusion (n=3), 1x5+5 min ischaemia-reperfusion (n=2), 2x5+5 min ischaemia-
reperfusion (n=2) or 4x5+5 min ischaemia-reperfusion n=3)) prior to 35 min ischaemia 
followed by 30 min reperfusion. Statistical differences were assessed using One Way 
ANOVA. Details of the IPC protocols are shown in Figure 3.3.  
 
The chosen IPC protocol of 4 cycles 5 min ischaemia and 5 min reperfusion lengthened the 
total myocardial perfusion time. Consequentially, in control hearts the stabilisation duration 
had to be extended to time match the IPC protocol prior to ischaemia. For more details on 
this protocol see Figure 3.4. The results are shown in Figure 3.11 and demonstrates a 
significant reduction in infarction (35.4 ± 4.09%, p<0.05). 
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Figure 3.11: Percentage of infarction in the risk area (I/R%) in C57BL/J6 myocardium 
with extended 55 min stabilisation (to mirror the duration of the ischaemic 
preconditioning (IPC) stabilisation period) or IPC consisting of 4x5+5 min ischaemia-
reperfusion: prior to 35 min ischaemia followed by 30 min reperfusion (n=5). Statistical 
differences were assessed using the students paired t-test, (*=p<0.05).  
 
In summary, we aimed to characterise the Langendorff model investigating the effects of 
different durations of ischaemia and reperfusion and different IPC protocols on myocardial 
ischaemia-reperfusion injury. Our results show significantly larger levels of infarction in 
myocardium from C57BL/J6 mice compared to NIH Swiss White mice. Furthermore, using 
C57BL/J6 we demonstrate that as the ischaemia time is extended, the level of infarction is 
also increased. We concluded that 30 min stabilisation and 35 min ischaemia followed by 30 
min reperfusion appears to provide a compliant platform to study ischaemia-reperfusion 
injury. As a positive control, protection using IPC in C57BL/J6 mouse myocardium was 
induced using 4 cycles 5 min ischaemia and 5 min reperfusion prior to the lethal ischaemia-Hilary Siddall 
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reperfusion protocol. Therefore, these ischaemia-reperfusion protocols were used as a 
starting point for subsequent studies in which we aim to examine the effects of PTEN 
inhibition on ischaemia-reperfusion injury in whole hearts.   
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3.4 Discussion 
3.4.1  Infarction and strain variance 
Initially, NIH Swiss white mice were used to validate the Langendorff technique, ensuring that 
reproducible infarct sizes were produced. However, it was found that myocardium from these 
mice develop very small levels of infarction. We thought the submersion buffer, used to keep 
the hearts at a constant temperature during ischaemia, may have provided some protection 
through capillary action and passive diffusion of oxygen into the myocardium. However, no 
significant differences in infarct size were observed from the use of oxygenated and non 
oxygenated submersion buffer. 
 
Subsequently, to try and understand this, the level of myocardial infarction between different 
strains of mice was investigated. Myocardial ischaemia-reperfusion injury in the NIH Swiss 
white mice was compared to that of the C57BL/J6 strain. The C57BL/J6 myocardium 
developed significantly larger (p<0.005) levels of infarction, comparable to infarct data 
previously published in this strain (Eckle et al., 2006).  Surprisingly, the infarct size in the NIH 
Swiss mice were significantly smaller. This demonstrates the importance of choosing an 
appropriate mouse strain to study myocardial protection. Not all strains have similar 
thresholds to ischaemia-reperfusion, posing the question as to why these differences are 
observed. To answer this, further investigations are required and may implicate new cellular 
pathways involved in resistance to ischaemia-reperfusion injury. To summarise, the 
oxygenation status of the submersion buffer does not affect infarct size. Furthermore, the 
C57BL/J6 mouse model gives the largest window of potential protection against ischaemia-
reperfusion injury. 
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3.4.2  Infarction: duration of ischaemia and reperfusion 
Previous studies have shown a direct relation between the length of ischaemia and 
myocardial infarct size (Eckle et al., 2006).  The  best and most practical duration of 
reperfusion is often debated.  To ensure that the optimum ischaemia-reperfusion protocol, 
providing the biggest window of potential protection and reproducible data was used, the 
effect of different ischaemia and reperfusion durations on infarct size was investigated. It was 
observed that extended ischaemia durations corresponded with an increase in infarct size. 
Moreover increases in reperfusion time from 30 min to 120 min appeared to increase the 
infarct size; albeit to a limited extent. Similarly, it should be noted that this observation was 
also seen in sham hearts, which were time matched control hearts perfused without 
ischaemia. This may be due to the crystalloid perfusion buffer and/or the presence of the 
balloon in the left ventricle. This suggests that in our hands, as the time on the perfusion 
apparatus increases, the basal damage to the heart can further increase. 
 
Throughout reperfusion it was observed that hearts show little or no visible ventricular activity. 
Some laboratories report functional recovery following global ischaemia in mice myocardium 
(Headrick et al., 2001). However this was not observed in our model of ischaemia-reperfusion 
injury and has not been recorded in the Hatter Institute previously (Simpkin et al., 2007; Smith 
et al., 2006; Bell and Yellon, 2003). To investigate any cardiac reserves following ischaemia 
in these hearts may involve infusing an ionotropic activator, such as adrenaline at 
reperfusion. As one would expect the act of perfusion using a Langendorff perfusion 
apparatus creates a basal level of injury. Additional studies may help understand this 
observation. Such investigations may include recording the effects on infarct size and cardiac 
reserves with and without the presence of the balloon. Furthermore, studies using a force 
transducer rather than a pressure transducer as used in other laboratories (Xi et al., 1998; 
Sumeray et al., 2000) may eliminate the need to use a balloon. The reduced recovery of 
function at the end of reperfusion in our C57BL/J6 model may be explained on the basis of Hilary Siddall 
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using a global versus a regional model of ischaemia. Rat hearts, undergoing global ischaemia 
released troponin at reperfusion however, this was not observed in rat hearts undergoing 
regional ischaemia (Feng et al., 2001). As troponin release is a measure of tissue damage, it 
is probable that complete functional recovery may never be obtained in models of global 
ischaemia (Jenkins et al., 1997). It also highlights the importance of comparing results 
between laboratories and awareness of the precise methods used in each group. Results 
from these studies suggest that the most reproducible and robust protocol of ischaemia-
reperfusion injury, is with 35 min ischaemia and 30 min reperfusion. 
 
3.4.3  Infarction and ischaemic preconditioning protocols. 
Optimisation experiments for the IPC protocols were carried out in C57BL/J6 mice. Four 
cycles of 5 min ischaemia and 5 min reperfusion, prior to a lethal period of ischaemia gave 
significant (p<0.05) protection. Published models of ischaemia-reperfusion injury and IPC can 
be very different, especially in the mouse model. Other groups have shown protection in 
C57BL/J6 mice using 3 cycles of 5 min ischaemia and 5 min reperfusion (Lange et al., 2007), 
even 5 min ischaemia and 15 min reperfusion (Turcato et al., 2006). Eckle et al., 2006 has 
undertaken similar IPC optimisation studies to our own and indicate there is a pattern for 
protection at 3 cycles but a significant protection only using 4 cycles IPC (Eckle et al., 2006). 
In our hands this model was used as a positive control. The optimisation experiments were 
completed and confirmed, by extending the stabilisation period of the IPC control protocol, to 
account for the increased time on the perfusion apparatus.  
 
In summary, the data obtained in these preliminary experiments were used to choose the 
best protocol of ischaemia-reperfusion injury. It was decided that in myocardium from 
C57BL/J6 mice the protocol of 35 min ischaemia and 30 min reperfusion was the best to 
study ischaemia-reperfusion injury. Furthermore, using IPC as a positive control, it was Hilary Siddall 
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shown that 4 cycles of 5 min ischaemia and 5 min reperfusion was the best protocol to study 
IPC induced cardioprotection against ischaemia-reperfusion injury. 
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4 Chapter 4 – Chemical inhibition of PTEN using 
bpV(HOpic) and SF1773; investigating the response to 
ischaemia-reperfusion 
4.1  Background, aims and hypothesis 
4.1.1 bpV(HOpic)   
The chemical bisperoxo (5-hyroxypyridine-2carboxy) oxovanadate (bpV(HOpic) (Figure 2.7) 
contains a vanadium ion. Vanadium compounds can mimic the effects of insulin and have 
anti diabetic effects (Posner et al., 1994; Huisamen, 2003). Others have shown that 
orthovanadate can increase AKT activity and decrease PTEN activity, which can protect 
against neuronal ischaemia-reperfusion injury. However, orthovanadate is a non specific 
general protein tyrosine inhibitor, which can confer protection by a number of mechanisms 
(Posner et al., 1994; Liem et al., 2004; Wu et al., 2006).  The chemical bpV(HOpic) is a 
protein tyrosine phosphatase inhibitor, with 100 fold specificity for inhibiting PTEN over other 
tyrosine phosphatases and it can induce an increase in AKT activity (Schmid et al., 2004). 
 
The effects of the PTEN inhibitor, bpV(HOpic) on ischaemia-reperfusion injury, in isolated 
perfused mouse hearts were investigated. It was hypothesised that the administration of the 
PTEN inhibitor bpV(HOpic) would activate the prosurvival PI3K/AKT pathway and confer 
cardioprotection against ischaemia-reperfusion injury. 
 
4.1.2  SF1773 (Semafore)  
The PTEN inhibitor, SF1773 (1-Anthraquinonesulfonanilide / 9,10-Dioxo-9,10-dihydro-
anthracene-1-sulfonic acid phenylamide), was a kind gift from Semafore Hilary Siddall 
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Pharmaceuticals,USA. The specificity to inhibit other enzymes as well as its mechanisms of 
action are unknown. Observations of the chemical structure, shown in Figure 2.7 reveal that 
the compound lacks vanadium ions (as well as other ions known to inhibit PTEN, for example 
Zinc). This may indicate that SF1773 has an alternative mechanism of action for PTEN 
inhibition. For instance, a naturally occurring naphthoquinone derivative, shikonin has been 
reported to poses insulin like actions, inhibiting PTEN and tyrosine phosphatases (Nigorikawa 
et al., 2006). The authors of this work propose that shikonin binds to a shared motif in the 
PTEN’s active site preventing substrate binding.  
 
The chemical SF1773 is currently being developed as a specific PTEN inhibitor to target the 
side effects of chemotherapy. It is expected that this compound will temporarily minimise cell 
death in healthy cells and improve survival following chemotherapy. The effects of this drug 
on ischaemia-reperfusion injury, in isolated perfused mouse hearts were investigated. It was 
hypothesised that the administration of the PTEN inhibitor, SF1773, would confer 
cardioprotection against ischaemia-reperfusion injury. 
 
4.2  Experimental protocols and methods  
4.2.1 bpV(HOpic) 
4.2.1.1   Ischaemia-reperfusion injury in the presence of bisperoxo (5-
hyroxypyridine-2carboxy) oxovanadate (bpV(HOpic) in 
isolated perfused C57BL/J6 mouse hearts 
The Langendorff perfusion apparatus was used to study the effects of ischaemia-reperfusion 
injury in isolated perfused C57BL/J6 mouse hearts, as described in chapter 2, section 2 and 
infarct size was assessed as an end point. The effect of bpV(HOpic) on ischaemia-Hilary Siddall 
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reperfusion injury was investigated. Isolated C57BL/J6 hearts were perfused with bpV(HOpic) 
(Calbiochem,UK) throughout reperfusion (at 0.02µM, 0.05µM, 0.1µM  and 0.5µM, n=5, 5, 4 & 
2, respectively) or throughout stabilisation and reperfusion (at 0.02µM,1µM and 10µM, n=3,7 
& 5, respectively). Additionally, as a positive control, isolated C57BL/J6 hearts were perfused 
with sodium orthovanadate (Na3VO4  or orthovanadate) (Sigma, UK) at 5.4mM during 
stabilisation and reperfusion, n=6. The vehicle control for these drugs was water. These 
hearts were subjected to our standard ischaemia-reperfusion protocol, as shown in Figure 4.1 
and the level of infarction was compared to that detected in C57BL/J6 myocardium perfused 
with control buffer (n=18). These initial drug concentrations were extrapolated from published 
data using an isolated PTEN enzyme, PIP3/PIP2, conversion assay. The authors of this study 
demonstrated an IC50  of 14nM. They also investigated the phosphorylation of AKT with 
bpV(HOpic) for which they obtained an EC50 of 20nM (Schmid et al., 2004). Using this study 
as a starting point the initial doses used in the study was 20nM. The effects of a range of 
concentrations, the maximum being 10µM were investigated.   
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Figure 4.1: The experimental protocols for investigating infarction in isolated C57BL/J6 
mouse hearts perfused with: A) control buffer; B) bpV(HOpic) administered at and 
throughout reperfusion; C) bpV(HOpic) administered at and throughout stabilisation 
and reperfusion and D) orthovanadate administered as a positive control at and 
throughout stabilisation and reperfusion. The stock concentrations of these drugs 
were made up in water and subsequently diluted in Krebs buffer to the appropriate 
concentrations. I/R% = percentage of infarction to risk area TTC = triphenyltetrazolium 
chloride. 
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4.2.1.2   Ischaemic preconditioning and bpV(HOpic) in isolated 
perfused C57BL/J6 mouse hearts 
Infarction 
The Langendorff perfusion apparatus was used to study the effects of IPC on ischaemia-
reperfusion injury, in the presence or absence of 1µM bpV(HOpic). As described in chapter 2, 
infarct size was assessed as an end point. As an additional positive control the number of 
IPC cycles required to confer cardioprotection in isolated perfused C57BL/J6 mouse hearts in 
the presence or absence of bpV(HOpic) administered throughout stabilisation and reperfusion 
was investigated. We explored the effects of control, 2 and 4 cycles IPC (5 min ischaemia 
followed by reperfusion) in the presence (n= 4,4 and 3, respectively) and absence (n= 6,4 
and 6, respectively) of bpV(HOpic) as shown in Figure 4.2.  
 
Signalling 
As shown in Figure 4.2 the protein expression of phosphorylated AKT (Ser473 and Thr308 
phosphorylation sites), total AKT, phosphorylated PTEN (Ser380Thr382/383) and total PTEN 
was investigated, as a consequence of bpV(HOpic). We used Western blot techniques to 
investigate changes in protein expression and assessed the results using densitometry. 
Samples were collected immediately prior to the lethal ischaemic event (n=3). It has been 
shown that changes in AKT activity, which occur in response to IPC, can be detected 
subsequent to the IPC stimulus (Tsang et al., 2005). All samples were snap frozen in liquid 
nitrogen immediately after removal from the Langendorff rig and stored in -80
oC. Hilary Siddall 
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Figure 4.2: The experimental protocols used to investigate ischaemia-reperfusion 
injury and cardioprotection with bpV(HOpic), administered throughout stabilisation 
and reperfusion in control and ischaemic preconditioned (IPC) isolated C57BL/J6 
hearts. A) control buffer; B) bpV(HOpic); C) control buffer with 2 cycle IPC; D) 
bpV(HOpic) with 2 cycle IPC;  E) control buffer and 4 cycles IPC and F) bpV(HOpic) 
with 4 cycles IPC. The stock concentration of bpV(HOpic) were made up in water and 
subsequently diluted in Krebs buffer to the appropriate concentrations. I/R% = 
percentage of infarction to risk area TTC = triphenyltetrazolium chloride. 
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4.2.2 SF1773  compound 
4.2.2.1   Ischaemia-reperfusion injury in the presence of SF1773 in 
isolated perfused C57BL/J6 mouse hearts 
The Langendorff perfusion apparatus was used to study the effects of ischaemia-reperfusion 
injury in isolated perfused C57BL/J6 mouse hearts, as described in chapter 2, section 2; 
infarct size was assessed as an end point.  The mechanisms of actions for SF1773 are 
unknown however, Semafore Pharmaceuticals,USA, report an IC50 of 221nM, for PTEN 
inhibition. A range of doses (0.06µM, 0.12µM, 0.24µM, 0.48µM and 0.96µM, n = 7,5,8,3 and 
5, respectively) were perfused throughout stabilisation and reperfusion of isolated C57BL/J6 
myocardium subjected to the standard ischaemia-reperfusion protocol, as shown in Figure 
4.3.  
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Figure 4.3: Experimental protocols used to investigate the infarction in isolated 
C57BL/J6 mouse hearts perfused with: A) control buffer or B) SF1773 administered at 
and throughout stabilisation and reperfusion. The stock concentration of SF1773 was 
made up in dimethyl sulfoxide (DMSO) and subsequently diluted in Krebs buffer to the 
appropriate concentrations, the total amount of perfused DMSO was <0.01%). I/R% = 
percentage of infarction to risk area TTC = triphenyltetrazolium chloride. 
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4.3 Results 
4.3.1 bpV(HOpic)   
4.3.1.1   Ischaemia-reperfusion injury in the presence of bisperoxo (5-
hyroxypyridine-2carboxy) oxovanadate (bpV(HOpic) in 
isolated perfused C57BL/J6 mouse hearts. 
The vanadium compound, bpV(HOpic), is a protein tyrosine phosphatase inhibitor with 100 
fold specificity for inhibiting PTEN over other tyrosine phosphatases (Schmid et al., 2004). It 
was hypothesised that myocardial perfusion with bpV(HOpic) would pharmacologically inhibit 
PTEN and confer cardioprotection in our model of ischaemia-reperfusion injury. Initially, the 
effects of different concentrations of the inhibitor administered at reperfusion only were 
investigated. Figure 4.4 shows that there was no change in infarction in the presence of the 
varying concentrations of bpV(HOpic) when given at reperfusion only. The level of infarction 
in control myocardium was 48.95±3.4% compared to 48.08±7.02%, 51.24±6.96%, 
60.55±2.93%, 59.05±4.45% infarction in myocardium perfused with 0.02µM, 0.05µM, 0.1µM 
and 0.5µM bpV(HOpic), respectively.  It is important to note that the precise mechanism of 
action of this drug is not fully understood. However it seems to be effective for PTEN 
inhibition in the NIH3T3 cell line (Schmid et al., 2004).  Subsequently, the inhibitor was 
administered throughout stabilisation and reperfusion, to ensure sufficient time was provided 
for the drug to enter the cells and take effect. Orthovanadate, a general protein tyrosine 
phosphatase inhibitor, was used as a positive control to demonstrate protection in our model. 
This inhibitor was administered at 5.4mM into the buffer throughout stabilisation and 
reperfusion. As shown in Figure 4.4 a significant reduction in infarction from 48.95±3.4% to 
26.5±4.1%, p<0.01 was observed using orthovanadate, when administered throughout Hilary Siddall 
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stabilisation and reperfusion. However, no changes were observed using bpV(HOpic) at a 
range of concentrations under similar conditions.  
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Figure 4.4: Percentage of infarction developed in the risk area (I/R%) in C57BL/J6 
myocardium treated with the PTEN inhibitor, bpV(HOpic). Control in solid black bar 
(n=18); bp(HOpic) at reperfusion, (0.02µM, 0.05µM, 0.1µM & 0.5µM, n= 5, 5, 4 & 2, 
respectively) in solid blue bars; bpV(HOpic) throughout stabilization and reperfusion 
(0.02µM, 1µM, and 10µM, n= 3, 7, and 5, respectively) in hatched blue bars and 
orthovanadate throughout stabilization and reperfusion (n=6) in hatched black bars. 
One Way ANOVA, (*=p<0.01).  
 
Unexpectedly, in the presence of orthovanadate, lower flow rates were observed at the 
beginning of stabilisation, for approximately 5 min. To eliminate the possibility of an IPC-like 
protection due to low flow ischaemia an additional group, in which 5 min of low flow 
(1.0ml/min) and reduced perfusion pressure (PP<50mmHg) was applied, to account for this 
observation. Figure 4.5 shows that there was no change in infarct size versus control 
(48.9±3.4%) to the 5 min low flow, low perfusion pressure group (47.6±4.2%). Hilary Siddall 
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Figure 4.5: Percentage of infarction developed in the risk area (I/R %) in C57BL/J6 
myocardium in controls (n=18) and in hearts subjected to a low flow stabilisation 
period, (n=5).  There was no statistical differences between groups, assessed using 
the Student’s paired t-test. 
 
 
In summary, orthovanadate, a protein tyrosine phosphatase inhibitor, confers protection to 
ischaemia-reperfusion. However, perfusion with a specific PTEN inhibitor, bpV(HOpic) was 
not sufficient to induce cardioprotection in our model of isolated myocardial ischaemia-
reperfusion injury. This unexpected result occurred regardless of using increasing 
concentrations and duration of perfusion with the PTEN inhibitor, bpV(HOpic). 
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4.3.1.2   Ischaemic preconditioning and bpV(HOpic) in isolated 
perfused C57BL/J6 mouse hearts 
Infarction 
It was hypothesised that, despite lack of protection against ischaemia-reperfusion injury in the 
presence of bpV(HOpic), perfusion with this PTEN inhibitor may decrease the level of 
infarction when other cardioprotective mechanisms are applied. To verify this hypothesis, the 
IPC stimulus required to confer protection was explored in a C57BL/J6 mouse model of 
ischaemia-reperfusion, in the presence of 1µM bpV(HOpic). The results presented in Figure 
4.6 show the infarct size incurred subsequent to 35 min global ischaemia and 30 min 
reperfusion, preceded by 2 or 4 cycles IPC (5 min ischaemia and 5 min reperfusion). In 
hearts perfused with control buffer, protection was achieved with 4 cycles IPC and the level of 
infarction was significantly reduced from 49.0± 3.1% to 36.7± 3.1%, p<0.05. In the presence 
of 1µM bpV(HOpic), protection was observed with 4 cycles IPC and the level of infarction was 
reduced from 53.10± 3.4% to 25.6± 4.5%, p<0.001. In the presence of bpV(HOpic) protection 
was  also observed even with 2 cycles IPC, where infarction was significantly reduced to 23.9 
± 3.89%, p<0.001).  
 Hilary Siddall 
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Figure 4.6: Percentage of infarction developed in the risk area (I/R%) in C57BL/J6 
myocardium subjected to ischaemic preconditioning (IPC) in the presence of 1µM 
bpV(HOpic) administered in the buffer throughout stabilisation and reperfusion. Solid 
bars = ischaemia-reperfusion (I/R) control (no IPC); striped bars = 2 cycles IPC and 
dotted bars = 4 cycles IPC (n=4 or more). The statistical differences were assessed 
from bpV(Hopic) control using One Way ANOVA (*=p<0.01, **=p<0.01). In the buffer 
control group a significant reduction in infarction at 4cycles IPC compared to I/R 
control was recorded only using Student’s t test (@=p<0.05).  
 
Signalling Pathways 
We have shown that the cumulative IPC stimulus, required to reduce infarct size, is lower in 
the presence of bpV(HOpic). Therefore, the potential cell signalling that may be involved was 
investigated. It was hypothesised that the phosphorylation (hence activation) of the pro 
survival protein AKT would be increased as a consequence of perfusion with the PTEN 
inhibitor, bpV(HOpic). In the isolated hearts perfused with bpV(HOpic) (no ischaemic injury) a 
significant increase in the ratio of phosphorylated AKT was observed. Levels of 
phosphorylated AKT (at Ser473 phosphorylation site) was increased from 0.139 ± 0.02 A.U in Hilary Siddall 
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buffer control to 0.401 ± 0.045 A.U, p<0.0024 following perfusion of bpV(HOpic), as shown in 
Figure 4.7. Furthermore, phosphorylated AKT (Thr308) was increased from 0.174 ± 0.05 A.U 
in buffer control to 0.443 ± 0.028 A.U, p<0.01 subsequent to perfusion of bpV(HOpic), as 
shown in Figure 4.8. 
 
Additionally, the expression of phosphorylated AKT in conjunction with the IPC stimuli was 
further investigated. The results investigating phosphorylated AKT (at Ser473 
phosphorylation site) are shown in Figure 4.7. Perfusion with control buffer in the presence of 
4 cycles IPC induced a significant increase in expression of phosphorylated AKT (Ser473 
site) (from 0.139 ± 0.02 A.U in the control to 0.245 ± 0.026 A.U, p<0.05 in the presence of 4 
cycles IPC). No changes were observed following 2 cycles IPC. Perfusion of bpV(HOpic) did 
not induce any further increases following 2 and 4 cycles IPC. However the level of 
phosphorylated AKT(Ser473) was significantly higher than the untreated hearts even without 
IPC. 
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Figure 4.7: Phosphorylated (p) AKT (Ser473 site) protein expression in C57BL/J6 
myocardium subjected to ischaemia-reperfusion control (solid), with 2 (stripes) or 4 
(dots) cycles of ischaemic preconditioning (IPC); perfused with buffer control (black 
bars) or 1µM bpV(HOpic) (blue bars) (n=3). Statistical differences were assessed from 
control and from bpV(HOpic) groups, using One Way ANOVA (*=p<0.05 in control 
group only). A Student’s t test was used to investigate the significant difference 
between buffer control and bpV(HOpic) subjected to the control protocol, (@=p<0.05).  
 
The results from our studies investigating phosphorylated AKT (at the Thr308 site) are shown 
in Figure 4.8. Examples of the Western blots used to investigate the phosphorylation of AKT 
at 473 and 308 sites are displayed in Figure 4.10. Interestingly, following 2cycles of IPC the 
expression of AKT(308) was reduced when control buffer and significantly, p<0.05, when 
bpV(HOpic) was perfused throughout the heart. Perfusion with control buffer or bpV(HOpic) 
during 2 and 4 cycles IPC caused no further significant differences in expression. Perfusion 
with bpV(HOpic) during 2 cycles of IPC increased the expression profile of phosphorylated 
AKT (at the Thr308 site), when compared to the same IPC stimulus in the presence of control 
buffer. Additionally, in hearts perfused with bpV(HOpic) there was an increase in Hilary Siddall 
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phosphorylated AKT (at Thr308 site) during 4 cycles IPC (0.306± 0.053 A.U) compared to 2 
cycles IPC (0.171 ± 0.04 A.U), however, these changes were not significant.  
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Figure 4.8: Phosphorylated (p) AKT (at Thr308 site) protein expression in C57BL/J6 
myocardium subjected to ischaemia-reperfusion control (solid), 2 (stripes) or 4 (dots) 
cycles of ischaemic preconditioning (IPC); perfused with buffer control (black bars) or 
1µM bpV(HOpic) (blue bars) (n=3). Statistical differences were assessed in control and 
bpV(HOpic) groups, using One Way ANOVA (*=p<0.05 in bpV(HOpic) group only). A 
Student’s t test was used to investigate the significant difference between buffer 
control and bpV(HOpic) subjected to the control protocol, (@=p<0.01).  The vehicle 
control used was water. 
 
PTEN 
The PTEN inhibitor was perfused throughout the myocardium over a period of 95 min. Figure 
4.9 represents the expression values of phosphorylated PTEN (at Ser380, Thr382/383 sites), 
which can be indicative of PTEN activity (Cai and Semenza, 2005; Al Khouri et al., 2005; Wu 
et al., 2006). Examples of the Western blots are displayed in Figure 4.10. No significant Hilary Siddall 
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changes in phosphorylated PTEN levels were observed. However, perfusion with bpV(HOpic) 
during 4 cycles of IPC provided a small, but not significant, reduction in the level of 
phosphorylated PTEN, from 0.665 ± 0.01 A.U to 0.469 ± 0.07 A.U. It appears that in our 
samples, perfusion with the bpV(HOpic) may not modify the phosphorylated PTEN 
expression profile, during this time frame.  
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Figure 4.9: Phosphorylated (p) PTEN (Ser380, Thr382/383 sites) protein expression in 
C57BL/J6 myocardium subjected to ischaemia-reperfusion: control (solid bars), 2 
cycles of ischaemic preconditioning (IPC) (stripes) or 4 cycles of IPC (dots) prior to 
ischaemia; perfused with either buffer control (black bars) or bpV(HOpic) (blue bars) 
(n=3), Statistical differences were assessed using One Way ANOVA.  
 
Perfusion with bpV(HOpic) increased the activation of the PI3K/AKT pathway, however this 
increase was not sufficient to confer cardioprotection against myocardial ischaemia-
reperfusion injury. Nevertheless, when combined with IPC, the threshold of protection was 
decreased and the infarct size was reduced with less IPC stimuli.  
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Figure 4.10: Examples of Western blots obtained when investigating total and 
phosphorylated (p) AKT (473 and 308 sites) and PTEN (Ser380, Thr382/383 sites) 
protein expression in C57BL/J6 myocardium subjected to (1) ischaemia-reperfusion 
control, (2) 2 cycles ischaemic preconditioning (IPC) or (3) or 4 cycles IPC; perfused 
with either buffer control or bpV(HOpic).   
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4.3.2 SF1773  (Semafore) 
4.3.2.1   Ischaemia-reperfusion injury in the presence of SF1773 
(Semaphore) in isolated perfused C57BL/J6 mouse hearts  
It was hypothesised that the perfusion with SF1773, an alternative PTEN inhibitor, in 
C57BL/J6 myocardium would induce cardioprotection against ischaemia-reperfusion injury. 
Based on our investigations using bpV(HOpic) and orthovanadate, the drug was perfused 
throughout stabilisation and reperfusion periods, using different concentrations (from 60 to 
960nM). The results are displayed in Figure 4.11. Perfusion of SF1773 does appear to 
reduce cell death induced by our model of ischaemia-reperfusion however, no dose response 
effect was observed. Infarction following perfusion with vehicle control was 46.2 ± 1.7%. An 
infarct size of 36.96 ± 3.9%, 36.28 ± 2.5%, 40.6 ± 5.7% and 36.5 ± 2.5% was observed using 
0.12 0.24, 0.48 and 0.96µM of SF1773, respectively. Only a significant reduction in infarction 
was observed at 0.24µM SF1773, (p<0.05) which may be due to the degree of variability in 
the infarct sizes, within these other groups. 
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Figure 4.11: Percentage of infarction developed in the risk area (I/R%) in vehicle 
control (solid black bar, n= 11) and in myocardium perfusion with SF1733 (0.06µM, 
0.12µM, 0.24µM, 0.48µM and 0.96µM, (blue bars, n= 7, 5, 8, 3 and 5, respectively). 
Statistical differences were assessed using One Way ANOVA, (*=p<0.05).  
 
4.4 Discussion 
4.4.1 bpV(HOpic)   
4.4.1.1   Ischaemia-reperfusion injury in the presence of bisperoxo (5-
hyroxypyridine-2carboxy) oxovanadate (bpV(HOpic) in 
isolated perfused C57BL/J6 mouse hearts. 
Historically, vanadium compounds are reported to have effects on the cardiovascular system, 
increasing blood pressure and decreasing force of myocardial contraction (Borchard et al., 
1981). They are also reported to have effects on PTEN, blocking its function (Schmid et al., 
2004). According to the literature bpV(HOpic) is a specific pharmacological inhibitor of PTEN Hilary Siddall 
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(Schmid et al., 2004). This drug was used in our model of ischaemia-reperfusion injury to 
investigate this potential cardioprotective agent. It was hypothesised that the administration of 
bpV(HOpic) would induce cardioprotection against ischaemia-reperfusion injury by 
decreasing the level of PTEN. This drug is a protein tyrosine phosphatase inhibitor with 
specificity for PTEN due to a 100 fold greater inhibitory activity over other tyrosine 
phosphatases (Schmid et al., 2004). The results from these studies showed that the 
administration of the drug, given in increasing concentrations at reperfusion alone, did not 
confer protection in our model of ischaemia-reperfusion injury. Other groups have shown that 
administration of drugs, such as leptin in pancreatic and hypothalamic cells, can modulate 
PTEN stability within 30 min (Ning et al., 2006). Therefore administration of bpV(HOpic) at 
reperfusion may not be sufficient to effect PTEN/PI3K/AKT pathway before the irreversible 
damage caused by ischaemia-reperfusion injury transpires. Hence, it was predicted that 
perfusion of bpV(HOpic) given prior to ischaemia may provide protection against infarction. 
However, when bpV(HOpic) was perfused throughout stabilisation and reperfusion, no 
reductions in infarction were observed.  
 
In our experiments orthovanadate was administered as a positive control. A significant 
(p<0.01) level of protection against ischaemia-reperfusion injury was recorded. This 
observation is in agreement with work by Liem et al., 2004 who perfused orthovanadate in a 
model of myocardial ischaemia-reperfusion and demonstrated cardioprotection. Monitoring 
for any non specific drug effects during perfusion of the isolated mouse hearts was 
performed. It was observed that a brief and temporary reduction in flow upon the 
administration of orthovanadate (at stabilisation), typical of a vasoconstrictor-like function, 
occurred. Further studies to investigate the effects of 5 min low flow and low perfusion 
pressure in control hearts were applied in order to mimic this functional effect and showed no 
protection. This suggests that the reduction in infarction using orthovanadate was not due to Hilary Siddall 
 
173
the reduction of flow and perfusion pressure (i.e IPC like effect), and that alternative 
mechanisms are responsible.  
 
Similar to our findings, others have shown that orthovanadate can reduce infarction following 
ischaemia-reperfusion (Liem et al., 2004). The authors of this study attributed the protection 
to the opening of KATP channels (Liem et al., 2004). In addition orthovanadate has been 
shown to inhibit the NaK-ATPase (Svoboda et al., 1984). Orthovanadate is a general protein 
tyrosine phosphatase inhibitor (Schmid et al., 2004). Huisamen et al, 2003 showed that 
orthovanadate can increase phosphorylated AKT levels and induce glucose uptake in 
isolated rat cardiomyocyte. As yet the direct effects on PTEN have not been investigated, this 
may be important for future studies, as orthovanadate can protect against brain ischaemia-
reperfusion injury and has been shown to phosphorylate and inhibit PTEN (Wu et al., 2006).   
 
The lack of protection against ischaemia-reperfusion, with bpV(HOpic) was unexpected. In 
contrast, other groups have shown protection in other tissues using similar inhibitors of 
PTEN. In a study investigating axon cell growth by Arevalo et al 2006 the PTEN inhibitor 
bpV(pic) (dipotassium bisperoxo(picolinato) oxovanadate) was used to facilitate cell growth. 
In lung epithelial cells PTEN inhibitors bpV(phen) and bpV(pic) increased the levels of 
phosphorylated AKT (at the Ser473 site) and decreased the time to wound healing in a 
scratch model of injury (Lai et al., 2007). In this monolayer assay of wound healing, 2µM of 
the inhibitors was used (Lai et al., 2007). This protective concentration is similar to the 
highest dose used in our isolated whole heart model of ischaemia-reperfusion injury. It is 
possible that, a higher dose of bpV(HOpic) may be required to induce cardioprotection, since 
it is difficult to extrapolate results obtained using cell models for application in a whole organ 
model. It may also be argued that at higher concentrations the specific effects could be lost 
and other phosphatases might also be affected. Further difference can be highlighted in the 
lung injury model, described above, as epithelial cells are proliferative cells unlike Hilary Siddall 
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cardiomyocytes. By 48h the scratch wound was fully healed regardless of any pro survival 
intervention. In contrast, within our experiments cardiomyocytes, which are differentiated 
cells, were investigated and as an end point cell death was measured. Ischaemia-reperfusion 
is a severe stress and potentially, the amount of PTEN inhibition may not be sufficient to 
protect the myocardium subjected to our ischaemia-reperfusion protocol.   
 
Schmid et al., 2004 have investigated the effects of many bisperoxovanadium compounds on 
specific PTEN inhibition and provided a short list of their most potent inhibitors. To achieve 
this, the group stimulated NIH3T3 cells with insulin and monitored the phosphorylation of AKT 
in the presence of the PTEN inhibitors. Furthermore they investigated the lipid phosphatase 
activity of recombinant PTEN in the presence of the PTEN inhibitors and PI(3,4,5) used a 
malachite green reagent to detect the changes in phosphate release (Schmid et al., 2004). In 
this study their most potent PTEN inhibitor, published at the time was bpV(HOPic). 
Subsequently, this group have communicated data which show better vanadium based PTEN 
inhibitors, which was not known or available at the time of our studies (Rosivatz et al., 2006). 
There may be functional differences between these vanadium compounds in situ. For 
example Lai et al.,2007 investigated 2 of these inhibitors in their lung cell wound healing 
model and observed that bpV(phen) caused LDH release, whereas bpV(pic) did not effect 
cytotoxicity (Lai et al., 2007).  
 
An additional explanation for the lack of cardioprotection in the presence of bpV(HOpic) may 
be due to the pharmacokinetics and pharmacodynamics of the drug. Initially, we perfused the 
PTEN inhibitor at reperfusion only, and saw no reduction in infarction. Subsequently the drug 
was perfused throughout stabilisation to afford sufficient time for PTEN inhibition. The half life 
and the duration of action of this inhibitor are unknown. Therefore it may be possible that 
during ischaemia (35min) the effects on PTEN are lost enabling full activation of residual Hilary Siddall 
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PTEN at reperfusion. Future work to address this issue could include administered the drug 
at stabilisation and measuring AKT activity at reperfusion. 
 
In summary, we observed no reductions in infarction using 0.02-10µM bpV(HOpic) and were 
able to demonstrate cardioprotection only by using the positive control orthovanadate. 
However, due to the non-specific actions of this general tyrosine phosphatase inhibitor further 
investigations using orthovanadate as an inhibitor of PTEN were not pursued.  
 
4.4.1.2   Ischaemic preconditioning and bpV(HOpic) in isolated 
perfused C57BL/J6 mouse hearts 
Infarction studies 
The cardioprotection obtained by IPC in isolated C57BL/J6 mouse hearts perfused with or 
without bpV(HOpic) was investigated. Myocardial infarction was compared following 
ischaemia-reperfusion alone or ischaemia-reperfusion preceded by 2 or 4 cycles of IPC (5 
min ischaemia and 5 min reperfusion). IPC stimulates the activity of the PI3K/AKT pathway 
(Yellon and Hausenloy, 2005). As shown in Figure 4.6, a reduced threshold for IPC induced 
protection in the presence of bpV(HOpic) was observed. Hearts perfused with control buffer 
were significantly (p<0.05) protected with 4 cycles IPC whereas myocardium perfused with 
bpV(HOpic) was significantly (p<0.01) protected with both 2 and 4 cycles IPC, respectively. 
This finding positively supports our hypothesis that the presence of a PTEN inhibitor can 
facilitate cardioprotection.  
 
Schmid et al., 2004 were the first to identify bpV(HOpic) as an inhibitor of PTEN (Schmid et 
al., 2004). Interestingly, the in vitro assay they use to demonstrate PTEN inhibition required 
the addition of insulin. This indicates that the effect of PTEN inhibition is detected or amplified 
once the PI3K/AKT pathway has been stimulated, with insulin. Inhibitors of PTEN can Hilary Siddall 
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manipulate the PI3K/AKT pathway, causing significant biological changes (Cai et al., 2008b; 
Lai et al., 2007; Zhang et al., 2007). The results obtained in this study indicate that in order to 
demonstrate the cardioprotective effects of this drug, a stimulus of the PI3K/AKT pathway 
seems to be required.  
 
Further evidence supporting our results is offered by studies investigating the effects of 
increased PTEN level in the myocardium. Goto Kakazaki rats are  a well known model of 
diabetes and their isolated hearts express higher PTEN levels than wild type animals 
(Mocanu et al., 2006). These rats have a de-sensitised PI3K/AKT pathway in conjunction with 
an increased PTEN level (Tsang et al., 2005). This may be why Tsang et al., 2005 
demonstrated the myocardium from these rats exhibit a higher threshold to IPC, where 3 
cycles of IPC were required to induced protection in these rats compared to the usual 1 cycle 
in their WT controls.  Therefore the threshold of IPC appears higher in the Goto Kakazaki rat 
myocardium (Tsang et al., 2005). In addition, studies by Cai and Semenza in 2005, showed 
that changes occur to PTEN activity during IPC stimuli. This work provides supporting 
evidence that PTEN can be manipulated in the heart and that its down regulation may be 
involved in survival following ischaemia-reperfusion  injury (Cai and Semenza, 2005). 
Moreover, work by Huisaman in 2003 demonstrates that vanadate can lower the signalling 
sensitivity in the heart, The combination of sub-maximal concentrations of 1mM vanadate 
with 10mM insulin induced an additive response similar to that seen with 100nM insulin alone 
(Huisamen, 2003). Not only does this implicate vanadate as a modulator of the PI3K/AKT 
pathway it may also indicate that there are mechanisms which can increase the sensitivity of 
stimulated PI3K/AKT signalling. 
 
In summary, perfusion of isolated C57BL/J6 mouse hearts with bpV(HOpic) is not able to 
reduce infarction from ischaemia-reperfusion alone, in our model. However, when associated Hilary Siddall 
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with IPC, which is known to activate the PI3K/AKT, the threshold to cardioprotection is 
reduced.   
 
Signalling studies 
AKT  
Cardiomyocytes incubated with vanadate, a general tyrosine phosphatase inhibitor, express a 
higher level of phosphorylated AKT(Huisamen, 2003). General tyrosine phosphates inhibitors 
such as vanadate can inhibit PTEN and have also been shown to induce increases in the 
level of AKT phosphorylation (Posner et al., 1994; Schmid et al., 2004; Lai et al., 2007). 
However, such compounds are not specific for PTEN inhibition and alternative compounds 
such as bpV(HOpic) have been shown to have more specificity (100fold) for PTEN inhibition 
over general tyrosine phosphatase inhibition (Schmid et al., 2004). We hypothesised that 
myocardial perfusion with the PTEN inhibitor bpV(HOpic) would increase the phosphorylation 
of the pro survival protein AKT, uniquely in cardiac tissue. Indeed we observed a significant 
increase in phosphorylation of AKT at both Thr308 and Ser473 phosphorylation sites, p<0.01. 
Increases in the phosphorylation of AKT have been associated with cardioprotection (Bell and 
Yellon, 2003; Hausenloy and Yellon, 2004a; Baines et al., 1999). However, in our study the 
increase in AKT phosphorylation due to bpV(HOpic) was not sufficient to protect against 
infarction in our model of ischaemia-reperfusion injury.  
 
Nevertheless, we confirmed that IPC (4 cycles IPC in our mouse model of ischaemia-
reperfusion injury) significantly (p<0.05) increased phosphorylation of AKT at Ser473 site 
(Hausenloy et al., 2005; Cai et al., 2008a). Furthermore, no significant changes in AKT 
phosphorylation were observed at 2 cycles IPC. It was shown that bpV(HOpic) reduced the 
threshold for protection, where 2 cycles IPC conferred protection, compared to 4 cycles in 
control. However, no additional significant changes in AKT phosphorylation were observed 
between control, 2 and 4 cycles of IPC. The reason for this is not clear, future work to Hilary Siddall 
 
178
address this issue may include assessing the activity of alternative prosurvival signalling 
pathways, in the presence of bpV(HOpic) and IPC, such as JAK/STAT or p42/p44 pathway. 
 
Conversely, the level of AKT phosphorylation in the presence of bpV(HOpic) is higher than 
that observed in the control IPC. This finding is discussed below. Further experiments 
addressing this issue may provide additional information, such as investigating the level of 
phosphorylated AKT following ischaemia and reperfusion.  
 
PTEN  
In the presence of bpV(HOpic) no significant changes in PTEN phosphorylation, which can be 
an indicator of PTEN inactivity and instability were observed (Wu et al., 2006; Ning et al., 
2006). It is unknown if this drug activates enzymes that can phosphorylate 
(Ser380,Thr382/383 sites) and inactivate PTEN, such as CK2 (Ning et al., 2006). However, in 
the brain, the inhibition of PTEN using bpV(pic) and PTEN antisense technology has been 
associated with further increases in PTEN tyrosine phosphorylation and degradation, 
AKT(Ser473) phosphorylation and a reduction in JNK1 phosphorylation. These changes have 
been associated with neuroprotection against brain ischaemia (Zhang et al., 2007). Such 
phosphorylation events were not recorded and cardioprotection against ischaemia-
reperfusion in our myocardial model of ischaemia-reperfusion injury was not observed. The 
mechanisms of PTEN inhibition by bpV(HOpic) are unknown, however past papers showed 
that vanadium has properties similar to phosphate ions (Lindquist et al., 1973). These 
compounds can inhibit enzymes involved in phosphoryl transfer reactions, such as 
phosphoglycerate mutase which is involved in glucose metabolism (Climent et al., 1981). It is 
suggested that vanadium mimics the structure of phosphate transition states causing 
associative displacement and potentially, protein instability (Climent et al., 1981). Therefore, it 
could be considered that changes in the phosphorylation of PTEN may not accurately reflect Hilary Siddall 
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the state of PTEN activity. Further experiments may include investigating the level of PTEN 
ubiquitination in the presence of bpV(HOpic).  
 
bpV(HOpic) and IPC  
IPC activates many other signalling pathways in addition to PI3K/AKT. In the presence of 
bpV(HOpic) the effects on the PTEN/PI3K/AKT pathway may not be sufficient to reduce 
infarction following ischaemia-reperfusion alone. However the combination of sub maximal 
IPC stimulus and the PTEN inhibitor seems to promote the signals for protection, possibly 
due to further PTEN modulation. For example, IPC can generate ROS which is known to 
inhibit PTEN (Kwon et al., 2004; Cai and Semenza, 2005). As discussed in Chapter 6, 
additional PTEN inhibition, possibly due to the generation of ROS during IPC may explain the 
reduction in the threshold to IPC; in the presence of bpV(HOpic). A proposed hypothesis for 
how PTEN may be further inhibited in the presence of either a PTEN inhibitor or genetic 
deletions is shown in Figure 6.24. 
 
To conclude, in the presence of the PTEN inhibitor bpV(HOpic) the changes detected in the 
PI3K/AKT signalling were not sufficient to confer cardioprotection in our mouse model of 
ischaemia-reperfusion. However, once the PI3K/AKT pathway had been stimulated by IPC, 
the presence of the PTEN inhibitor reduced the threshold for protection induced by IPC.  
 
4.4.2 SF1773  (Semafore) 
4.4.2.1   Ischaemia-reperfusion injury in the presence of SF1773 
(Semafore) in isolated perfused C57BL/J6 mouse hearts 
The use of SF1773, a specific PTEN inhibitor, donated by Semafore Pharmacuticals was 
investigated, in our model of myocardial ischaemia-reperfusion injury. The initial dose used Hilary Siddall 
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was recommended by Semafore Pharmaceuticals, which tested the IC50 value for the drug by 
measuring the ability of isolated PTEN to convert PIP3 into PIP2. Using this drug in a range 
of concentrations, from 0.06 to 0.96µM, a small but significant (p<0.05) reduction in infarction 
against ischaemia-reperfusion injury was observed. However, a dose response effect with 
this compound was not detected. Only at 0.24µM was significance recorded, at the additional 
doses of 0.12, 0.48 and 0.96µM a small but insignificant reduction in infarct size was found. 
This may be because the standard error at these doses was to large. Other cardioprotective 
agents demonstrate dose response effects against ischaemia-reperfusion injury, such as 
adenosine or bradykinin (Maddock et al., 2002; Bell and Yellon, 2003). Therefore, if this 
reduction in infarction is a real effect the physiological relevance of this finding in terms of 
cardioprotection may be debated. It is possible that the bioavailability of the drug in a whole 
organ model is reduced and therefore provides limited biological effects, and increasing the 
concentrations further may address this issue. However, little is known about its mechanisms 
of action in PTEN inhibition. Therefore, we did not pursue the use of SF1773 as a PTEN 
inhibitor in our models of ischaemia-reperfusion injury.  
 
In conclusion, the effects of chemical inhibitors of PTEN on myocardial ischaemia-reperfusion 
injury were investigated. No protection was observed in the presence of bpV(HOpic) alone. 
However, when the PI3K pathway was stimulated by IPC, the threshold of protection was 
reduced in the presence of this drug. Using SF1773 (semaphore) a small reduction in 
infarction was recorded, however; no dose response effect was detected. Hilary Siddall 
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5  Chapter 5 – Biochemical modulation of PTEN using the 
p53 inhibitor pifithrin alpha  
5.1  Background, aims and hypothesis 
It has been demonstrated that p53, a transcription factor implicated in cell survival and death, 
can up regulate PTEN (Stambolic et al., 2001). Down regulation of the tumour suppressor 
p53 has been associated with a decrease in PTEN (Wang et al., 2005; Tang and Eng, 2006). 
Pifithrin alpha (PFTα) is a p53 inhibitor; however, its exact mechanism of action is not clear. 
The chemical structure of this compound is shown in Figure 2.7. Intra peritoneal injections of 
PFTα in rats can reversibly inhibit p53 dependent apoptosis caused by myocardial and renal 
ischaemia-reperfusion injury (Kelly et al., 2003; Liu et al., 2006). Furthermore, in mice, the 
deleterious effects of chemotherapy have been reduced using PFTα (Komarov et al., 1999).  
 
We aimed to establish whether it is possible to manipulate PTEN activity by modulating the 
levels of p53. If successful, this could provide a tool for investigating the effects of PTEN 
reduction on ischaemia-reperfusion injury. It was hypothesised that reducing the level of p53 
(using the known inhibitor PFTα)  would down regulate PTEN expression and that these 
hearts would be protected against ischaemia-reperfusion injury. 
 
5.2  Experimental protocol and methods  
NIH Swiss White mice (20-30g) were subjected to one of the following conditions every 24h 
for 3days, via i.p injection (n=5 in each group). These experiments were performed at the 
very start of this body of research and at that time we were using NIH Swiss White mice in 
our studies, see Chapter 3. 
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1)  Sham (0.9% saline) 
2)  Vehicle (0.1% DMSO/0.9%saline)  
3) PFTα (2.2mg/kg PFTα in 0.1% DMSO/0.9% saline)  
 
Four hours following the final injection cervical dislocation was performed and hearts were 
rapidly excised into ice cold Krebs-Henseleit buffer containing approx 500U heparin. Hearts 
were rapidly trimmed and the atrium and any blood clots were removed.  
 
Samples were then immediately snap frozen in liquid nitrogen and processed for Western blot 
analysis, as described in Chapter 2, section 6. Thereafter, the expression of total p53, 
phosphorylated and total PTEN (Ser380,Thr382/383 phosphorylation sites) and 
phosphorylated and total AKT (Ser473 phosphorylation site) was investigated. 
 
5.3  Results –Reducing PTEN levels using the p53 inhibitor pifithrin 
The results are shown in Figures 5.1, 5.2, 5.3 and 5.4 respectively. No significant differences 
were observed between sham, vehicle and PFTα groups. A small, but non significant, 
decrease in total p53, between the vehicle control group and the PFTα treated group was 
detected. However, under these experimental conditions this decrease was not sufficient to 
elicit changes in PTEN and, ultimately, in AKT expression. Hilary Siddall 
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Figure 5.1:  Total p53 protein expression in the myocardium from Swiss White mice 
exposed to saline control (0.9% saline), vehicle control (0.1%DMSO/0.9% saline) or 
2.2mg/kg PFTα (0.1%DMSO/0.9% saline) every 24h for 3 days, (n=5). There was no 
statistical differences between groups, assessed using the Student’s paired t-test. 
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Figure 5.2:  Phosphorylated versus to total PTEN (p/t) protein expression in 
myocardium from Swiss White mice exposed to saline control(0.9% saline), vehicle 
control (0.1%DMSO/0.9% saline)or 2.2mg/kg PFTα (0.1%DMSO/0.9% saline) every 24h 
for 3 days, (n=5). There was no statistical differences between groups, assessed using 
the Student’s paired t-test. 
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Figure 5.3: Phosphorylated versus to total (p/t) AKT (at Ser473 phosphorylation site) 
protein expression in myocardium from Swiss White mice exposed to saline 
control(0.9% saline), vehicle control (0.1%DMSO/0.9% saline) or 2.2mg/kg PFTα 
(0.1%DMSO/0.9% saline) every 24h for 3 days, (n=5). There was no statistical 
differences between groups, assessed using the Student’s paired t-test. 
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Figure 5.4:  Representative Western blots of the results shown in Figure 5.1-5.3.  Hilary Siddall 
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5.4 Discussion 
5.4.1  Reducing PTEN levels using the p53 inhibitor pifithrin alpha  
The tumour suppressor, p53 can up regulate the transcription of PTEN (Stambolic et al., 
2001). Therefore, it was predicted that the inhibition of p53 using PFTα, (a p53 inhibitor), 
would decrease the level of PTEN and maybe up regulate the PI3K/AKT survival pathway. 
We aimed to investigate if PFTα can be used as a tool for studying PTEN inhibition on 
ischaemia-reperfusion injury.  
 
Our results do not show any significant differences in the expression of p53, PTEN and AKT 
following the administration of PFTα. A possible explanation may be the absence of p53 
activation. Apoptotic stimuli such as UV light or doxorubicin are commonly used to up 
regulate p53 (Komarov et al., 1999; Wang et al., 2005). In MEF cells UV light up regulated 
p53 and induced cell death which was attributed to an increase in BAX induced membrane 
permeability. This effect was independent of its promoter activity (Chipuk et al., 2004). The 
authors of this work observed that, in the absence of UV light, this effect was abolished 
(Chipuk et al., 2004), indicating that part of p53 apoptotic effects are dependent on a stress 
stimulus such as UV light.  
 
In addition, a longer duration of PFTα administration may also be required. Eipel et al, have 
used this compound for up to 7 days in a hepatic model of tissue regeneration (Eipel et al., 
2005). Moreover, p53 knock out mice are available and may provide a more direct model to 
investigate the link of p53 to PTEN in the myocardium. These mice manifest cardioprotection 
against ischaemia-reperfusion injury (Matsusaka et al., 2006) and we predict down regulation 
of PTEN may contribute to this protection. 
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The mechanism by which PFTα induces p53 inhibition is unknown. It was identified that PFTα 
may not alter the expression of p53, however, it can affect p53 function, as assessed by p21 
and BAX expression. This implies that the total protein expression does not effect the protein 
function. Localisation of p53 can be important to cell signalling. In the presence of PFTα a 
reduction in p53 localisation at the nucleus and mitochondria can be observed following 
ischaemia-reperfusion (Kelly et al., 2003). Others have shown that PFTα is cardioprotective in 
a rat model of ischaemia-reperfusion injury (Mocanu and Yellon, 2003; Liu et al., 2006). 
Collectively this indicates that PFTα is cardioprotective by means of a number of different 
mechanism; from protein transcription to direct effects on mitochondrial survival (Stambolic et 
al., 2001; Kelly et al., 2003; Chipuk et al., 2004). PTEN reduction is included in this list; 
however, we were unable to demonstrate this. 
 
In summary, administration of PFTα did not reduce protein expression of p53 or PTEN and no 
changes were observed in AKT. Hence, we decided that our treatment with PFTα does not 
offer a reliable tool for reducing myocardial PTEN; therefore we aimed to investigate 
alternative methods for inhibiting PTEN. 
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6  Chapter 6 –The effect of ischaemia-reperfusion injury in 
myocardium from PTEN haploinsufficient mice 
6.1  Aims, hypothesis and experimental protocols 
Mice with PTEN deletions (PTEN haploinsufficient mice heterozygous for PTEN
+/-) exhibit 
multiple organ neoplasms, enhanced cell proliferation and defective apoptotic abilities. Their 
homozygous littermates (PTEN
-/-) do not survive gestation further than embryonic day E6.5 
(Podsypanina et al., 1999). In response to insulin, myocytes from these PTEN
+/- mice have 
enhanced glucose uptake and increased levels of AKT activity (Wong et al., 2007). The main 
hypothesis of this study was that the myocardium from these mice would be protected against 
cell death, induced by ischaemia-reperfusion. On commencement of this investigation the 
PTEN haploinsufficient (PTEN
+/-) mouse model was not available commercially. As a kind gift, 
2 breeding pairs were donated from Dundee University. Therefore, it was necessary to 
establish a breeding programme and characterise the strain within our colony prior to 
studying the response to ischaemia-reperfusion injury. The steps taken to investigate the 
hypothesis are listed below in brief and are described in more detail further in this chapter. 
The methods, results and discussion for each section are as follows.  
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1)  Characterising the PTEN
+/- mouse 
•  Monitoring breeding 
•  Measuring body weight and blood glucose 
•  Measuring myocardial PI3K/AKT/PTEN signalling 
 
2)  Investigating the response of the PTEN
+/- myocardium to ischaemia-reperfusion injury 
•  Measuring the response of isolated hearts to ischaemia-reperfusion injury 
•  Measuring the response of isolated cardiomyocytes to ROS induced 
mitochondrial damage 
 
3)  Investigating the response of the PTEN
+/- myocardium to ischaemic preconditioning 
•  Measuring the ischaemic preconditioning protocol required to induce 
protection in isolated hearts 
•  Measuring myocardial PI3K/AKT/PTEN signalling 
 
4)  Investigating reasons for the lack of protection against ischaemia-reperfusion injury in 
the PTEN
+/- mouse 
•  Measuring alternative regulators of the PI3K/AKT/PTEN pathway  
•  Measuring alternative mechanisms that contribute to ischaemia-
reperfusion injury 
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6.2  Characterising the PTEN
+/- haploinsufficient mouse model 
6.2.1 Experimental  protocols 
6.2.1.1   Monitoring Breeding 
With the support of the Biological Service Unit within UCL, the breeding pattern of the PTEN 
haploinsufficient mice (PTEN
+/-) was monitored. All animals were genotyped prior to 
experimentation. Tail or ear DNA was extracted and analysed by PCR amplification, 
thereafter, the DNA was separated and visualised by agarose gel electrophoresis, as 
described in chapter 2 section 4.2. 
 
6.2.1.2   Measuring body weight and blood glucose 
Prior to experimentation the body weights of the haploinsufficient mice and their littermate 
controls were recorded. In addition to measuring body weight, non fasting blood glucose 
levels were measured from the tails, immediately following cervical dislocation, n=6. An Accu-
Chek® compact plus glucose meter (Roche, UK) was used to monitor glucose levels. The 
results were expressed in mmol/L. 
 
6.2.1.3   Monitoring myocardial PTEN/PI3K/AKT signalling 
Possible changes in the activity and protein expression of the PTEN/PI3K/AKT pathway were 
investigated by measuring PTEN lipid phosphatase activity and the expression of 
phosphorylated PTEN and AKT. 
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6.2.1.3.1  Measuring PTEN lipid phosphatase activity 
The PTEN lipid phosphatase activity was investigated in the PTEN
+/- myocardium and it was 
hypothesised that there would be a reduced PTEN activity in these hearts compared to 
littermate controls. The lipid phosphatase activity was estimated using an Echelon ELISA 
assay, as described in chapter 2, section 4.3, Samples were collected from isolated hearts 
perfused on the Langendorff apparatus, without ischaemia-reperfusion, as shown in Figure 
6.1 A and described in chapter 2, section 1, n=3 and each heart was examined in replicates 
of 3.   
 
Optimisation experiments were performed to further validate this assay, for the detection of 
PTEN phosphatase activity, within the Hatter Institute. We investigated the most efficient 
dilution of myocardial homogenate to use in the assay. It was hypothesised that there would 
be a reduction in PTEN phosphatase activity in the PTEN
+/- myocardium. 
 
6.2.1.3.2  Measuring PTEN and AKT expression 
The levels of PTEN and AKT were investigated in the PTEN
+/- mouse hearts, using Western 
blot analysis, as described in chapter 2, section 6. Samples were collected from isolated 
hearts perfused on the Langendorff perfusion apparatus for 10 min, with no ischaemia, as 
shown in Figure 6.1, A, n=3. This perfusion was done in order to ensure that blood 
contaminants were removed from the tissue.  
 
PTEN - Phosphorylated and total levels of PTEN. Phosphorylated PTEN expression is 
indicative of PTEN inactivity (Ning et al., 2006; Wu et al., 2006; Zhang et al., 2007). 
Therefore, it was hypothesised that in the PTEN
+/- myocardium there would be an increase in 
phosphorylated PTEN and a decrease in total PTEN, compared to hearts from PTEN
+/+ mice. 
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AKT - Full activation of the pro survival kinase AKT requires phosphorylation of amino acids 
Ser473 and Thr308 (Alessi et al., 1996). The profile of these two phosphorylation sites were 
investigated. It was hypothesised that in the PTEN
+/- myocardium there would be an increase 
in phosphorylated AKT.  
 
= Infarct measurement (I/R%) using TTC staining = Ischaemia
= Western blot sample collection = bpV(HOpic)
35min global
ischaemia
30min 
reperfusion
30min
stabilisation
A) Male myocardium 
(PTEN+/+  and PTEN+/-)
C) Female myocardium
ageing
(PTEN+/+  and PTEN+/-)
D) Male myocardium
and bpV(HOpic) 
(PTEN+/+  and PTEN+/-)
B) Female myocardium
(PTEN+/+  and PTEN+/-)
= Infarct measurement (I/R%) using TTC staining = Ischaemia
= Western blot sample collection = bpV(HOpic)
35min global
ischaemia
30min 
reperfusion
30min
stabilisation
A) Male myocardium 
(PTEN+/+  and PTEN+/-)
C) Female myocardium
ageing
(PTEN+/+  and PTEN+/-)
D) Male myocardium
and bpV(HOpic) 
(PTEN+/+  and PTEN+/-)
B) Female myocardium
(PTEN+/+  and PTEN+/-)
 
 
Figure 6.1: Experimental protocols used to investigate infarction in isolated hearts 
from PTEN
+/+ and PTEN
+/- mice. A) male hearts; B) female hearts; C) Ageing (20wk vs 
10wk) female hearts; D) male myocardium perfused with the PTEN inhibitor 
bpV(HOpic).  I/R% = percentage of infarction to risk area TTC = triphenyltetrazolium 
chloride. 
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6.2.2 Results 
6.2.2.1   Breeding 
PTEN haploinsufficient mice were good breeders if pairs were establish at a young age (6-8 
weeks). On average, a litter produced 6-8 pups. However, due to the onset of tumour 
development, breeding periods were short. PTEN
+/- females were especially sensitive and 
only produced a total of 3-5 litters: in contrast PTEN
+/- males bred 2-3 times longer. 
Therefore, preferentially we paired (PTEN
+/+ females) with (PTEN
+/- males); producing litters 
containing 50:50% average PTEN
+/+ to PTEN
+/- phenotypes. As previously mentioned, PTEN
-
/- animals are not viable and the embryos die in uterus (Podsypanina et al., 1999). The 
presence of PTEN
-/- pups were therefore, not observed in our litters. 
 
PTEN
+/+ samples amplified 2 PCR products: a non-specific band running as 100base pairs 
(bp) and  a second band running as 240bp. PTEN
+/- samples amplified a total of 3 PCR 
products, with a third additional band running as 320bp. A photographic representation of the 
PCR products from a typical litter is shown in Figure 6.2.  
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1    2     3     4      5      6     7     8     9    10    11   12   13
bp
200 
100 
500 
1    2     3     4      5      6     7     8     9    10    11   12   13
bp
200 
100 
500 
 
Figure 6.2:  Photographic example of genotyping a litter containing PTEN
+/+ and 
PTEN
+/- mice. Lane 1 = 100 base pairs (bp) ladder. Lane 2 = positive control donated 
from Dundee University. Lanes 3,6,7 and 8 = PTEN
+/- mice; lanes 4,5,9 and 10 = PTEN
+/+. 
Lanes 11-13 = negative controls containing no Taq Polymerase.  
 
6.2.2.2   Body weight and blood glucose 
Body weight 
Figure 6.3 displays the body weight of the mice. As expected males are heavier than females, 
for example PTEN
+/+ males weigh 29.17 ± 1.21g compared to PTEN
+/+ females weighing 
22.33±0.619g. However, in PTEN
+/- males and females only, a small insignificant increase in 
weight was observed. For example the female PTEN
+/+ mice weighed an average of 
22.33±0.619g compared to the PTEN
+/- mice which had an average weight of 23.816±0.97g. 
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Figure 6.3:  Female and male body weight in grams (g) in PTEN
+/+ (black bars) 
compared to PTEN
+/- (blue bars) mice (n=6). There was no statistical differences 
between groups, assessed using the Student’s paired t-test. 
 
Blood glucose 
Figure 6.4 displays the values of the blood glucose measured from tail samples (non-fasted). 
No differences in blood glucose were observed between PTEN
+/+ and PTEN
+/-mice. Male 
blood glucose was reduced from 11.06±0.29mmol/L in PTEN
+/+ mice to 10.34±0.33mmol/L in 
the PTEN
+/-mice, however, this change was not significant.  
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Figure 6.4:  Female and male blood glucose (mmol/L) from PTEN
+/+ (black bars) 
compared to PTEN
+/- (blue bars) mice (n=6). There was no statistical differences were 
assessed using the Student’s paired t-test. 
 
6.2.2.3   Myocardial PTEN/PI3K/AKT signalling 
6.2.2.3.1 Myocardial  PTEN  lipid phosphatase activity 
The lipid phosphatase activity was estimated using an ELISA assay which monitors the level 
of PI(3,4,5)P3 that is converted into PI(4,5)P2, and is recorded by changes in absorbance 
(O.D). The results are displayed in Figure 6.5 which represents the average OD values 
obtained from basal PTEN
+/- hearts without any ischaemia-reperfusion. There were no 
significant differences in PI(3,4,5)P3 phosphatase activity between PTEN
+/- and their PTEN
+/+ 
littermates.  
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Figure 6.5:  PTEN lipid phosphatase activity in the myocardium of the PTEN
+/+ (black 
bars) compared to PTEN
+/- (blue bars) mice, samples were homogenised in suspension 
buffer and assayed using the Echelon PTEN ELISA kit, (n=3). There was no statistical 
differences between groups, assessed using the Student’s paired t-test. 
 
These results were surprising, as it was expected that the myocardium from PTEN
+/- mice 
would have less phosphatase activity. The following results show what we did to investigate if 
this effect was real or if they reflected an operator error. Figure 6.6 and Figure 6.7 show the 
optimisation steps performed in our investigations. Figure 6.6 demonstrates the typical 
absorbance values obtained with the PI(4,5)P2 standard curve provided in the ELISA assay 
kit. As shown in Figure 6.6 a sample from PTEN
+/+ myocardium provided an OD values of 
0.542±0.02 O.D. It was observed that although the samples were not at the lowest point of 
the standard curve neither were they in the most linear part of the scale, approx 0.75 O.D. Hilary Siddall 
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Figure 6.6:  Illustration of the phosphatidylinositol 2 phosphate (PI(4,5)P2) standard 
curve required for the PTEN lipid phosphatase ELISA activity assay (n=3).  
 
We have included the assay optimisation results with the aim to explain why no differences in 
PTEN lipid phosphatase activity were observed in the PTEN
+/- myocardium. Figure 6.7 
indicates that as you dilute the myocardial homogenate samples, the OD value increases. 
This indicates that, when our enzyme preparation was diluted, more PI(4,5)P2 was 
converted. These preliminary optimisation results suggested that a component in the 
myocardial homogenate buffer may be interfering with the activity of PTEN in our lysed 
samples. In summary, we could not confidently address the question regarding PTEN activity 
in the PTEN
+/- hearts using this model. 
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Figure 6.7:  Optimisation data for the PTEN lipid phosphatase ELISA activity assay, 
investigating dilutions of myocardial sample homogenate (n=2).  
 
6.2.2.3.2  The expression of myocardial PTEN and AKT in the PTEN
+/- 
myocardium 
PTEN 
It was hypothesised that in the PTEN
+/- myocardium there would be reduced level of total 
PTEN expression and/or increased levels of phosphorylated PTEN expression (indicative of 
PTEN inactivity). As predicted, the basal level of total PTEN was significantly (p<0.05) 
reduced from 0.84±0.1 arbitrary units (A.U) in PTEN
+/+ controls to 0.35±0.07 A.U in 
haploinsufficient PTEN
+/- myocardium, shown in Figure 6.8. In addition, a small but significant 
(p<0.05) increase in phosphorylated PTEN in the PTEN
+/- mice was also observed, being 
increased from 1.12 ± 0.07 A.U in PTEN controls
+/+ to 1.40 ± 0.09 A.U in the PTEN
+/- 
myocardium, as shown in Figure 6.9. These results demonstrate a reduced PTEN expression 
and also indicate the remaining PTEN may be less active in the PTEN haploinsufficient 
myocardium.  Hilary Siddall 
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Figure 6.8:  Total PTEN protein expression in myocardium from PTEN
+/+ (black bars) 
compared to PTEN
+/- (blue bars) mice (n=3). Statistical differences were assessed 
using the Student’s paired t-test, (*p<0.05). 
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Figure 6.9:  Phosphorylated PTEN (p/t PTEN) protein expression in myocardium from 
PTEN
+/+ (black bars) compared to PTEN
+/- (blue bars) mice (n=3). Statistical differences 
were assessed using the Student’s paired t-test, (*p<0.05).  
 
AKT 
It was hypothesised that in the PTEN
+/- myocardium there would be an increased expression 
of phosphorylated AKT (indicative of AKT activity). As predicted, the basal level of 
phosphorylated AKT, at the Ser473 phosphorylation site, was significantly increased in 
PTEN
+/- haploinsufficient myocardium. The levels were increased to 0.62±0.156 A.U from 
0.20±0.088 A.U, p<0.05, in control myocardium, as shown in Figure 6.10. Furthermore, a 
significant (p<0.05) increase in phosphorylation of AKT at the Thr308 phosphorylation site 
was observed in the PTEN
+/- myocardium. The levels were increased to 0.27±0.037 A.U from 
0.10±0.035 A.U in the control myocardium, as shown in Figure 6.11.   Hilary Siddall 
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Figure 6.10: Phosphorylated AKT at Ser473 site (pAKT(Ser473)) protein expression in 
myocardium from PTEN
+/+ (black bars) compared to PTEN
+/- (blue bars) mice (n=3). 
Statistical differences were assessed using the Student’s paired t-test, (*p<0.05).  
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Figure 6.11: Phosphorylated AKT at Thr308 site (pAKT(Thr308)) protein expression in 
myocardium from PTEN
+/+ (black bars) compared to PTEN
+/- (blue bars) mice (n=3). 
Statistical differences were assessed using the Student’s paired t-test, (*p<0.05).  
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Taken together this data indicate that the myocardium from the PTEN haploinsufficient mice 
have a significant reduction in PTEN expression and increased AKT phosphorylation in 
comparison to their PTEN
+/+ littermate controls. This may have consequences for the survival 
of the ischaemic-reperfused myocardium.  
 
6.2.3 Discussion 
6.2.3.1   Characterising the PTEN
+/- haploinsufficient mouse model 
As shown by Podsypanina et al., 1999 and Wong et al., 2007, and in this study, we 
demonstrated that the PTEN
+/- mice were heterozygous for PTEN. No significant differences 
in body weight or blood glucose was observed between PTEN
+/- and PTEN
+/+ mice, 10-15 
weeks of age. In contrast Wong et al., found a small but significant reduction in tail vein blood 
glucose in the PTEN
+/- mice, undergoing ad libitum feeding. They recorded blood glucose 
levels directly from the tail vein, as 7.1±0.4 mmol/L from the PTEN
+/+ mice compared to 
6.3±0.2 mmol/L from the PTEN
+/- mice. We recorded higher levels of blood glucose from our 
mouse colony, 11.06±0.29 mmol/L in the PTEN
+/+ controls and 10.34±0.33 mmol/L in the 
PTEN
+/- mice. 
 
6.2.3.2   PTEN haploinsufficiency and myocardial PTEN/PI3K/AKT 
signalling 
The aim of this section was to investigate the functional consequences of the PTEN mutation 
in the myocardium from our PTEN haploinsufficient mouse colony. Myocardial PTEN 
phosphatase activity was investigated, using an Echelon PTEN ELISA kit, which detects the 
level of PI(3,4,5)P3 that is converted into PI(4,5)P2. In addition the level of phosphorylated Hilary Siddall 
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and total PTEN and AKT expression in the myocardium from these mice was investigated, 
using Western blot analysis.  
 
6.2.3.2.1 Myocardial  PTEN  lipid phosphatase activity  
It was expected that in the in PTEN
+/- myocardium there would be a reduction in PTEN lipid 
phosphatase activity. However, no changes in the PI(3,4,5)P3 phosphatase activity between 
PTEN
+/- and PTEN
+/+ hearts were detected. These results were surprising however, the data 
from the assay optimisation studies indicate that the signals obtained in these samples were 
not large enough to detect potential differences between PTEN
+/+ and PTEN
+/- myocardium. 
Furthermore, the manufacturer of this kit only provided a protocol for detecting activity in cell 
lysates, not whole organ lysates. Western blot suspension homogenate buffer (described in 
chapter 2.7) was used to assay myocardial samples. Consequentially, when this buffer was 
diluted, we observed that the assay signal was amplified. It is not clear to us what the 
reasons for this are. A possible explanation could be that the ingredients on the cell lysis 
buffer, such as sodium pyrophosphate, may be inhibiting PTEN and or the ELISA assay. This 
may explain the observation that as the buffer was diluted the activity of PTEN appeared to 
increase. However, these observations may be due to changes on the ELISA assay itself, 
such as the substrate (PIP3). Regardless of the mechanisms of this interference, future work 
would require the investigation and application of an alternative homogenisation buffer, as 
discussed in section 6.4.3. Our results indicated that the suspension buffer may have 
interfered with the assay.  
 
Even though the standard curve worked well our results indicated that calculating the level of 
PI(4,5)P2 conversion in whole hearts, using our ELISA technique may not be reliable. In 
summary, we could not confidently address the question regarding PTEN activity in the 
PTEN
+/- hearts using this model. Hilary Siddall 
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6.2.3.2.2  The expression of myocardial PTEN and AKT 
PTEN 
It was hypothesised that in the PTEN
+/- myocardium there would be a reduction in total PTEN 
protein expression and/or an increase in phosphorylated PTEN expression, indicative of 
PTEN inactivity (Ning et al., 2006; Wu et al., 2006). As predicted, in the PTEN
+/- myocardium 
the basal level of total PTEN was reduced, by 58% and the phosphorylated compared to total 
PTEN was significantly increased (p<0.05). This indicates that in the PTEN haploinsufficient 
myocardium there is a decreased level of PTEN expression and that the remaining PTEN 
may be less active. The individual blots used to assess these differences, shown in Figure 
6.9, are not the best quality however; these findings were consistant when repeated. 
 
The PTEN mouse model used contained a heterozygous mutation, meaning that there was a 
remaining allele with normal PTEN function. This may explain the reason why no further 
reductions in total PTEN protein were observed. The level of PTEN reduction, recorded in 
these mice can vary between groups. Bayascas et al., 2005 have shown a reduction in the 
expression of PTEN in the liver. These changes were not significant, however a significant 
increase in the phosphorylation of AKT was observed in the PTEN
+/- mice (Bayascas et al., 
2005). In contrast, Huang et al., 2005 recorded a 50% reduction in the levels of liver and 
myocardial PTEN expression (Huang et al., 2008). In these knockout mice the effected region 
is within Exon 5 of the PTEN gene, which has been linked to activity (Podsypanina et al., 
1999). Our PTEN
+/- mouse colony tests positive for this deletion. As described by 
Podsypanina et al., 1999, these mice are predisposed to the development of tumours in 
proliferative tissue such as prostate and endometrial tissue, supporting the fact that an allele 
for PTEN has been deleted (Podsypanina et al., 1999). Our data coincides with work 
published by others indicating the total protein reduction in these mice can be minimal yet still 
have physiological consequences (Podsypanina et al., 1999). For example these mice exhibit Hilary Siddall 
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insulin hypersensitivity (Wong et al., 2007) and we have observed an increased incident of 
tumours. This suggests that there is insufficient PTEN function and up regulation of growth 
and survival pathways. Others groups have shown that the remaining PTEN appears to have 
reduced PTEN activity (Bayascas et al., 2005; Wong et al., 2007). Post translational 
modifications can also affect PTEN, for example phosphorylated PTEN is associated with 
reduced activity. Furthermore, PTEN phosphorylation by CK2 can inhibit activity and 
additionally make the phosphatase more susceptible to further phosphorylation and 
inactivation (Al Khouri et al., 2005; Ning et al., 2006).  
 
AKT 
It was hypothesised that the myocardium from PTEN
+/-  mice would have an increased 
expression of phosphorylated AKT (indicative of AKT activity). As predicted, the basal level of 
phosphorylated AKT (at Ser473 and Thr308 phosphorylation sites) was significantly 
increased in PTEN haploinsufficient myocardium (p<0.05). The individual blots used to 
assess this are shown in Figure 6.10 and are not the best quality, nevertheless the findings 
were consistent when repeated. Other laboratories have also successfully measured 
increases in AKT phosphorylation as an indicator of PTEN inactivity, in cells (Schmid et al., 
2004; Lai et al., 2007) and in the brain (Wu et al., 2006). The data shown in this section 
indicates that the PI3K/AKT signalling pathway is up regulated in the PTEN
+/- myocardium.  
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6.3 Investigating the response of the PTEN
+/-  myocardium to 
ischaemia-reperfusion injury 
6.3.1 Experimental  protocols 
The response of PTEN haploinsufficiency to simulated ischaemia-reperfusion injury was 
investigated. An isolated heart model of ischaemia-reperfusion injury and an isolated 
cardiomyocyte model of ROS induced mitochondrial damage was used. As described in 
chapter 2, section 2 and 5, respectively. It was hypothesised that the PTEN
+/- myocardium 
would be more resistant to ischaemia-reperfusion induced cell death due to up regulation of 
the PI3K/AKT prosurvival pathway. 
 
6.3.1.1   Ischaemia-reperfusion injury in isolated perfused mouse 
hearts 
As a standard, male mice are the preferred choice for use in experiments that investigate 
myocardial infarction, in order to avoid the possibility of cardioprotective effects from 
estrogens. Therefore, the following experiments, primarily used male mice. However, we 
aimed to maximise the use of each litter and additional validation studies entailed the use of 
female mice. 
 
1)  Isolated perfused male PTEN
+/- and PTEN
+/+ myocardium (n=6) were subjected to the 
standard protocol of ischaemia-reperfusion, as shown in Figure 6.1 and the level of 
infarction was measured as an endpoint. It was hypothesised that the PTEN
+/- 
myocardium will bestow protection against ischaemia-reperfusion injury.  
 
2)  Female, PTEN haploinsufficient mice develop tumours more readily than males; which 
reflects a higher activation of the PI3K/AKT pathway (Podsypanina et al., 1999). Hilary Siddall 
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Therefore it was additionally hypothesised that the female PTEN
+/- myocardium may 
be better protected against ischaemia-reperfusion injury. We subjected isolated 
perfused female PTEN
+/- and PTEN
+/+ myocardium (n=6) to our standard protocol of 
ischaemia-reperfusion, as shown in Figure 6.1,B and measured infarction as an 
endpoint.  
 
3)   Tumour progression in these mice is positively correlated with age. (Podsypanina et 
al., 1999). Therefore, it was additionally hypothesised that a better protection may be 
achieved with age and that the older PTEN
+/-  myocardium would develop smaller 
infarcts than the littermate controls. The effect of PTEN haploinsufficiency in the aging 
myocardium was investigated and the infarct size in mice at 10wks to mice at 20wks 
of age was compared. Female mice were used in this investigation and subjected to 
our standard protocol of ischaemia-reperfusion, as shown in Figure 6.1,C, n= 5.  
 
4)  The PTEN haploinsufficient mouse is a congenital model of PTEN down regulation in 
which the PTEN/AKT pathway is expected to be affected (Wong et al., 2007). 
However, an allele remains native for PTEN. We aimed to maximise PTEN inhibition 
in these mice using the PTEN inhibitor bpV(HOpic). Consequently, it was 
hypothesised that perfusion of the PTEN
+/- myocardium with the PTEN inhibitor 
bpV(HOpic) would bestow an even bigger reduction in infarction following ischaemia-
reperfusion injury. Isolated PTEN
+/- and PTEN
+/+ myocardium (male, 10-15wks) were 
perfused with either control buffer or with buffer containing 1µM of bpV(HOpic) (n=5) 
throughout stabilisation and reperfusion, as shown in Figure 6.1,D. The vehicle control 
for this drug was water. Infarction was measured as an endpoint.  
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6.3.1.2   Response of isolated cardiomyocytes to ROS induced 
mitochondrial damage 
Opening of the mitochondrial permeability transition pore has been associated with the final 
stages of cell death and plays an important role in ischaemia-reperfusion injury  (Halestrap et 
al., 2004). Primary cardiomyocytes were isolated from PTEN haploinsufficient mouse hearts 
and subjected to ROS induced mitochondrial damage, as described in Chapter 2, section 5. 
ROS was generated in the mitochondria to mimic reperfusion injury (Hausenloy et al., 2003). 
The time to mitochondrial depolarisation was measured and compared to that recorded from 
PTEN
+/+ littermate control cells. As a positive control, CsA (0.4µM) was administered as an 
inhibitor of mPTP opening, 15 min prior to ROS stimulation. Cells were isolated from 3 hearts 
in separate experiments (n=3), which provided 37±2 cells for each condition tested. It was 
hypothesised that cardiomyocytes from the PTEN
+/- myocardium would exhibit a delay in the 
time to mPTP opening, compared to myocytes from littermate control myocardium. 
 
6.3.2 Results 
6.3.2.1   Ischaemia-reperfusion injury in isolated perfused PTEN
+/- 
myocardium 
Isolated perfused male PTEN
+/- myocardium were subjected to the standard protocol of 
ischaemia-reperfusion injury. Unexpectedly, no protection in response to ischaemia-
reperfusion was detected in the haploinsufficient myocardium as shown in Figure 6.13. 
Isolated hearts from male PTEN
+/- mice developed an infarct size of (42.1± 5.0%) which was 
similar to the infarction developed in male PTEN
+/+ hearts 45.6±3.3%. Furthermore, no 
difference in the heart function prior to ischaemia or at reperfusion was observed.  
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As mentioned above, it was hypothesised that the female PTEN
+/- myocardium may be more 
resistant to ischaemia-reperfusion. These mice develop tumours more readily than males and 
therefore appear to be more effected by the mutation (Podsypanina et al., 1999). However, 
as shown in Figure 6.12, again no protection was observed in the female PTEN
+/- 
myocardium. These female PTEN
+/- hearts developed a similar infarct size (52.2± 6.2%) 
compared to male PTEN
+/- and PTEN
+/+ myocardium. 
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Figure 6.12: Percentage infarction developed in the risk area (I/R%) in male and female 
PTEN
+/+ and  PTEN
+/- myocardium subjected to ischaemia-reperfusion injury (n=6). 
There was no statistical differences between groups, assessed using the Student’s 
paired t-test. 
 
As described on page 210, tumour progression in these mice is positively correlated with age 
(Podsypanina et al., 1999). Therefore, it was hypothesised that the protection may be 
increased in older PTEN
+/- myocardium. However, no significant differences were recorded 
between myocardium from mice 10 weeks of age compared to those at 20 weeks of age, as Hilary Siddall 
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shown in Figure 6.13. The isolated hearts from PTEN
+/+ mice at 20 weeks of age developed 
an infarct size of 51.9±5.98% which was similar to hearts from PTEN
+/- mice of the same age 
(42.88± 5.17%). 
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Figure 6.13: Percentage infarction developed in the risk area (I/R%) in female PTEN
+/+ 
and PTEN
+/- myocardium subjected to ischaemia-reperfusion: at 10wks and 20wks of 
age (n=5). No significant differences were identified, assessed using a One way 
ANOVA test. 
 
The PTEN haploinsufficient mouse is a congenital model containing a PTEN mutation and as 
previously shown, the PTEN/AKT pathway is affected in these mice. However, an allele 
remains native for PTEN. Consequently, it was hypothesised that perfusion of the PTEN 
inhibitor bpV(HOpic) in the PTEN
+/- myocardium would bestow protection against ischaemia-
reperfusion injury. Surprisingly, again no significant differences in the level of infarction were 
recorded, as shown in Figure 6.14. For example isolated hearts perfused with 1µM Hilary Siddall 
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bpV(HOpic) from PTEN
+/+ developed an infarct size of 39.16±6.5% which was similar to the 
PTEN
+/- hearts which developed an infarct size of 37.14± 3.15%.  
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Figure 6.14: Percentage infarction developed in the risk area (I/R%) in male PTEN
+/+ and 
PTEN
+/-  myocardium (10-15wks) subjected to ischaemia-reperfusion in the presence 
and absence of bpV(HOpic) (n=6). No statistical differences observed using a One way 
ANOVA test.  
 
In summary, the PTEN haploinsufficient myocardium appears to have enhanced activity of 
the PI3K/AKT pro survival pathway. However, this level of activation is not sufficient to induce 
protection against our models of myocardial ischaemia-reperfusion injury. 
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6.3.2.2   Isolated PTEN
+/- cardiomyocytes and ROS induced 
mitochondrial damage 
We investigated whether cardiomyocytes isolated from the PTEN
+/- myocardium were 
protected against ROS induced mPTP opening. It was hypothesised that there would be a 
delay in the time to mPTP opening. The results are shown in Figure 6.15 and indicate there is 
no significant difference in time to mPTP opening in myocytes isolated from PTEN
+/- (195 ± 2 
sec) myocardium compared to the  PTEN
+/+  (224  ± 4 sec) cardiomyocytes. As expected, 
incubation of isolated cardiomyocytes with CsA delayed the time to mPTP opening. CsA 
reduced time to mPTP opening to 366 ± 64 sec in PTEN
+/- myocytes and 351 ± 74 sec in 
PTEN
+/+ myocytes. No differences in the time to mPTP opening were detected between 
PTEN
+/- and PTEN
+/+ myocytes incubated with CsA.  
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Figure 6.15: Time to ROS induced mitochondrial depolarisation, time to mitochondrial 
permeability transition pore (mPTP) opening in PTEN
+/+ and PTEN
+/- mouse 
cardiomyocytes with or without cyclosporine A (CsA), an inhibitor of mPTP (cells 
isolated from 3 hearts, providing 37±2 cells for each condition). Statistical differences 
were assessed using the students paired t-test, compared to each control (*= p<0.05).   
 
In summary, reducing PTEN (either using a chemical inhibitor or a genetically manipulated 
mouse strain) does not confer protection against myocardial infarction; despite AKT 
activation. However, because AKT activation is increased, it was hypothesised that the 
threshold for cardioprotection is lowered in the PTEN
+/- hearts. IPC was selected as the 
model to verify this hypothesis. 
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6.3.3 Discussion 
6.3.3.1   The response of isolated hearts to ischaemia-reperfusion 
injury 
It was hypothesised that the genetic disruption of PTEN would facilitate a decrease in 
myocardial ischaemia-reperfusion injury. However, PTEN haploinsufficient mice did not 
present with any further protection against ischaemia-reperfusion in comparison to their 
littermate controls. Firstly, isolated perfused myocardium from male PTEN
+/- mice were 
subjected to our standard protocol of ischaemia-reperfusion, and unexpectedly no protection 
was detected, as the infarct size was similar to the level from their PTEN
+/+ littermates. 
Additionally, it was hypothesised that the female PTEN
+/- myocardium may be more resistant 
to ischaemia-reperfusion, however, no protection was observed relative to littermate controls. 
In light of these observations, it was hypothesised that protection may be achieved in the 
older PTEN
+/-  myocardium, however, no significant differences were recorded between 
myocardium from mice 10 weeks of age compared to those at 20 weeks of age. Cai et al., 
2008 have studied ischaemia-reperfusion injury in HIF1α heterozygous knockout mouse, in 
their experiments they used mice that were 24 weeks old (Cai et al., 2008a). Unfortunately, 
we could not investigate PTEN
+/- mice older than 20 weeks, as they exhibited the onset of 
tumours and needed to be euthanased. The PTEN haploinsufficient mouse is a congenital 
model of PTEN down regulation and, as we have shown, the PTEN/PI3K/AKT pathway is 
affected in these mice. However, as discussed previously, one allele remains wild type for 
PTEN. Consequently, it was hypothesised that perfusing the PTEN inhibitor bpV(HOpic) 
through the PTEN
+/- myocardium would bestow protection against ischaemia-reperfusion 
injury. Surprisingly, even under these conditions, no significant differences in infarct size were 
recorded.  
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Interestingly, Crackower et al., 2002 have produced a homozygous knock out (-/-) of PTEN, 
organ targeted for mouse hearts and skeletal muscle only. Consequently, the hearts become 
hypertrophic and had impaired contractility (Crackower et al., 2002). This is a different knock 
out model to the one used in this study, however the finding by Crackower et al., 2002 
highlighted that the complete ablation of PTEN can have major physiological implications, 
such as cardiac hypertrophy and reduced myocardial contractility.  
 
6.3.3.2   The response of isolated cardiomyocytes to ROS induced 
mitochondrial damage 
The opening of the mPTP in relation to apoptosis and myocardial ischaemia-reperfusion 
injury has been studied (Griffiths and Halestrap, 1995; Halestrap et al., 2004; Argaud et al., 
2005a). Interestingly, isolated rabbit hearts were perfused with CsA or the non 
immunosuppressive derivative NIM811 are protected against ischaemia-reperfusion injury. 
Mitochondria isolated from these hearts required a higher concentration of Ca
2+ overload in 
order to open the mPTP and induce cell death (Argaud et al., 2005a). The authors of this 
work attributed cardioprotection in the myocardium to this delay in mPTP opening.  
 
In order to investigate weather PTEN
+/- cardiomyocytes are protected against mPTP opening; 
an isolated cardiomyocyte model of mPTP opening was used. This assay was a secondary 
model of simulated ischaemia-reperfusion injury, which mimics the accumulation of 
mitochondrial ROS that occurs during reperfusion. It was hypothesised that there would be a 
delay in the time to mPTP opening in isolated PTEN
+/- cardiomyocytes compared to myocytes 
from PTEN
+/+mice. As a positive control cardiomyocytes from littermate controls were 
incubated with CsA. In agreement with work published by others (Lim et al., 2008; Halestrap 
et al., 1997; Argaud et al., 2005a)  it was demonstrated that CsA provided a delay in mPTP 
opening in the myocardium from PTEN
+/+  and PTEN
+/- mice. Conversely, no significant Hilary Siddall 
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differences in time to mPTP opening was observed in isolated myocytes from PTEN
+/- 
compared to PTEN
+/+  mice. No differences in the time to mPTP opening were detected 
between PTEN
+/- and PTEN
+/+  myocytes in the presence of CsA, verifying that down 
regulation of PTEN does not confer protection against ROS induced mitochondrial damage. 
 
In this study, the TMRM dye was used as an indicator of mPTP opening, which is a widely 
used method (Lawrence et al., 2004; Davidson et al., 2007). Additionally, it is also possible to 
detect mPTP opening by using the green fluorescent dye, calcein-AM, which accumulates 
throughout the cell but can be visualised in the mitochondria by quenching cytosolic 
fluorescence using colbolt chloride. When the mPTP opens calcein moves out and the 
fluorescence is quenched (Hausenloy et al., 2004a; Saotome et al., 2009). It would be 
interesting to use this dye to confirm our results; however, because the positive control (CsA) 
worked in our model, we can assume that the results will be the same. However, incubation 
of cardiomyocytes from PTEN
+/- mice with a subprotective dose of a PI3K/AKT activator, such 
as insulin, in may cause a delay in the time to mPTP opening when compared to a similar 
treatment  in myocytes from PTEN
+/+ hearts. 
  
Results with all knock out models should be interpreted with care as there may be adaptation 
or compensation to the lack of the target that is knocked out. The absence of cardioprotection 
against ischaemia-reperfusion injury in the PTEN
+/- mice could be explained by compensatory 
mechanisms, such as up regulation of alternative lipid phosphatases. The PI3K/AKT pathway 
is also negatively regulated by the lipid phosphatase SHIP2 (Chi et al., 2004), which has 
specificity for the 5’ phosphate of  PI(3,4.5)P3 to produce PI(3,4)P2 whereas PTEN has 
specificity for the 3’ phosphate creating PI(4,5)P2 (Chi et al., 2004), as shown in Figure 1.6. 
Surprisingly, the inhibition of SHIP2 was not associated with formation of cancers. Unlike 
PTEN, which acts on basal AKT activity, SHIP2 acts on stimulated levels of AKT (Lazar and Hilary Siddall 
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Saltiel, 2006). Therefore, this makes it a potentially attractive target for cardiovascular 
research and, possibly, an alternative target to PTEN (Pesesse et al., 1997). 
 
In addition to SHIP2, other phosphatases such as PHLPP and PP2A can negatively regulate 
the PI3K pathway, directly inactivating AKT (Sugano et al., 2005; Gao et al., 2005a; Zuluaga 
et al., 2007). These phosphatases could be up-regulated in the PTEN haploinsufficient mice 
and could be classed as targets of cardioprotection in their own right.  It is important to 
investigate these alternative negative regulators of the PI3K/AKT pathway in the myocardium 
of our PTEN haploinsufficient mice.  
 
6.4 Investigating the response of the PTEN
+/- myocardium to 
ischaemic preconditioning 
6.4.1 Experimental  protocols 
IPC is regarded as the most powerful mechanism for cardioprotection and is often used as a 
positive control in myocardial survival studies (Yellon and Downey, 2003). Cardioprotection 
was investigated in the PTEN haploinsufficient myocardium, the aim was to determine the 
IPC protocol required to confer protection in these mice. The Langendorff model of isolated 
perfused myocardium was used to study the effects of IPC on ischaemia-reperfusion injury, 
as described in chapter 2, section 2. We investigated the effects of the perfusion protocols 
listed below on 1) infarction and 2) cell signalling. 
 
1)  The response to IPC in the PTEN
+/- and PTEN
+/+ myocardium was investigated. The 
level of infarction developed in response to ischaemia-reperfusion alone or preceded 
by 2,4,or 6 cycles of IPC, n= 5, was recorded. Each IPC cycle consisted of 5 min 
ischaemia followed by 5 min reperfusion, as shown in Figure 6.16.   Hilary Siddall 
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2)  The cell signalling that occurred in the myocardium subjected to IPC was investigated 
by exploring the response to ischaemia-reperfusion alone or preceded by 4 or 6 
cycles of IPC, n= 3. Western blot analysis, as described in chapter 2, section 2 was 
used to investigate the level of PTEN and AKT as a consequence of IPC in the PTEN 
haploinsufficient myocardium. Phosphorylated and total levels of PTEN 
(Ser380,Thr382/383 sites) and AKT(Thr308 and Ser473 sites) were measured. 
Previously, it was shown that changes in AKT activity during IPC can be detected 
following the IPC stimulus (Tsang et al., 2005). Therefore, samples were collected 
immediately prior to the lethal ischaemic event, as shown in Figure 6.16. These 
samples were used to investigate the PTEN lipid phosphatase activity during IPC, 
using the Echelon PTEN ELISA assay, as described in chapter 2, section 4. It was 
hypothesised, that in the PTEN
+/- hearts, as a consequence of IPC there would be 
further increases in the PI3K/AKT signalling. 
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Figure 6.16: Experimental protocols used to study ischaemia-reperfusion injury and 
cardioprotection in isolated PTEN
+/+ and PTEN
+/- myocardium. Investigating the number 
of ischaemic preconditioning (IPC) cycles required to confer protection, where 1 cycle 
consists of 5 min ischaemia followed by 5 min reperfusion. Comparing: A) ischaemia-
reperfusion alone; B) 2 cycles IPC; C) 4 cycles IPC and D) 6 cycles IPC. I/R% = 
percentage of infarction to risk area TTC = triphenyltetrazolium chloride. 
 
6.4.2 Results 
6.4.2.1   IPC in the isolated perfused PTEN
+/- myocardium 
Cardioprotection in the PTEN haploinsufficient myocardium was investigated, the aim was to 
explore the minimal IPC stimulus protocol required to confer protection in these mice. 
Myocardial infarction following ischaemia-reperfusion alone or ischaemia-reperfusion 
preceded by 2,4,or 6 cycles of IPC (5 min ischaemia and 5 min reperfusion) was investigated. Hilary Siddall 
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The results are shown in Figure 6.17 and indicate that fewer cycles of IPC are needed in the 
PTEN
+/- haploinsufficient mouse heart to confer tissue salvage. Protection was induced as a 
consequence of 6 cycles IPC in the PTEN
+/+ and PTEN
+/- myocardium. In these groups, 
infarction was significantly reduced from 44.71 ± 1.97% in ischaemia-reperfusion control to 
30.87 ± 5.06% (p<0.05) in the PTEN
+/+ myocardium and similarly was reduced from 44.28 ± 
4.36% to 28.33 ± 2.66% (p<0.05) in the PTEN
+/- myocardium. Interestingly, only in the 
PTEN
+/- myocardium, 4 cycles of IPC stimulus also significantly reduced infarction to 29.07.± 
3.05% p<0.05, an effect not observed in the PTEN
+/+ myocardium. These results indicate the 
myocardium from PTEN haploinsufficient animals have a reduced threshold for IPC induced 
cardioprotection. 
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Figure 6.17: Percentage infarction developed in the risk area (I/R%) in male PTEN
+/+ and 
PTEN
+/- hearts subjected to ischaemia-reperfusion (solid bars); with 2 (stripes); 4 (dots) 
or 6 (bricked) cycles of ischaemic preconditioning (IPC) (n=5). Statistical differences 
were assessed using One Way ANOVA, @=p<0.05 in PTEN
+/+ and *=p<0.05 in PTEN
+/-).  
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6.4.2.2   Expression of PTEN/PI3K/AKT pathway in IPC induced 
cardioprotection 
It was hypothesised that the PI3K/AKT pathway in the PTEN
+/- mouse myocardium would be 
increased by our IPC protocol. Tissue collected following the IPC protocol was measured for 
PTEN lipid phosphatase activity using the PTEN ELISA kit and the expression of 
phosphorylated and total PTEN and AKT using Western blot analysis. The results are 
described below. 
 
PTEN lipid phosphatase activity in IPC 
No significant differences in the absorbance values were observed in samples obtained from 
PTEN
+/- or PTEN
+/+ myocardium subjected to either perfusion control, 4 or 6 cycles of IPC; as 
shown in Figure 6.18. As previously stated (in chapter 6, section 2) we are not confident that 
the ELISA kit is sensitive enough for measuring PTEN activity in homogenised tissues.  
 
 
 
 
 Hilary Siddall 
 
223
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
I/R control 4cycles IPC 6 cycles IPC
A
b
s
o
r
b
a
n
c
e
 
(
4
5
0
n
m
)
PTEN+/+ PTEN+/-
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
I/R control 4cycles IPC 6 cycles IPC
A
b
s
o
r
b
a
n
c
e
 
(
4
5
0
n
m
)
PTEN+/+ PTEN+/-
 
Figure 6.18: PTEN lipid phosphatase activity in the PTEN
+/+ and PTEN
+/- myocardium 
subjected to ischaemia-reperfusion (solid bars); with 4 (dots) or 6 (bricked) cycles of 
ischaemic preconditioning (IPC) (n=3). Statistical differences were assessed using One 
Way ANOVA. 
 
PTEN protein expression 
Figure 6.19 presents the data obtained following investigations into phosphorylation of PTEN 
(Ser380,Thr382/383) during preconditioning of the PTEN
+/- myocardium. It shows that basal, 
non preconditioned, non ischaemic PTEN
+/- hearts expressed a significantly (p<0.01) higher 
level of PTEN phosphorylation, (1.26 ± 0.0126, A.U) compared to PTEN
+/+ (0.67 ± 0.03, A.U) 
hearts, indicative of PTEN inactivity. Following 4 cycles of IPC a significant (p<0.01) increase 
in phosphorylation of PTEN (Ser380,Thr382/383) is observed in the PTEN
+/- myocardium, 
compared to PTEN
+/+ hearts subjected to ischaemia reperfusion control. The phosphorylation 
of PTEN (Ser380,Thr382/383) in PTEN
+/- myocardium was higher than PTEN
+/+ myocardium 
at 4 (0.99 ± 0.20) and 6 cycles (0.73 ± 0.05) of IPC, however this differences was not Hilary Siddall 
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significant. Examples of the Western blot scans showing PTEN
+/- myocardium with and 
without IPC are displayed in Figure 6.20. 
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Figure 6.19: Phosphorylated (p) PTEN (at Thr380/Ser382/383 sites) protein expression 
in PTEN
+/+ and PTEN
+/- myocardium subjected to ischaemia-reperfusion control (solid 
bars); and 4 (dots) or 6 (bricked) cycles of ischaemic preconditioning (IPC) (n=3). 
Statistical differences were assessed using One Way ANOVA, @=p<0.01 compared to 
PTEN
+/+ I/R control. 
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Figure 6.20: Example of Western blots illustrating total and phosphorylated (p) PTEN 
(at Thr380/Ser382/383 sites) in PTEN
+/+  and PTEN
+/- myocardium subjected to 
ischaemia-reperfusion control, 4 or 6 cycles of ischaemic preconditioning (IPC).   
 
AKT protein expression 
Figure 6.21 and Figure 6.22 illustrate the phosphorylation of AKT at Ser473 and Thr308 
phosphorylation sites (respectively) in the preconditioned PTEN
+/- myocardium. Figure 6.23 
represents the Western blot scans. As previously shown, phosphoryation of AKT at Ser473 
and Thr308 phosphorylation sites is significantly increased in PTEN
+/- compared to PTEN
+/+ 
hearts that were subjected to perfusion control, (no preconditioning). The phosphorylation of 
AKT at Ser473 phosphorylation site is significantly increased during 4 as well as 6 cycles of 
ischaemic preconditioning, in both PTEN
+/+ and PTEN
+/- hearts. However, the infarct data Hilary Siddall 
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shows that PTEN
+/+ hearts are not protected with 4 cycles IPC. This may highlight the 
importance of the phosphorylation of AKT at Thr308 in cardioprotection. Figure 6.22 shows 
that, while the haploinsufficient hearts have already high levels of phosphorylated Thr308 and 
are protected by IPC,  PTEN
+/+ hearts are protected at only at 6 cycles when the level of 
Thr308 phosphorylation in higher to that at 4 cycles.  
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Figure 6.21: Phosphorylated (p) AKT (at Ser473 site) in PTEN
+/+ and PTEN
+/- 
myocardium subjected to ischaemia-reperfusion control (solid bars); or 4 (dots) or 6 
(bricked) cycles of ischaemic preconditioning (IPC). Statistical differences were 
assessed using one way ANOVA, @=p<0.05 compared to PTEN
+/+  baseline (non 
preconditioned) and *=p<0.05 compared to PTEN
+/- baseline (non preconditioned) 
(n=3).  
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Figure 6.22: Phosphorylated (p) AKT (at Thr308 sites) expression in PTEN
+/+ and 
PTEN
+/- myocardium subjected to 4 (dots) or 6 (bricked) cycles of ischaemic 
preconditioning (IPC). Statistical differences were assessed using One Way ANOVA, 
@=p<0.05 compared to PTEN
+/+ baseline (non preconditioned), (n=3).  
 
 
 Hilary Siddall 
 
228
1 2 3 4 56 78 9
PTEN+/+
I/R
pAKT(308)
tAKT(308)
PTEN+/+
4 x IPC
PTEN+/+
6 x IPC
10 11 12 13 14 15 16 17 18
PTEN+/-
I/R
PTEN+/-
4 x IPC
PTEN+/-
6 x IPC
pAKT(473)
tAKT(473)
pAKT(308)
tAKT(308)
pAKT(473)
tAKT(473)
1 2 3 4 56 78 9
PTEN+/+
I/R
pAKT(308)
tAKT(308)
PTEN+/+
4 x IPC
PTEN+/+
6 x IPC
10 11 12 13 14 15 16 17 18
PTEN+/-
I/R
PTEN+/-
4 x IPC
PTEN+/-
6 x IPC
pAKT(473)
tAKT(473)
pAKT(308)
tAKT(308)
pAKT(473)
tAKT(473)
1 2 3 4 56 78 9
PTEN+/+
I/R
pAKT(308)
tAKT(308)
PTEN+/+
4 x IPC
PTEN+/+
6 x IPC
10 11 12 13 14 15 16 17 18
PTEN+/-
I/R
PTEN+/-
4 x IPC
PTEN+/-
6 x IPC
pAKT(473)
tAKT(473)
pAKT(308)
tAKT(308)
pAKT(473)
tAKT(473)
 
Figure 6.23: Examples of Western blots illustrating total and phosphorylated (p) AKT 
(Ser473 and Thr308 sites) protein expression in PTEN
+/+ and PTEN
+/- myocardium 
subjected to (1) ischaemia-reperfusion control, (2) 2 cycles of ischaemic 
preconditioning (IPC) or (3) 4 cycles IPC.   
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In summary, in the isolated PTEN haploinsufficient myocardium, which already has a higher 
basal level of phosphorylated AKT compared to littermate controls, IPC increases the 
phosphorylation of AKT at Ser473 phosphorylation sites above the basal levels. In the 
PTEN
+/- myocardium cardioprotection induced by IPC was achieved with less IPC stimuli: in 
which 4 and 6 cycles conferred protection. In contrast the littermate controls were protected 
with only 6 cycles of IPC. Thus it appears that the PTEN
+/- myocardium may have an 
increased sensitivity towards cardioprotection.  
  
6.4.3 Discussion 
IPC in isolated perfused myocardium 
Reducing PTEN (either using a chemical inhibitor or by using a genetically manipulated 
mouse strain) does not confer myocardial protection against ischaemia-reperfusion injury; 
despite AKT activation. Nevertheless, as described in chapter 4, section 3.1.2 perfusion of 
bpV(HOpic) in an isolated heart model of ischaemia-reperfusion injury reduces the threshold 
for IPC; it was predicted that the PTEN
+/- myocardium may follow similar patterns for 
protection. Therefore the threshold for tissue salvage in the PTEN
+/- myocardium was 
investigated and it was predicted that the threshold may be lowered in these hearts.   
 
As predicted, there was a reduced threshold to cardioprotection in the myocardium from 
PTEN
+/- mice. PTEN
+/+ controls were significantly protected (p<0.05) with 6 cycles whereas, 
PTEN
+/- hearts were significantly (p<0.05) protected with 6 and 4 cycles of IPC stimuli, an 
effect not observed in the PTEN
+/+ myocardium. These results indicated that the myocardium 
from PTEN
+/- mice had a reduced threshold for IPC induced cardioprotection. This finding 
positively supports our hypothesis that PTEN inhibition can be cardioprotective by 
contributing to the reduction of infarct size following ischaemia-reperfusion injury.  
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Similarly, Wong et al, have used these PTEN haploinsufficient mice to investigate insulin 
sensitivity. This group showed that in these mice, injections of insulin cause enhanced 
glucose uptake, increased insulin receptor substrate signalling activity and increased 
phosphorylation of AKT compared to littermate controls (Wong et al., 2007). Additionally, as 
described in Chapter 1, PTEN and the PI3K/AKT signalling pathway has a role in the 
development of diabetes. Mice lacking the insulin receptor substrate develop a diabetic 
phenotype and have disruption of pancreatic cells and loss of insulin (Kushner et al., 2005). 
When these mice are crossed with the PTEN haploinsufficient mice (developed by 
Podsypanina  et al., 1999) the sensitivity to insulin is restored, glucose injections can be 
tolerated, phosphorylated AKT is increased and the diabetic phenotype is abolished (Kushner 
et al., 2005). This indicated that, PI3K/AKT signalling can be further enhanced with insulin or 
glucose in the presence of reduced PTEN. This also highlights the very interesting possibility, 
that the capability to induce IPC (which is diminished in diabetic animals (Tsang et al., 2005; 
Mocanu et al., 2006)) might be restored in mice that are engineered to contain the PTEN
+/- 
allele, or those that are treated with the PTEN inhibitor bpV(HOpic). 
 
The data presented in this thesis indicates that, to demonstrate the functional effects of PTEN 
mutation in the PTEN haploinsufficient myocardium, a stimulus of PI3K/AKT pathway, above 
basal level, is required. Studies performed by Cai and Semenza in 2005 demonstrated 
changes which occur in PTEN during IPC stimuli. As discussed in chapter 4 and in more 
detail below, Their work provides supporting evidence that PTEN can be manipulated and 
reduced in the heart by IPC which is implicated to be involved in survival after ischaemia-
reperfusion injury (Cai and Semenza, 2005). In the PTEN haploinsufficient mouse heart, 
which have a native allele for functional PTEN, IPC may contribute to the protection by 
reducing PTEN activity further; this idea is discussed in greater detail below.  
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To conclude, PTEN haploinsufficiency alone is not able to reduce infarction from ischaemia-
reperfusion injury. However, when associated with an increase in PI3K/AKT activity, PTEN 
haploinsufficiency can induce cardioprotection by reducing the threshold to protection 
obtained with IPC.  
 
Expression of PI3K/AKT/PTEN pathway in IPC induced cardioprotection  
Tissue collected subsequent to the IPC protocol was measured for PTEN lipid phosphatase 
activity using the PTEN ELISA kit and expression of phosphorylated and total PTEN and 
AKT, using Western blot analysis.  
 
PTEN lipid phosphatase activity in IPC 
No significant differences in lipid phosphatase activity were observed in samples obtained 
from myocardium that had been subjected to ischaemia-reperfusion control, 4 or 6 cycles of 
IPC, from either PTEN
+/- or PTEN
+/+ mice. However, significant changes in the PTEN lipid 
phosphatase activity have been observed during IPC (Cai and Semenza, 2005). In this study 
the malachite green reagent, which detects free phosphates, was used as an indictor of lipid 
phosphatase activity (Schmid et al., 2004; Connor et al., 2005; Cai and Semenza, 2005). As 
previously described we are not confident that the ELISA kit we used is adequate for 
measuring PTEN activity in homogenised whole tissues. Other groups have used this PTEN 
ELISA to measure lipid phosphatase activity (Eickholt et al., 2007; Papakonstanti et al., 
2007). Differences include, the sample type (whole heart compared to cancer cell lines) and 
the enzyme preparation (tissue homogenation compared to PTEN imunoprecipitation prior to 
assaying the phosphatase activity). Therefore, more time is needed in order to develop the 
use of this assay for assessing samples obtained from whole hearts.   
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PTEN protein expression  
Previously, we showed that basal, non preconditioned, non ischaemic PTEN
+/- hearts 
manifest an increase in the level of PTEN phosphorylation, which is indicative of PTEN 
inactivity. The data from these IPC studies showed a similar increase in PTEN 
phosphorylation in PTEN
+/- compared to PTEN
+/+ hearts. In the IPC samples, an increase in 
phosphorylation of PTEN was observed in the PTEN
+/+ myocardium subjected to 6 cycles 
IPC. The level of PTEN phosphorylation in the PTEN
+/- myocardium was significantly higher 
at 4 cycles of IPC (p<0.05) compared to PTEN
+/+ control hearts. The phosphorylation of 
PTEN is associated with enzyme inactivity and as described previously, CK2 phosphorylation 
of PTEN encodes protein instability, ubiquitination and proteasomal degradation (Torres and 
Pulido, 2001). This indicates that in the PTEN
+/- myocardium, overall there may be more 
inactive PTEN. These results are in agreement with work by others, associating PTEN 
phosphorylation with PTEN inactivation (Torres and Pulido, 2001; Al Khouri et al., 2005; Ning 
et al., 2006). 
 
AKT protein expression 
Previously, we showed that basal, non preconditioned, non ischaemic PTEN
+/- hearts 
contained increased levels of AKT phosphorylation. Following these IPC studies an additional 
increase in AKT phosphorylation was induced in the PTEN
+/- myocardium. The 
phosphorylation of AKT at the Ser473 phosphorylation site was significantly increased with 4 
as well as 6 cycles of IPC in both PTEN
+/+ and PTEN
+/- hearts. However, the infarct data 
showed that PTEN
+/+ hearts are not protected with 4 cycles IPC. This may highlight the 
importance of phosphorylation of AKT at the Thr308 phosphorylation site in cardioprotection. 
The PTEN
+/+ hearts are protected only after 6 cycles, when the level of Thr308 
phosphorylation is different to that at 4 cycles. Therefore, this amplified phosphorylation may 
be necessary for cardioprotection in the PTEN
+/+  hearts to counterbalance the effects of 
PTEN.  Hilary Siddall 
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The PTEN
+/- myocardium was not protected against ischaemia-reperfusion alone; however, a 
reduced threshold for IPC induced cardioprotection was recorded in these hearts. 
Furthermore, in addition to activation of the PI3K/AKT pathway, other signalling events occur 
in IPC that may account for these observations. The IPC protocol consists of cycles of sub 
lethal ischaemia-reperfusion. Paradoxically, this procedure generates ‘beneficial’ ROS 
(Baines et al., 1997). ROS can oxidise and reversible inhibit PTEN.(Connor et al., 2005; 
Kwon et al., 2004) It has been shown that IPC induced ROS production can inhibit PTEN. 
(Cai and Semenza, 2005). In addition, the sub lethal ischaemia generated in IPC is sufficient 
to up regulate hypoxia inducible factor 1 alpha (HIF1α), which is thought to regulate PTEN 
function during the IPC trigger which contributes to ROS signalling and consequentially 
activation of the PI3K/AKT pathway. (Cai et al., 2008a). The data in this thesis shows that in 
the PTEN haploinsufficient myocardium cardiprotection is induced, because a reduction in the 
threshold of IPC was observed. In an attempt to explain this observation it could be 
hypothesised that these results were caused by further inhibiting PTEN due to a form of 
positive feedback. Whereby IPC/ROS induced inhibition of PTEN may be amplified in the 
PTEN haploinsufficient myocardium. This idea is outlined in Figure 6.24. We hypothesise that 
during IPC the PTEN hapolinsufficient myocardium would contain a greater amount of 
oxidised PTEN compared to their littermate controls. Importantly, alternative pathways that 
are activated in IPC should be investigated in future studies, such as JAK/STAT and p42/p44 
pathways, which have a protective role in IPC. Hilary Siddall 
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Figure 6.24: Proposed hypothesis for further reduction of PTEN activity during 
Ischaemic preconditioning (IPC) in the presence of either a PTEN inhibitor or genetic 
deletions of PTEN. A) Cellular PTEN activity under basal conditions. B) Cellular PTEN 
activity as a consequence of IPC. Inhibition of PTEN by oxidation and potential positive 
feedback causing further PTEN inhibition when PTEN is inhibited using a PTEN 
inhibitor such as bpV(HOpic) or in the presence of PTEN deletions. However 
nitrosylation has been shown to inhibit PTEN (Pei et al., 2009), which may act to 
control such situations chronically. HIF1α = hypoxia inducible factor 1 alpha, NOS = 
nitric oxide synthasse, NO = nitric oxide, PIP2 = phosphatidylinositol 2 phosphate, 
PIP3 = phosphatidylinositol 3 phosphate, PI3K = phosphatidylinositol 3 kinase and 
ROS = reactive oxygen species. 
 
To summarise, in the isolated PTEN
+/- myocardium, IPC increased the phosphorylation of 
AKT at Ser473 and Thr308 phosphorylation sites, above the baseline, which is already higher Hilary Siddall 
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than in the control littermates. However, no additional changes in phosphorylation of PTEN 
were observed.  Nevertheless, IPC induced cardioprotection was achieved with less IPC 
stimuli. In the PTEN
+/- myocardium 4 and 6 cycles induced protection, whereas only 6 cycles 
conferred protection in littermate controls. Thus it appears that the PTEN
+/- myocardium may 
have an increased sensitivity towards cardioprotection.   
 
6.5  Investigating reasons for the lack of protection against 
ischaemia-reperfusion injury 
6.5.1 Experimental  protocols 
6.5.1.1   Investigating alternative regulators of the PI3K/AKT pathway 
We aimed to investigate potential changes in the PTEN
+/- myocardial cell signalling network, 
which may compensate for altered function of PTEN. The protein expression of other 
potential down regulators of the PI3K/AKT pathway was investigated, using Western blot 
analysis as described in chapter 2, section 6, samples were collected as shown in Figure 6.1, 
(n=3). 
 
Firstly, the level of phosphatases known to reduce the PI3K/AKT pathway was measured, as 
described in chapter 1, section 4. The level of SHIP2, PHLPP, and PP2A was recorded. It 
was hypothesised that these phosphatases would be increased in the PTEN
+/- myocardium to 
compensate for the partial loss of PTEN. 
 
6.5.1.1.1  Investigating PINK1 expression 
As described in chapter 1, section 5, the level of PTEN induced kinase 1 (PINK1), a 
mitochondrial pro survival kinase, can be increased by the re-expression of cellular PTEN Hilary Siddall 
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(Unoki and Nakamura, 2001). However, the association of PTEN and PINK1 in the 
myocardium is currently unknown. Therefore, the expression of PINK1 was investigated in 
the PTEN
+/- and PTEN
+/+ myocardium, n=3, as shown in Figure 6.1,A, using  Western blot 
analysis as described in chapter 2, section 6. It was hypothesised that there would be a 
reduced level of PINK1 in the PTEN
+/- myocardium.  
 
6.5.1.2   Investigating alternative contributors of ischaemia-
reperfusion injury 
Finally, alternative mechanisms that may explain the lack of protection against ischaemia-
reperfusion injury were investigated in the PTEN
+/-  myocardium. In addition to its lipid 
phosphatase activity PTEN has a role in maintaining DNA stability and cell cycle (Shen et al., 
2007). Cells in a pro apoptotic state have been associated with DNA fragmentation and can 
be visualised on an agarose gel, as an increase in DNA fragments, which can be observed as 
a laddering effect (Fliss and Gattinger, 1996). It was hypothesised that the PTEN
+/- 
myocardium, which expresses a reduced level of PTEN protein, may be more susceptible to 
cell damage. To assess this DNA laddering and caspase 3 activation was investigated in the 
PTEN
+/- hearts, as outlined below.  
 
1)  Myocardial tissue was collected at the end of the final IPC reperfusion cycle, as shown 
in Figure 6.16, and described in Chapter 2, section 6 (n=3-5). DNA was extracted from 
PTEN
+/+ and PTEN
+/- myocardium and the level of DNA fragmentation was monitored 
subsequent to control, ischaemia-reperfusion, 4 and 6 cycles IPC, as described in 
chapter 2, section 2. Equal quantities of DNA were separated by agarose gel 
electrophoresis and visualised using ethidium bromide. It was hypothesised that the 
PTEN
+/- myocardium may exhibit an increase in DNA laddering. 
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2)  Caspase 3 activity in the PTEN
+/- myocardium was investigated, as a marker of cell 
damage. Samples were collected without ischaemia-reperfusion, as shown in Figure 
6.16, and was investigated using Western blot analysis, and described in chapter 2, 
section 6. Caspase 3, is activated when it is cleaved, producing a pro death fragment 
(Nicholson et al., 1995; Kothakota et al., 1997). The caspase 3 antibody used in this 
study detects cleaved and uncleaved caspase 3. Therefore, the total caspase 3 value 
was estimated by adding the A.U value obtained from the uncleaved caspase 3 band 
(running to 35kDa) with the A.U acquired from the cleaved caspase 3 fragment 
(running to 17kDa). The level of caspase activation was obtained by comparing the 
ratio of cleaved and uncleaved caspase 3. It was hypothesised that there may be an 
increase in the basal level of caspase 3 activation. 
 
6.5.2 Results 
6.5.2.1   Alternative regulators of the PI3K/AKT pathway 
Originally, it was assumed that the PTEN
+/- myocardium would manifest cardioprotection 
against ischaemia-reperfusion injury. However, thus far, a reduction in the level of infarction 
following 35 min ischaemia and 30 min reperfusion was not observed. In the following 
experiments we aimed to investigate potential explanations for this lack of protection 
observed in the PTEN haploinsufficient myocardium. It was hypothesised that changes may 
occur in the cell signalling network, which may compensate for altered expression of PTEN. 
Therefore, the expression of other potential down regulators of the PI3K/AKT pathway, such 
as the phosphatases SHIP2, PHLPP and PP2A (which are described in chapter 1, were 
investigated. 
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The data, presented in Figure 6.25, 6.26 & 6.27 shows that there were no significant changes 
in the expression of either SHIP2, PHLPP or PP2A, respectively,  between PTEN
+/+ and 
PTEN
+/- myocardium.  
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Figure 6.25:  SRC homology 2 containing inositol 5 phosphatase 2 (SHIP2) protein 
expression in PTEN
+/+ and PTEN
+/- myocardium, normalised to beta actin. (Arbitrary 
Units = A.U.) No statistical differences were observed, assessed using the Student’s 
paired t-test, (n=3).   
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Figure 6.26:  PH domain leucine rich repeat protein phosphatase (PHLPP) protein 
expression in PTEN
+/+ and PTEN
+/- myocardium, normalised to beta actin. (Arbitrary 
Units = A.U.) No statistical differences were observed, assessed using the Student’s 
paired t-test, (n=3).  
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Figure 6.27: Protein phosphatase 2A (PP2A) protein expression in PTEN
+/+ and PTEN
+/- 
myocardium, normalised to beta actin. (Arbitrary Units = A.U.) No statistical 
differences were observed, assessed using the Student’s paired t-test, (n=3).  
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6.5.2.1.1  PTEN Induced Kinase 1 (PINK1) expression 
As described in Chapter 1, PINK1 is a prosurvival mitochondrial kinase that is up regulated in 
cells by the expression of PTEN (Unoki and Nakamura, 2001; Petit et al., 2005). The 
association of PTEN and PINK1 in the myocardium is currently unknown. Interestingly, it was 
observed that PINK1 expression was reduced in the PTEN
+/- myocardium. Figure 6.28 
displays the PINK1 expression data and showing that PTEN
+/- myocardium expressed 
significantly less PINK1 protein (25.6 ± 1.6 A.U, p<0.05) compared to their littermate controls 
(31.4  ± 1.4 A.U). The decrease in PINK1 may contribute to the lack of cardioprotection 
against ischaemia-reperfusion in the PTEN
+/- myocardium; however, this hypothesis needs 
further investigation. 
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Figure 6.28:  PTEN induced kinase 1 (PINK1) protein expression in PTEN
+/+ and PTEN
+/- 
myocardium, normalised to beta actin. Expressed in Arbitrary Units (A.U), (n=3). 
Statistical differences were observed, assessed using the Student’s paired t-test, 
(*p<0.05).  Hilary Siddall 
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6.5.2.2   Alternative contributors of ischaemia-reperfusion injury 
Alternative mechanisms for the lack of protection in the PTEN
+/-  myocardium were also 
investigated. In addition to its lipid phosphatase activity, it has been demonstrated that PTEN 
plays a role in maintaining DNA stability (Puc and Parsons, 2005; Shen et al., 2007). It was 
hypothesised that the PTEN
+/- myocardium, which expresses reduced PTEN protein, may 
exhibit damaged DNA. The results are presented in Figure 6.29 however, they are difficult to 
compare and therefore inconclusive because clear DNA fragments are not identifiable. 
Nevertheless, a slightly greater degree of DNA smearing occurs in PTEN
+/- myocardial 
extracts. In summary, the relation between the degree of DNA fragmentation and PTEN level 
in the myocardium does not seem to be proven by our data and more investigations are 
needed.    
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Figure 6.29:  DNA separation in myocardium subjected to sham, ischaemia-reperfusion 
control (I/R), 4 and 6 cycles ischaemic preconditioning (IPC). DNA was extracted from 
whole hearts using the Qiagen DNA extraction kit and quantified using a 
spectrophotometer. A DNA ladder (L) and ethidium bromide (orange) was used to 
visualise the results.  
 
Additionally, the expression of caspase 3 was investigated as a marker of cell damage. The 
results were investigated by Western blot techniques, analysed by densitometry and are 
displayed in Figure 6.30. No changes in the expression of caspase 3 cleavage in the PTEN
+/+ 
mycocardium (0.488 ± 0.158 A.U) compared to PTEN
+/- hearts (0.502 ± 0.195 A.U) were 
observed. Representative blots are shown in Figure 6.31 , it should be noted that the quality Hilary Siddall 
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of the blots are not good and future work may include repeating these experiments to provide 
clearer data. 
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Figure 6.30:  Cleavaed caspase 3 normalised to total caspase 3 expression in PTEN
+/+ 
and PTEN
+/- myocardium. Expressed in Arbitrary Units (A.U). No statistical differences 
were assessed using the Student’s paired t-test, (n=3).   
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Figure 6.31:  Example of western blots illustrating the cleaved (active 17kDa) and intact 
(inactive 25kDa) caspase 3 in PTEN
+/+ and PTEN
+/- myocardium subjected to ischaemia 
reperfusion (I/R) control (perfused without ischaemia).  Hilary Siddall 
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To summarise, no differences in the expression of other phosphatases known to negatively 
regulate PI3K/AKT activity, such as SHIP2, PHLPP and PP2A were observed in the PTEN
+/- 
myocardium. Furthermore, no changes in cell stability, as measured by DNA fragmentation 
and caspase 3 cleavage were detected. Nonetheless, we discovered a reduction in the 
expression the pro survival mitochondrial kinase PINK1. 
 
6.5.3 Discussion 
6.5.3.1   Alternative regulators of the prosurival PI3K/AKT pathway  
Originally, it was predicted that the PTEN
+/- myocardium would manifest cardioprotection 
against ischaemia-reperfusion injury, however, this was not confirmed in our studies. 
Therefore, we aimed to investigate potential explanations for this lack of protection. It was 
hypothesised that there may be compensatory signalling mechanisms occurring in these 
hearts to counteract the altered expression of PTEN. Therefore, the expression of other 
potential down regulators of the PI3K/AKT pathway, such as SHIP2, PHLPP and PP2A were 
investigated in the PTEN
+/- myocardium. The results showed that no differences in total 
protein levels were observed. However, we did not investigate the activities of these 
phosphatases.  
 
Additionally, future work may include investigating the localisation and activity of these 
phosphatases. Interestingly, studies in cell lines showed that PTEN or SHIP2 reduction using 
siRNA can enhance the level of phosphorylation of AKT in the presence of LY294002, a PI3K 
inhibitor. Interestingly, following the incubation with LY294002 and the dual reduction of 
PTEN and SHIP2, AKT was eventually dephosphorylated (Sharrard and Maitland, 2006). This 
work indicates alternative phosphatase/s other than PTEN and SHIP2 can dephosphorylate Hilary Siddall 
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AKT, however, the authors of this work do not attempt to address the identity of these 
phosphatases.  
 
Recently, a second isoform of PHLPP (PHLPP2) has been discovered, it contains 50% 
homology to PHLPP1 with a predicted molecular weight of 150kDa and similarly, 
dephosphorylates AKT at the Ser473 site (Brognard et al., 2007). Activation of the PI3K/AKT 
pathway using EGF increases the phosphorylation of AKT. The deletion of PHLPP1 and 
PHLPP2 stimulated a 30 fold increase in the EGF induced increase in phosphorylation of 
AKT (Brognard et al., 2007). Therefore, it would be interesting to investigate the levels of 
PHLPP2 in our PTEN
+/- hearts. 
  
Interestingly, PHLPP1 can bind and dephosphorylate AKT at the Ser473 of AKT isoforms 2 
and 3. In contrast PHLPP2 binds to and dephosphorylates AKT at the Ser473 of AKT 
isoforms 1 and 3 (Brognard et al., 2007). AKT1 is involved in growth and proliferation and 
AKT2 is involved in glucose homeostasis (Brognard et al., 2007; Heron-Milhavet et al., 2006). 
We also investigated PP2A, and inhibition of this phosphatase in rat adipocytes, using 
okadaic acid, has been shown to cause an increase in phosphorylation of AKT1. In contrast, 
the authors of this work showed no changes in the phosphorylation of AKT2 (Resjo et al., 
2002). The results from our study showed that no changes in PHLPP1 or PP2A were 
observed in the PTEN
+/- myocardium. However, it would be interesting to establish which AKT 
isoforms are affected in the PTEN
+/- myocardium.  
 
Other regulators of the PI3K/AKT pathway 
The results from this study indicate that the levels of, SHIP2, PHLPP and PP2A are not 
altered in the PTEN
+/- myocardium. However, the list of negative regulators of the PI3K/AKT 
pathway is much larger than this, some of which are discussed below. The Src homology 
domain 2 (SH2) containing tyrosine phosphatase 1 (SHP1) is known to negatively regulate Hilary Siddall 
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Fas receptor signalling. SHP1 inhibition using siRNA confers cardioprotection against 
myocardial ischaemia-reperfusion (Sugano et al., 2005). Similarly, the Src homology domain 
2 (SH2) containing tyrosine phosphatase 2 (SHP2) is a phosphatase that has been 
associated with regulating cell growth (Zito et al., 2007). In fibroblasts SHP2 appears to 
negatively regulate cell size, in periods of low ATP. The authors of this work conclude that 
SHP2 controls the cell growth by suppressing the mTOR/p70S6K pathway (Zito et al., 2007). 
The levels of SHP1 or SHP2 may be enhanced in the PTEN
+/- myocardium. 
 
In addition, skeletal muscle and kidney enriched inositol phosphatase (SKIP), a 50kDa lipid 
phosphatase that dephosphorylates PI(3,4,5)P3 to PI(4,5)P2, can negatively regulate the 
PI3K/AKT pathway (Ijuin and Takenawa, 2003). Over expression of SKIP in CHO cells can 
decrease insulin stimulated phosphorylation of AKT and inhibited insulin stimulated glucose 
uptake (Ijuin and Takenawa, 2003). 
 
Finally, the potential impact of unknown or novel phosphatases yet to be discovered is 
discussed. Phosphatase activities are complex and can be tightly regulated. Already 2 splice 
variants of PHLPP have been discovered (Brognard et al., 2007). There is evidence that a 
novel phosphatases with homology to PTEN exists. These are known as 1) the 
Transmembrane Phosphatase with Tensin Homology (TPTE) and 2) the PTEN homolog 
inositol lipid phosphatase (TPIP). These are 2 splice variants which, to date, have been 
localised to the testis, stomach and brain. Nonetheless, these phosphatases may be 
regulated in other tissues (Walker et al., 2001). 
 
It is important to note that in this section the quality of some of the western blots are not high, 
in some cases. For example the blots for SHIP2 and PHLPP appear dirty. In addition, some 
of the loading controls are not equal, as in the representative blots used for PHLPP and 
PP2A. Therefore, the results must be interpreted with caution. Future work would include Hilary Siddall 
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repeating for loading control and optimising the conditions required for probing larger proteins 
such as SHIP2 and PHLPP. 
 
In summary, the expression of SHIP2, PHLPP and PP2A were investigated in the PTEN
+/- 
myocardium. Dissimilar to the hypothesis, our results showed that the total protein expression 
of these phosphatases in our samples appeared unchanged in the PTEN
+/- myocardium. This 
indicates that in our samples the total expression of these phosphatases did not change to 
compensate for the PTEN mutation. 
 
 
PTEN Induced Kinase 1 (PINK1) expression 
It has been shown that in endometrial cancer cells (HEC-151) the expression of PINK1 is 
dependent on the level of PTEN (Unoki and Nakamura, 2001), however, the association of 
PTEN and PINK1 in the myocardium is currently unknown. PINK1 is frequently researched in 
the brain and mutations have been associated with Parkinson’s disease. In neuronal tissue, 
PINK1 deficiency results in changes in mitochondrial morphology and decreased 
mitochondrial membrane potential (Wood-Kaczmar et al., 2008). Over expression of PINK1 
can protect against H202 induced oxidative stress, by preventing cytochrome c release 
(Pridgeon et al., 2007). Mitochondrial PINK1 co-localises with and phosphorylates TNF 
receptor associated protein (TRAP1), also known as heat shock protein (HSP)75, and HSP90 
where is thought to have a role in protein stability, cell viability and prevention of mPTP 
opening (Wang et al., 2007a; Lin and Kang, 2008b). Our data shows that in the PTEN
+/- 
myocardium changes in PTEN level cause a small but significant (p<0.05) reduction in 
PINK1. Collectively, this and other published studies indicate that PINK1 is essential for 
mitochondrial integrity and function. It is most abundantly expressed in the heart (Mills et al., 
2008), however, the precise mechanism involved in cell survival, has yet to be investigated.  
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In summary, it was hypothesised that the level of PINK1 would be reduced in the PTEN
+/- 
myocardium, which may explain the lack of protection against ischaemia-reperfusion in these 
hearts. A small but significant (p<0.05) decrease in PINK1 expression was observed in these 
hearts. Our results suggest that in the PTEN
+/- hearts any possible protection due to an 
increased activation of the PI3K/AKT pathway may be counterbalanced by the deficiency in 
mitochondrial PINK1. This may, in part, explain the lack of cardioprotection against 
ischaemia-reperfusion injury in the PTEN
+/-  myocardium; however, this hypothesis needs 
further investigation. Moreover, PINK1 may be a novel cardioprotective kinase in its own 
right.  
 
6.5.3.2   Alternative contributors to ischaemia-reperfusion injury  
In addition to negatively regulating the PI3K/AKT pathway, PTEN has a role in maintaining 
DNA stability (Puc and Parsons, 2005; Shen et al., 2007). However, our results were 
inconclusive and we were not able to investigate our hypothesis completely. Reasons for this 
may be due to experimental approach. The method we used to investigate DNA 
fragmentation did not seem to work and may have prevented the detection of DNA laddering 
in our samples. Fliss and Gattinger, 1996 showed that in rat hearts detection of DNA 
laddering, as an indicator of apoptosis, required the induction of ischaemia using permanent 
coronary occlusion. More importantly the myocardium had to be reperfused for 3-4 hours 
(Fliss and Gattinger, 1996). The authors of this work showed that 2 hours of reperfusion was 
not sufficient to detect a laddering effect and observed a similar DNA smearing pattern to that 
in our samples. This may indicate that sufficient time to observe any changes in DNA stability 
was not operational in our experiments. Collectively, these observations create an additional 
discussion point about the association and detection of necrosis and apoptosis in ischaemia 
reperfusion injury. Smearing of DNA can be interpretated as necrotic activity, whereas a 
laddering effect can be used to indicate apoptotic events within a sample (Kajstura et al., Hilary Siddall 
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1996; Fliss and Gattinger, 1996; Taimor et al., 1999; Kim et al., 2003). Therefore, this may 
signal that there is more necrotic activity in our samples. However, this work may indicate that 
the methods we used to study DNA fragmentation may not be sensitive enough to detect the 
level of apoptosis and DNA fragmentation occurring in our samples.  
 
Secondly, caspase 3 cleavage expression was investigated as a marker of cell damage. 
However, no significant differences between PTEN
+/+ and PTEN
+/- myocardium could be 
detected. Similarly, this may be due to the experimentation design, as heart samples were 
not subjected to lethal ischaemia-reperfusion injury.  
 
In summary, in the PTEN
+/- myocardium no changes were observed in the expression of 
phosphatases that are involved in decreasing PI3K/AKT activity, such as SHIP2, PHLPP and 
PP2A. No significant decrease in cell stability, as measured by DNA fragmentation and 
caspase 3 cleavage was observed. However, a decrease in the expression of the pro survival 
mitochondrial kinase PINK1 was discovered, which may be a cardioprotective kinase its own 
right, and may in part explain the lack of protection against ischaemia-reperfusion in the 
PTEN
+/- hearts.  
 
6.5.4 Chapter  summary 
In conclusion, the PTEN haploinsufficient data indicates that there was reduced levels of total 
PTEN expression in PTEN
+/- myocardium. Furthermore, PTEN activity may be decreased, as 
indicated by an increase in phosphorylated PTEN expression. Consequently, increases in 
AKT activity were observed. However, this increase in AKT activity was not sufficient to 
confer cardioprotection, either in isolated cardiomyocytes or in isolated perfused hearts, 
subjected to simulated ischaemia-reperfusion injury. Subsequent to investigating the role of 
possible compensatory signalling mechanisms in the PTEN
+/- myocardium, we revealed that a 
reduction in PINK1 occurs. Nevertheless, IPC induced cardioprotection is achieved with less Hilary Siddall 
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stimuli, thus is appears that the PTEN
+/- myocardium may have an decreased threshold for 
cardioprotection.  
 
Obtaining a specific and reliable manipulation of PTEN levels and activity has been 
problematic. Inhibitors are limited and are not readily investigated, reliable or readily 
available. PTEN haploinsufficiency studies have proved useful to us and others (Wong et al., 
2007; Bayascas et al., 2005; Podsypanina et al., 1999). However, we have to ask if it is the 
best tool for investigating the role of PTEN in cardioprotection?  
 
The PTEN KO mice used in this study have a PTEN haploinsufficient phenotype (PTEN
+/-), 
their homozygous littermates with total knock down of PTEN (PTEN
-/-) do not survive 
gestation; and therefore were not valid for use in our studies (Podsypanina et al., 1999). In 
this PTEN haploinsufficient model all tissues are affected and there is a proportion of residual 
PTEN remaining that preserves function. Perhaps a model of cardiac tissue specific inhibition 
may prove a more powerful tool in understanding the biological importance and role of PTEN 
in ischaemia-reperfusion injury.  
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7  Chapter 7 – Reduction of PTEN using small interfering 
RNA  
7.1  Background, aims and hypothesis 
Within this thesis, the isolated perfused myocardial model of ischaemia-reperfusion injury was 
primarily used to study the effects of PTEN reduction on cell death. Additionally, we also used 
an isolated cardiomyocyte model of ROS induced mitochondrial damage. However, neither of 
these experimental models conferred significant protection against ischaemia-reperfusion 
injury, as shown in chapters 4 and 6. Therefore, we decided to go one step further and study 
the effects of PTEN silencing, using small interfering RNA, in a cellular model of hypoxia-
reoxygenation. 
 
As described in Chapter 2.8, siRNA silencing is a technique involving the manipulation of the 
cells’ own transcription and translation mechanisms, to silence the expression of the protein 
of interest. The addition of double stranded RNA with specificity to a target protein prevents 
the synthesis of that protein (Caplen et al., 2001).  
 
Initially, the method for knockdown of PTEN protein levels in H9c2 cells was optimised using 
various pre-designed siRNA constructs with specify to PTEN. It was hypothesised that PTEN 
protein knockdown in H9c2 cells, using siRNA with specificity to PTEN, would confer 
protection against hypoxia-reoxygenation injury. 
 Hilary Siddall 
 
252
7.2  Experimental protocols and methods 
7.2.1  Optimising protein silencing using siRNA 
Transfection of siRNA and protein knockdown are dependent on transfection efficiency and 
the rate of the target protein turnover in the cells used (H9c2 in this case). In our initial 
optimisation experiments we investigated the effect of:  
 
1) Transfection reagent, comparing Fugene6, FugeneHD and X-tremeGENE (Roche,UK)  
2) The ratio of transfection reagent (µl): siRNA(ng) (1:1-5-1),  
3) Transfection time (24-72h),  
4) Primer set (1-3),  
5) siRNA concentration (100pmol/well-5pmol/well) and  
6) Cell number on protein silencing.  
 
These initial optimisation experiments were performed in 6 and 12 well culture plates. 
(Orange Scientific, Belgium) These experiments focused on identifying the most effective 
method for transfecting H9c2 cells. To explore the effects of these variables on transfection 
efficiency, we investigated the following:  
 
1) The effect of different transfection reagents on transfection. Fluorescently tagged 
siRNA was not available for us to use at the time of this study. We compared the 
transfection reagents Fugene6 and the recently modified FugeneHD; at various 
reagent (l) to plasmid expressing green fluorescent protein (GFP) (ng) ratios (1:1-4:1).  
 
Transfection efficiencies were estimated by counting the percentage of total cells 
expressing and translating the GFP: a positive cell was counted as green, an example Hilary Siddall 
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of which is shown below in Figure 7.1. Average number of cells counted per condition 
was 114.5±8.7.   
 
A B
C
A B
C
 
Figure 7.1:  Example of the transfection efficiency using FugeneHD, in H9c2 cells (A, 
light image) identified by overlapping the green fluorescence (as a measure of green 
fluorescent protein  (GFP) uptake) image (B) to identify the % of total cells transfected 
with the GFP that translate the green fluorescence (C).  
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2) The effects of different transfection reagents on protein expression; initially the 
certified GAPDH siRNA was used as a positive control.  
Principally, we aimed to achieve a reduction in translational activity. Therefore, 
GAPDH protein expression was investigated in the presence of GAPDH siRNA, which 
was used as a positive control to confirm that the process of siRNA silencing works in 
our laboratory.   
 
Transfection reagents FugeneHD or the siRNA specific transfection reagent, X-
tremGENE were used to investigate GAPDH protein expression. Protein expression 
was compared, using either GAPDH specific siRNA (Ambion, UK) or scrambled 
siRNA (no transcript specificity) n=2 performed in 6 well plates. Protein expression 
was investigated using Western blot analysis and assessed changes by densitometry, 
described in more detail in chapter 2.6. 
 
3)  The effects of GAPDH siRNA concentration and transfection reagent to siRNA ratio, 
on GAPDH protein expression. 
The effects of various concentrations (100,50 and 25pmol) and ratios of transfection 
reagent(ul) to GAPDH siRNA(ng) (2:1, 3:1 and 5:1) on GAPDH protein expression, 
n=2 were investigated. These experiments were carried out in 12 well plates, to 
assess the effects of reducing well size and therefore cell number on protein 
knockdown. This is because hypoxia-reoxygenation experiments are performed in 12 
well plates.  
 
4)  The effects of PTEN siRNA primer sequence and concentration of siRNA on PTEN 
protein expression  
The Silencer
® pre-designed PTEN primers were purchased from Ambion with a 
guarantee that 1 out of 3 purchased siRNA primers would knockdown PTEN protein Hilary Siddall 
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with 80% efficiency. Therefore the changes in PTEN protein using 100pmol siRNA 
and X-tremGENE transfection reagent at 3 to 1 ratio in 6 well plates, n=2 were 
investigated. 
 
5)  The effects of PTEN siRNA concentration and duration of transfection using PTEN 
primers 1 and 3 on PTEN protein expression. 
We strived to achieve maximal PTEN protein knockdown and therefore, optimisation 
studies focused on the PTEN primers 1 and 3. The PTEN protein knockdown after 48 
and 72h, in the presence of 50 and 100pmol and X-tremGENE transfection reagent at 
3 to 1 ratio in 12 well plates, n=2 was investigated. 
 
6)  The effects of PTEN siRNA concentration of using primer 3 per 4,000 cells 
We aimed to attain the maximal PTEN protein knockdown possible in our hands. The 
PTEN siRNA primer 3 was investigated. Cells were incubated for 72h at a range of 
concentrations (30pmol/well-5pmol/well) with X-tremGENE transfection reagent at 3 to 
1 ratio, in 12 well plates (in the presence of 4,000cells which was the number of 
cells/well of a 12 well plate required for subsequent hypoxia-reoxygenation 
experiments.), n=4.  
 
7.2.2  Response to hypoxia-reoxygenation: optimising and inducing cell 
death 
The level of cell death in H9c2 cells silenced for PTEN protein expression was investigated 
following our protocol of hypoxia-reoxygenation injury, as described in chapter 2.8 and 
outlined in Figure 7.2. Different methods were investigated to measure cell damage, such as 
percent of adherent cells positive for propidium iodide (PI), lactate dehydrogenase (LDH) 
release, and caspase 3 cleavage, which are described below. As a positive control cells were Hilary Siddall 
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incubated with insulin (10µg/ml) at the onset of reoxygenation. The vehicle control used for 
insulin was reoxygenation buffer. 
 
1) Propidium  iodide 
Injured or damaged cells with permeabilised membranes permit the penetration of 
dyes such as propidium iodide (PI), the detection of which can be used to monitor cell 
death (Jonassen et al., 2004).  
 
Injured cells were identified by counting the percentage of adherent H9c2 cells 
staining positive for PI (red), n=4. It was expected that, following hypoxia-
reoxygenation the number of PI stained cells would increase in comparison to cells 
maintained in normoxia. It was hypothesised that fewer cells, silenced for PTEN 
protein expression, would stain positive for PI following hypoxia-reoxygenation. Insulin 
was used as a positive control, which was expected to reduce the number of cells 
staining positive for PI following hypoxia-reoxygenation. 
 
2) LDH 
Additionally, injured or damaged cells with perturbed membranes permit the release of 
cellular components such as LDH, usually located in the cytosol. The ratio of released 
LDH into the culture media compared to the remaining LDH levels can be used in 
order to estimate cell viability (Jonassen et al., 2004). LDH release following hypoxia-
reoxygenation was measured using an LDH/cytotoxic assay kit from Promega, UK, as 
described in chapter 2.8. The absorbance of samples was measured and the results 
were expressed in A.U; relating to the total LDH present. Total LDH was the sum of 
LDH measured in cell supernatant and the LDH measured in the remaining whole cell 
population, n=4.  
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As a part of the assay optimisation experiments the effects of sample dilution on the 
sensitivity of the assay was investigated. The absorbance values obtained with 
various dilutions of neat LDH enzyme, supplied in the assay kit as a positive control 
were measured: 1.6units/ml, 3.2units/ml and 6.4units/ml were compared to the values 
obtained for buffer control (culture media only, no cell content).  
 
It was expected that, following hypoxia-reoxygenation, LDH released would be 
increased compared to cells maintained in normoxia. Furthermore, it was 
hypothesised that following hypoxia-reoxygenation LDH release would be lower in 
cells silenced for PTEN protein expression and used insulin as a positive control.    
 
3)  Caspase 3 cleavage 
Injured or damaged cells may undergo an increase in apoptosis, which can be 
reflected by an increase in the activation of caspases. The end effector caspase, 
caspase 3, is cleaved and therefore activated in apoptosis; producing a pro death 
fragment (Nicholson et al., 1995; Kothakota et al., 1997). The extent of caspase 3 
cleavage was measured using Western blot analysis, as described in chapter 2.6. The 
results were normalised to the total caspase 3 levels and expressed as a percentage 
of control. The total caspase 3 value was estimated by combining the A.U value 
obtained from the uncleaved caspase 3 fragment (running to 35kDa) with the A.U 
acquired from the cleaved caspase 3 fragment (running to 17kDa), n=4.  
 
It was expected that, following hypoxia-reoxygenation greater caspase 3 cleavage 
would occur compared to those cells maintained in normoxia. Furthermore, it was 
hypothesised that following hypoxia-reoxygenation caspase 3 cleavage would be less 
in cells silenced for PTEN protein expression and, insulin was used as a positive 
control.   Hilary Siddall 
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Figure 7.2: Hypoxia-reoxygenation protocol (24h hypoxia/4h reoxygenation) performed 
in H9c2 cells transfected with either scrambled (negative control) small interfering RNA 
(siRNA) or PTEN siRNA. Insulin at the onset of reoxygenation was used as a positive 
control, for which reoxygenation buffer was used as the vehicle control. 
 
7.2.3 Possible  compensatory signalling mechanisms in cells silenced for 
PTEN expression. 
Previously, it was shown that the myocardium from PTEN
+/- mice do not confer 
cardioprotection against our model of ischaemia-reperfusion injury. In these isolated hearts a 
reduced level of PINK1 expression was observed and it was proposed that this may be a 
possible explanation for the absence of protection in these hearts, as shown in chapter 6.  
 
Similarly, in this chapter PINK1 protein expression was investigated in H9c2 cells silenced for 
PTEN protein expression. Western blot analysis was used, as described in chapter 2.6 to Hilary Siddall 
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measure this, n=3. It was hypothesised that cells silenced for PTEN would have lower levels 
of PINK1 protein expression.  
 
7.3 Results 
7.3.1  Optimising protein silencing using siRNA 
1) Investigating the effect of different transfection reagents on transfection  
Figure 7.3 represents the transfection efficiencies which were estimated by counting the 
percentage of total cells expressing and translating the GFP. The results indicate that there 
were no differences in the transfection ratios of reagent to DNA when comparing Fugene6 
and FugeneHD transfection reagent. Nevertheless, the percentage of cells transfected 
efficiently was higher (59.4 ±5.1%) using Fugene HD compared to Fugene6 (24 ±2%) 
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Figure 7.3: Transfection efficiency of Fugene6 (red diamonds) compared to FugeneHD 
(green squares) transfection reagent. Mimicking siRNA uptake in of H9c2 cells 
incubated with green fluorescent protein (GFP) measured by the % of cells fluorescing 
green.  
 
2) Investigating the effects of different transfection reagents on protein expression; initially 
using the certified GAPDH siRNA as a positive control.   
As shown in Figure 7.3 transfection of H9c2 cells with plasmid DNA expressing GFP was 
achieved using Fugene6. In contrast, as shown in Figure 7.4 GAPDH protein expression was 
not reduced in cells transfected using Fugene6. Nonetheless, GAPDH protein expression 
was reduced in cells transfected using X-tremGENE.  
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Figure 7.4:  Transfection efficiency in H9c2 cells using FugeneHD (green bars) or X-
tremeGENE (purple bars) transfection reagent, measured by assessing GAPDH protein 
expression normalised to transfection control using either scrambled siRNA or GAPDH 
siRNA (n=2). 
 
3 The effects of GAPDH siRNA concentration and transfection reagent to siRNA ratio on 
GAPDH protein expression. 
The results are shown in Figure 7.5 and highlight that 100 and 50pmol GAPDH siRNA 
provide maximal protein knockdown. The results also indicated that 3µls reagent to1ng of 
siRNA (3:1) provided the maximum and most specific GAPDH protein knockdown.   
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Figure 7.5: GAPDH protein knockdown with: A) 2:1, B) 3:1 or C) 5:1 ratios of 
transfection reagent (ul) to 1ng siRNA. 100pmol, 50 and 25pmol siRNA (n=2).  Hilary Siddall 
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4) The effects of PTEN siRNA primer sequence and concentration of siRNA on PTEN protein 
expression  
The initial studies investigating PTEN silencing were performed in 6 well plates. As shown in 
Figure 7.6, the preliminary studies indicated 2 out of the 3 primers successfully reduced the 
levels of PTEN (primer 1 and 3). 
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Figure 7.6: PTEN protein knockdown, investigating efficiency of 3 different PTEN 
siRNA primers at 100pmol, normalised to reagent control (n=2).   
 
5) The effects of PTEN siRNA concentration and duration of transfection using PTEN primers 
1and 3 on PTEN protein expression. 
The results are shown in Figure 7.7 and indicate that the difference between PTEN protein 
expression at 48 and 72h is small. However, following 72h protein knockdown with primer 3 
provided maximal silencing of PTEN protein.  
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Figure 7.7: PTEN protein expression transfected with 100 and 50pmols PTEN siRNA 
primers 1 and 3 for either 48h (green bars) or 72h (purple bars), investigating maximal 
PTEN protein knockdown in 12 well plates (n=2).   
 
6) The effects of PTEN siRNA concentration of using primer 3 per 4,000 cells 
The results are shown in Figure 7.8 and shows that a dose response effect (of protein 
knockdown) occurs with varying concentrations of siRNA. The more siRNA present the more 
PTEN protein silencing was observed. Conversely, these results indicate that the scrambled 
siRNA had some off target effects, itself causing a reduction in PTEN protein expression at 
higher concentrations. This highlights the importance of including a scrambled siRNA control 
in all experiments with siRNA. The most efficient PTEN silencing occurred with 30pmol siRNA 
primer 3. 
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Figure 7.8: PTEN protein expression with 5 (green bars), 10 (purple bars), 20 (red bars) 
and 30 (light blue bars) pmol of PTEN siRNA primer 3 per 4,000 cells. Incubated for 72h 
(n=2).  
 
In summary, the optimised method for siRNA induced PTEN silencing in H9c2 cells is 
described below. H9c2 cells were transfected with 30pmol/4,000cell/12 well plate using 3ul X-
tremGene reagent to 1ng siRNA. Protein analysis was assessed 72h later conveying a 
significant (p<0.001) reduction in PTEN protein; PTEN expression was silenced to 17.6 
±4.0% of the scrambled siRNA control (100%), as shown in Figure 7.9.  
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Figure 7.9: PTEN protein expression with 30pmol/4,000 cells of either scrambled siRNA 
(black bars) or PTEN primer 3 siRNA (green bars) transfected for 72h (n=4). Statistical 
differences were assessed using the Student’s paired t-test, (*<0.001).  
 
7.3.2  Response to hypoxia-reoxygenation injury: optimising and 
inducing cell death. 
Measuring cell death following hypoxia-reoxygenation 
Methods to measure cell death following hypoxia-reoxygenation were investigated, such as 
measuring the percent of adherent cells positive for propidium iodide (PI), lactate 
dehydrogenase (LDH) released, and caspase 3 cleavage: the results are described below.    
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1) Propidium iodide 
To identify and assess injured cells the percentage of adherent H9c2 cells staining positive 
for PI (red) were counted. The results are shown in Figure 7.11. A significant increase in the 
number of cells staining positive for PI was observed in cells following hypoxia-reoxygenation 
(29.2 ± 3.8%) compared to cells maintained in normoxia (7.3 ± 1.3%, p<0.005). Figure 7.10 
shows a representative example of the differences in PI staining in H9c2 cells subjected to 
hypoxia-reoxygenation compared to normoxia. 
Propidium Iodide staining
Control Hypoxia-reoxygenation
A
B
C
D
Propidium Iodide staining Propidium Iodide staining
Control Hypoxia-reoxygenation
A
B
C
D
Propidium Iodide staining
 
Figure 7.10: H9c2 cell viability: A) maintained in normoxic conditions or B) subjected 
to hypoxia-reoxygenation and C) the uptake of propidium iodide as indicated by red 
fluorescence in normoxia or D) following hypoxia-reoxygenation.  Hilary Siddall 
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Figure 7.11: H9c2 cell viability monitored by visualising percentage of total cells 
positive for propidium iodide (PI) staining: normoxic conditions (black bars) or 
subjected to hypoxia-reoxygenation (blue bars) (n=4). Statistical differences were 
assessed using Student’s paired t-test, (*<0.005).  
 
It was hypothesised that fewer cells (silenced for PTEN expression) would stain positive for 
PI compared to cells transfected with control siRNA. However, we were not able to prove this, 
the results are shown in Figure 7.12 and indicate no significance differences in PI staining 
between cells transfected with PTEN specific siRNA and scrambled non specific siRNA. 
Unexpectedly, no reduction was observed in the presence of insulin. The variability in PI 
staining was large and the process of siRNA silencing in H9c2 cells appeared to cause some 
background staining. Therefore, alternative mechanisms to assess cell vulnerability 
subsequent to hypoxia-reoxygenation were explored. 
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Figure 7.12: The effect of PTEN silencing on the number of cells staining positive for 
propidium iodide (PI) following hypoxia-reoxygenation (n=4). Reoxygenation buffer 
was used as a control for insulin. Statistical differences were assessed using One Way 
ANOVA. 
 
LDH 
LDH release was measured as an indicator of cell vulnerability following hypoxia-
reoxygenation and was compared to that of the cells maintained in normoxia. It was 
hypothesised that there would be an increase in LDH release from cells subjected to hypoxia-
reoxygenation injury. The results are shown in Figure 7.13, It was observed that an increase 
in LDH release occurred from cells subjected to hypoxia-reoxygenation (0.2590 ± 0.175 A.U) 
compared to cells maintained in normoxia (0.4119 ± 0.03 A.U). However, this increase was 
not significantly different.   
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Figure 7.13: H9c2 cell viability following hypoxia-reoxygenation, monitored by 
detecting lactate dehydrogenase (LDH) release: LDH release from cells in normoxic 
conditions (black bars) compared to LDH release from cells subjected to hypoxia-
reoxygenation (blue bars), expressed in arbitrary units (A.U). Statistical differences 
were assessed using the Student’s paired t-test, (n=4).  
 
As shown in Figure 7.14, following hypoxia-reoxygenation no significance differences in LDH 
release occurred between cells transfected with PTEN specific or scrambled siRNA. 
Furthermore, no reduction in LDH release was recorded in the presence of insulin at 
reoxygenation.  
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Figure 7.14: The effect of PTEN silencing on lactate dehydrogenase (LDH) release from 
cells maintained in normoxia (black bars) compared to cells subjected to hypoxia-
reoxygenation (blue bars). Statistical differences were assessed using One Way 
ANOVA. (n=4).  
 
To eliminate the possibility of any experimental set up errors, the effects of LDH sample 
dilution on the sensitivity of this assay were investigated. Figure 7.15 represents the typical 
absorbance values obtained with various dilutions of the neat LDH enzyme, supplied in the 
assay kit as a positive control. The absorbance values obtained in our samples were lower 
than the LDH positive control containing 1.6units/ml. Furthermore, the sample absorbance 
values were closer (but still higher) to the buffer control (culture media only, no cell contact). 
We investigated methods to increase the absorbance signal, however, these were 
unsuccessful. Therefore, alternative mechanisms to assess cell vulnerability subsequent to 
hypoxia-reoxygenation were explored. 
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Figure 7.15: Absorbance (optical density (OD) values) obtained with various amounts 
of the lactate dehydrogenase (LDH) enzyme (used as a positive control) that was 
supplied with the LDH assay (replicates 2).  
 
3) Caspase 3 cleavage 
As shown in Figure 7.16, a significant increase in caspase 3 cleavage were observed in cells 
subjected to hypoxia-reoxygenation (231.9 ± 55.3%, p<0.05) compared to cells maintained in 
normoxia (100%).  
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Figure 7.16: H9c2 cell viability monitored by detecting caspase 3 cleavage in cells 
maintained in normoxic conditions (black bars) compared to cells subjected to 
hypoxia-reoxygenation (blue bars). The caspase 3 cleavage is presented as a percent 
of the total caspase 3 expression (n=4). Statistical differences were assessed using 
Student’s paired t-test, (*<0.05).  
 
As shown in Figure 7.17 the addition of insulin at reoxygenation significantly reduced 
expression of caspase 3 cleavage fragment (38.83 ± 7.4%, p<0.01) compared to scrambled 
siRNA (100%). However, the expression of caspase 3 cleavage in cells silenced for PTEN 
was not reduced (120 ± 7.5%).  Representative blots of caspase 3 in H9c2 cells are shown in 
Figure 7.18, it should be noted that the quality of the blots is not optimal due to changes in 
protein content in cell populations from normoxic and hypoxic populations and the presence 
and absence of siRNA. Future work may include repeating these experiments to provide 
clearer data. 
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Figure 7.17: The effects of PTEN silencing following hypoxia-reoxygenation on the 
level of caspase 3 cleavage (n=4). Statistical differences were assessed using One Way 
ANOVA, (*<0.01).  
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Figure 7.18:  Example of Western blots illustrating cleaved (active 17kDa) and intact 
(inactive 35kDa) caspase 3 in H9c2 cells (samples in duplicate, A + B) subjected to 
normoxic conditions in the presence of 1 = transfection control and hypoxic 
conditions 2 = transfection control, 3 = scrambled siRNA, 4 = PTEN primer 3 siRNA, 5 = 
scrambled siRNA + 1µg/ml insulin and 6 = scrambled siRNA + 10µg/ml insulin.      
 
7.3.3 Possible  compensatory signalling mechanisms in cells silenced for 
PTEN protein expression 
Possible compensatory signalling mechanisms that may explain the lack of protection in cells 
silenced for PTEN and subjected to hypoxia-reoxygenation injury were investigated. As 
shown in chapter 6 the myocardium from PTEN
+/- mice was not protected against ischaemia-
reperfusion injury. In the myocardium from these mice a reduction in PINK1 expression was 
detected. Therefore, PINK1 protein expression was investigated in H9c2 cells silenced for 
PTEN protein expression. As shown in Figure 7.19 the results demonstrates that cells 
silenced for PTEN express significantly less PINK1 (73.3 ± 15.3%, p<0.05) compared to cells 
incubated with scrambled siRNA (100.0%). 
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Figure 7.19: PTEN induced kinase 1 (PINK1) protein expression in H9c2 cells silenced 
for PTEN protein expression, expressed in arbitrary units (A.U). Statistical differences 
were assessed using Student’s paired t-test, (*= <0.05), (n=3).  
 
In summary, the PTEN protein expression was silenced by 82.4% in H9c2 cells, using siRNA 
specific for PTEN. Subsequent to hypoxia-reoxygenation the level of PI staining, LDH release 
and caspase 3 cleavage is increased. However, in cells treated with insulin (used as a 
positive control) measuring only the expression of caspase 3 cleavage was sufficient to 
detect a significant reduction in hypoxia-reoxygenation injury. Unexpectedly PTEN silencing 
in H9c2cells did not bestow protection against hypoxia-reoxygenation injury. In these cells a 
decrease in the expression of the mitochondrial pro survival kinase PINK1 was measured, 
which may in part explain the lack of protection against hypoxia-reoxygenation injury.   
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7.4 Discussion 
As discussed in chapter 6, using KO models can be associated with a risk of adaptation or 
compensation to the knocked-out target. Small interfering RNA (siRNA) technology is widely 
employed as an alternative to KO models. SiRNA technology is based on a naturally 
occurring process and takes advantage of cellular transcription-translation mechanisms. 
Whereas, the DNA of the target remains unaltered, the mRNA levels are decreased, 
preventing the synthesis of the target protein. SiRNA can be effective within the timescale of 
several days, as opposed to genetic deletions which are typically present throughout the 
lifetime of the organism. Therefore, the application of siRNA technology may limit genetic 
adaptation and may provide a more beneficial tool for studying the role of PTEN inhibition on 
cardioprotection. Sugano et al., 2005 have published positive studies using such techniques. 
For example, the administration of siRNA specific for the protein tyrosine phosphatase in vivo 
(to rats), can prevent SHP-1 activation and caused an increase in myocardial survival 
following ischaemia-reperfusion (Sugano et al., 2005). Owing to the limited number and 
specificity of tools to inhibit PTEN, it is common to observe the use of siRNA methods in 
published studies researching PTEN (Chang et al., 2006; Puri et al., 2007). For example 
PTEN was successfully silenced in mouse adipose tissue (Puri et al., 2007) and in HEK293 
cells (Chang et al., 2006). The later study implicated apoptosis signalling with an increased 
activity of rho associated coiled coil protein kinase 1 (ROCK-1) and PTEN (Chang et al., 
2006). In addition Butler et al, 2002 used antisense technology, which acts at the DNA level 
to prevent mRNA synthesis, to inhibit PTEN in a diabetic obese mouse (Butler et al., 2002). 
We planned to use siRNA as an alternative tool by which to reduce PTEN. Initially, this 
technology was optimised in H9c2 cells prior to studying the effects on hypoxia-reoxygenation 
injury. If these experiments had proved successful we could have potentially use this 
technique to asses the effects of PTEN reduction on whole hearts subjected to ischaemia-
reperfusion injury. Hilary Siddall 
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7.4.1.1   Optimising protein silencing using siRNA  
When trying to silence protein with siRNA the gene of interest, cell line and transfection 
technique must be considered. It was necessary to perform optimisation experiments with the 
aim of efficiently maximising protein knock down. Using scrambled (negative control), 
GAPDH (positive control) and PTEN siRNA, we aimed to obtain maximum protein 
knockdown. The effects of varying the transfection reagent type, concentration of transfection 
reagent and siRNA, cell number and duration of transfection. Three predesigned PTEN 
siRNA primers were purchased with a guarantee 1 out of these 3 primers would knockdown 
PTEN protein by 80%. Two out of the 3 primers were successful at silencing PTEN. We 
further optimised the use of one of the primers to maximise the level of protein knockdown.  
 
It was shown that there was a dose response effect, associated with protein knockdown, 
whereby the more siRNA present the more protein silencing was observed. Conversely, 
these results indicate there were some off target effects of scrambled siRNA which affected 
PTEN protein expression. This is a common limitation of the approach, and we optimised 
protocols to keep this to a minimum. Furthermore, this work highlighted the importance of 
including a scrambled siRNA control in each experiment. Changes in protein expression were 
detected using Western blot techniques, which can be variable, as indicated by some large 
error bars in our results. This highlights another limitation of this assay and indicates the 
importance of including a number of replicates within each experiment. 
 
The finalised method for siRNA-induced protein silencing in H9c2 cells is described below. 
H9c2 cells were transfected with GAPDH or PTEN siRNA at 50pmol and 30pmol 
(respectively) per well of a 12 well plate containing 4,000cells per well. siRNA was 
transfected using 3ul X-tremGene reagent to 1ng siRNA. Protein analysis was assessed 72h 
later conveying a significant (p<0.001) reduction in protein expression. The results were Hilary Siddall 
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compared to that of the scrambled siRNA control.  PTEN expression was silenced by 82.4%, 
which conformed to the guaranteed knockdown of 80% or more when using siRNA primer 
constructs predesigned by Ambion, UK. Puri et al., 2007 knocked down PTEN by 70% in 
white adipose tissue incubated with 16nmol PTEN siRNA; which is comparable to our 
protocol and results (Puri et al., 2007). In addition, Chang et al., have used PTEN siRNA in 
HEK293 cells and successfully showed a reduction in the expression of PTEN. However, the 
authors of this work did not quantify the amount of protein reduction; instead they assessed 
this by measuring the level of phosphorylated AKT, which was increased by 56% (Chang et 
al., 2006).  
 
7.4.1.2   Response to hypoxia-reoxygenation: optimising and 
measuring cell death. 
The response of PTEN silencing in H9c2 cells subjected to hypoxia-reoxygenation injury was 
examined. It was hypothesised that reduced PTEN protein would protect against hypoxia-
reoxygenation injury. To examine this we investigated ways of detecting cell death in our 
model of hypoxia-reoxygenation injury. Changes in propidium iodide staining, LDH release 
and caspase 3 cleavage were recorded. 
 
Propidium iodide 
Injured cells were assessed and localised following hypoxia-reoxygenation, by counting the 
percentage of adherent H9c2 cells staining positive for PI. It was observed that a significant 
(p<0.005) increase in PI staining occurred in cells subjected to hypoxia-reoxygenation. 
However, no differences were recorded between PTEN specific siRNA and scrambled siRNA. 
Similarly, the administration of insulin did not reduce the number of cells staining positive for 
PI. In these studies the variability of PI staining was large and the process of inducing siRNA 
into the H9c2 cells appears to increase PI staining. This variability may have been due to cell Hilary Siddall 
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type and or cell passage number. Each passage number correlates to the number of times 
the cell population has been sub cultured and is therefore an indicator of the total duration of 
cell culture and age. Older cells can be more susceptible to cell death (Hoffmann et al., 
2001). It was noted that following reoxygenation a number of cells were dying and detaching 
from the well surface, and that this effect appeared random which may have been linked to 
uneven plating of the cells. Additionally, the hypoxia-reoxygenation protocol may have been 
too severe. These studies indicate that using PI as an indicator of cell death in H9c2 cells, 
following our hypoxia-reoxygenation protocol was not sufficient to detect changes in the level 
of cell death. Therefore, we aimed to find an alternative model for assessing cell vulnerability 
following hypoxia-reoxygenation in H9c2 cells. 
 
LDH  
LDH release was measured as an indicator of cell vulnerability following hypoxia-
reoxygenation. It was observed that an increase in LDH release from cells subjected to 
hypoxia-reoxygenation occurred, however, this increase was not significantly different from 
cells maintained in normoxia. Additionally, H9c2 cells silenced for PTEN expression or cells 
stimulated with insulin showed no significance difference in LDH release. The absence of any 
differences in LDH release may have been due to an error in the experimental set up. The 
absorbance values obtained in our samples were lower than the 1.6units/ml LDH positive 
control supplied by the manufacturers of the LDH detection assay. Furthermore, the sample 
absorbance values were low, but still higher than the buffer control (culture media only, no 
cell contact). We have since found out that phenol red in cell culture media (like the media we 
used in reoxygenation) can interfere with this assay and should be avoided. Future work may 
include using a phenol free culture media to reoxygenate the cells in. Other groups have 
successfully used LDH release as an indicator of cell death however; it was not clear what 
media the samples were collected in (Potts et al., 2005; Taimor et al., 1999). However, to Hilary Siddall 
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save time we thought it was still necessary to explore an alternative mechanism for assessing 
cell death subsequent to hypoxia-reoxygenation. 
 
Caspase 3 cleavage 
Caspase 3 cleavage was measured using Western blot analysis, as an indicator of apoptosis 
and cell vulnerability following hypoxia-reoxygenation. A significant increase (p<0.05) in 
caspase 3 cleavage was observed, which was significantly reduced by the presence of insulin 
at reoxygenation (p<0.01).  However, the expression of caspase 3 cleavage was not reduced 
in cells silenced for PTEN. Others have used caspase 3 cleavage as a method for detecting 
apoptosis (Stephanou et al., 2000; Hamacher-Brady et al., 2006b; Chang et al., 2006).  
 
Cell death occurs after periods of hypoxia and reoxygenation, however, the importance of 
apoptosis and necrosis is still debated (Fliss and Gattinger, 1996; Ohno et al., 1998; Taimor 
et al., 1999; Lemasters et al., 2002; Potts et al., 2005). In this chapter, we did not address this 
issue, our aim was to measure cell death following hypoxia-reoxygenation. In the future it 
would be prudent to confirm the data obtained in a secondary model of cell vulnerability. We 
were not able to confirm our findings using either LDH or PI staining as these models had 
some practical limitations. Other groups have detected cell death using either Tunel staining 
for DNA fragmentation, Hoechst staining for chromatin condensation, Annexin V labelling of 
phosphatidylserine externalisation, immuno detection of cytochrome c and DNA laddering 
(Taimor et al., 1999; Hamacher-Brady et al., 2006a; Hamacher-Brady et al., 2006b). 
Alternatively, we could have used the trypan blue dye. Cellular exclusion of this dye can be 
used as an indicator of cell viability (Hansson and Schwartz, 1983). Future studies may entail 
using these methods to investigate the effects of PTEN silencing in H9c2 cells subjected to 
hypoxia-reoxygenation. Alternatively, we could try studying a different hypoxia-reoxygenation 
protocol, the method we used may be too severe, as a number of cells became rounded up 
and detached from the well surface following reoxygenation. Other groups studying hypoxia Hilary Siddall 
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reoxygenation in H9c2 cells have used quite different protocols. These ranging from 24hr 
hypoxia and 12hr reoxygenation, measuring Bax translocation as an end point (Hou and Hsu, 
2005), to 6hr hypoxia and 12hr reoxygenation, measuring morphological changes and 
annexin V staining as an end point (Chen et al., 2002). Alternatively, a different myocardial 
cell line such as the HL1 cell line, which is an atrial myocyte cell line that maintains contractile 
properties (Claycomb et al., 1998), may respond differently to transfection of siRNA and 
hypoxia reoxygenation. 
 
7.4.1.3   Investigating potential compensatory signalling effects in 
H9c2 cells silenced for PTEN expression. 
By measuring caspase 3 cleavage we were not able to confirm our hypothesis, which 
predicted cells silenced for PTEN expression would have reduce cell death following hypoxia 
re-oxygenation. The reasons for this observation were explored. As shown in chapter 6, we 
showed that the myocardium from PTEN
+/- mice was not protected against ischaemia-
reperfusion injury. The myocardium from these mice express a reduced level of PINK1. This 
protein is a prosurvival kinase and drosophila with PINK1 mutations have muscle 
degeneration, altered mitochondrial morphology and reduced ATP levels. In the presence of 
paraquat, a complex I inhibitor, used to induce oxidative stress, these knockouts were less 
resistant to injury (Clark et al., 2006). The mechanisms for the protective effects of PINK1 is 
not fully understood, Clark et al., 2006 suggest this occurs by the phosphorylation and 
activation of Parkin. We investigated PINK1 protein expression in H9c2 cells silenced for 
PTEN protein expression. Our data indicates that cells silenced for PTEN have a small but 
significant (p<0.05) reduction in PINK1. This result is similar to the reduction in PINK1 
expression in the PTEN
+/- myocardium and may in part explain why we do not record 
protection when PTEN is reduced at the protein level. However, it should be noted that the 
individual blots used to assess this observation are illustrated in Figure 7.19 and are not the Hilary Siddall 
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best quality therefore; future work would include optimising the protocols according to the 
sample type and antibody used.  
 
Previously, published studies have shown that in dopaminergic cells silenced for PINK1 
expression using siRNA, PINK1 mRNA and protein levels were reduced by 87% and 80% 
respectively. And as a consequence, the authors of this work observed a 22% decrease in 
cell viability (Deng et al., 2005). Moreover, induction of oxidative stress using the pesticide 
and complex I inhibitor, rotenone, further reduced cell viability (Deng et al., 2005); indicating 
PINK1 reduction is associated with impaired response to oxidative damage and is required 
for survival. Inhibition of thioredoxin-interacting protein (Txnip) an endogenous inhibitor of 
thioredoxin, can decrease PTEN activity and increase, AKT activity and enhance insulin 
sensitivity in skeletal muscle. The authors of this work additionally observed impaired 
mitochondrial respiration in this tissue (Hui et al., 2008). In neuronal tissue, PINK1 deficiency 
results in changes in mitochondrial morphology and decreased mitochondrial membrane 
potential (Wood-Kaczmar et al., 2008). Collectively therefore, future work may include 
investigating the mitochondria morphology and function in our samples with reduced PTEN to 
confirm this idea. PINK1 was first identified in 2001 when PTEN was re-expressed in 
previously PTEN null cells. In this study PINK1 was one of the genes that was 
consequentially increased. Interestingly, an additional 72 genes were decreased as a result 
of PTEN re-expression (Unoki and Nakamura, 2001). These genes may provide novel targets 
for future survival studies.  
 
In summary, PTEN expression was silenced in H9c2 cells by 82.4% using siRNA specific for 
PTEN. The cellular response of PTEN knockdown against hypoxia-reoxygenation injury was 
investigated. It was demonstrated that subsequent to hypoxia-reoxygenation, in cells 
transfected with scrambled siRNA, the level of PI staining, LDH release and caspase 3 
cleavage was increased. However, only measuring the expression of caspase 3 cleavage Hilary Siddall 
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was sensitive enough to detect a significant reduction in injury when using insulin as a 
positive control. Unexpectedly, PTEN silencing in H9c2cells did not bestow protection against 
hypoxia-reoxygenation injury. A reduction in PINK1 expression in these hearts was observed, 
which may explain the lack of protection.  Hilary Siddall 
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8  Chapter 8 –Future work and conclusions 
8.1  Study limitations and future work 
Measuring PTEN activity 
Within this thesis we unsuccessfully attempted to optimise a PTEN ELISA assay for detecting 
PTEN lipid phosphatase activity in whole hearts. As discussed previously, in chapter 1, there 
are many ways in which PTEN activity can be reduced, for example changes to location, 
phosphorylation, oxidation, stability and degradation.(Connor et al., 2005; Trotman et al., 
2007; Lai et al., 2007) Therefore, it is important to establish an additional reliable activity 
assay for use in tissue homogenates from whole hearts. Furthermore, we did not investigate 
the location of PTEN within the myocardial cell. Such investigation may lead to the 
identification of cytoplasmic versus membrane fractions of PTEN As described previously, in 
chapter 1, the location of PTEN has been linked to activity, for example cytoplasmic and 
nuclear PTEN has been associated with reduced PTEN lipid phosphatase activity (Wu et al., 
2000a; Valiente et al., 2005; Lindsay et al., 2006).   
 
Alternative PTEN inhibitors 
Zinc and thioredoxin have been shown to reduce PTEN function in human airway epithelial 
cells (Wu et al., 2003; Meuillet et al., 2004). However, their specificity must be considered. In 
this study the effects of bpV(HOpic) on ischaemia-reperfusion injury were investigated. 
Additionally, other bisperoxvanadium compounds appear to have greater physiological effects 
with more specificity for PTEN, such as bpV(phen), bpV(pic) & VO-OHpic (Schmid et al., 
2004; Rosivatz et al., 2006; Zhang et al., 2007).  
 
The generation of tissue specific PTEN knockout mouse models may offer a greater degree 
of PTEN reduction sufficient to confer cardioprotection against ischaemia-reperfusion injury. Hilary Siddall 
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Such models are not commercially available and are difficult to obtain. Crackower et al., in 
2002 and 2008 have used cardiac specific PTEN mutant mice to show that inhibition of PTEN 
is associated with hypertrophy and reduced contractility. However, this group also showed 
that reduced PTEN confers protection against pressure overload, as shown by a reduction in 
the level of remodelling following permanent aortic banding (Crackower et al., 2002; Oudit et 
al., 2008). In 2009 Ruan et al., published data showing that cardiac targeted PTEN 
inactivation protects against ischaemia-reperfusion injury (Ruan et al., 2009). In this study 
PTEN reduction was induced by daily injections of tamoxifan, which may be cardioprotective 
in its own right (Ek et al., 2008).  
 
PTEN inhibition and the threshold for cardioprotection 
We have shown that reducing PTEN function (by perfusing isolated C57BL/J6 mouse hearts 
with the PTEN inhibitor bpV(HOpic) and using the PTEN
+/- myocardium) can reduce the 
threshold to IPC induced protection. Adenosine, bradykinin and insulin are pharmacological 
preconditioning mimetics that confer cardioprotection against ischaemia-reperfusion (Baines 
et al., 1999; Maddock et al., 2002; Bell and Yellon, 2003). Therefore, it was hypothesised that 
in the case of PTEN reduction, a lower concentration of preconditioning mimetics would be 
required to induce cardioprotection. Such future work would support the results from this 
thesis and further validate PTEN reduction for treating ischaemia-reperfusion injury.  
 
Atorvastatin is cardioprotective, Mensah et al., 2005 showed that treatment in rats for 3 days 
can protect the myocardium from ischaemia-reperfusion injury (Mensah et al., 2005). 
However, chronic treatment for 2 weeks abolished this protection, these results were 
attributed to an enhanced level of PTEN (Mensah et al., 2005). Many patients with CVD are 
prescribed statins (Ferdinandy et al., 2007) and therefore may be at risk of increased PTEN 
levels. Potentially, any therapy which increases the PI3K/AKT pathway may not be sufficient 
to confer protection against ischaemia-reperfusion injury in these patients. If this became Hilary Siddall 
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evident, we hypothesise that the reduction of PTEN levels may prevent the potential ablation 
of cardioprotection as a consequence of chronic atorvastatin treatment. To investigate this 
idea future work may involve studying the effects of chronic atorvastatin therapy in the 
presence of a PTEN inhibitor or in the PTEN
+/- myocardium. For example, it may be predicted 
that myocardium from PTEN
+/- mice subjected to chronic atorvastatin treatment may confer 
cardioprotection against ischaemia-reperfusion injury.  
 
Cardioprotection and AKT activity 
In this thesis the effects of reducing myocardial PTEN level was studied using a variety of 
models, and was associated with an increased level of phosphorylated AKT. However, these 
changes were not sufficient to confer protection against ischaemia-reperfusion injury. Firstly, 
the perfusion of mouse hearts on Langendorff apparatus, in the presence of an 
intraventricular balloon (as used in our studies) has been linked to inadvertent increases in 
phosphorylation of AKT (Stenslokken et al., 2009). The authors of this work suggest that this 
may be responsible for false positive results. This indicates that use of an alternative model of 
ischaemia-reperfusion, such as an in vivo model may be required.  
 
Secondly, three AKT isofoms AKT exist, however, it is not clear what the significance of each 
isoform has on cardioprotection (Sasaoka et al., 2004). In 3T3-L1 cells insulin stimulates an 
increase in the phosphorylation of AKT1 and AKT2. Data suggests that SHIP2 may 
preferentially dephosphorylate and diminish AKT2 activity (not AKT1) in these cells (Sasaoka 
et al., 2004). There does appear to be different roles for different isofoms, and this may be 
tissue specific. It is unknown if there is any isoform of AKT that is preferentially affected by 
PTEN reduction and future work may include investigating this.   
 
If AKT is activated and a down stream signalling factor is inhibited, reduced or mutated 
cardioprotection can be lost (Bell and Yellon, 2003). In isolated mouse hearts the activation of Hilary Siddall 
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the PI3K/AKT pathway with bradykinin conferred protection against ischaemia-reperfusion 
injury. This protection was associated with an increase in AKT and eNOS activity which was 
abolished in the presence of the PI3K inhibitor wortmanin. The authors of this work showed 
that in eNOS knockout mice bradykinin failed to confer protection even in the presence of 
enhanced phosphorylation of AKT (Bell and Yellon, 2003). This indicates that eNOS is 
required to confer protection downstream of the PI3K/AKT pathway. Future work may include 
investigating the expression and activity of other signalling pathways down stream of AKT in 
the PTEN
+/- myocardium.  
 
Finally, Nogueira et al., 2008 discovered an ‘Achilles’ heel of AKT and show that the 
presence of AKT can be detrimental to the cell, in some situations. The authors of this work 
suggest that AKT activity increases the level of ROS by inhibiting ROS scavengers and 
therefore the survival is effected following ROS mediated apoptosis. Additionally, they show 
that cells lacking PTEN undergo an enhanced level of apoptosis (as measured by DAPI 
staining, in response to H2O2 (Nogueira et al., 2008). This work may have major implications 
when studying ischaemia-reperfusion injury and may explain why in our studies we were 
unable to show protection when the activation of AKT was enhanced. Future work using our 
models of PTEN knockdown may involve assessing cell death in response to increasing 
concentrations of H2O2. 
 
The role of PINK1 in cardioprotection 
The results from these studies indicate that the myocardium from PTEN
+/- mice and H9c2 
cells silenced for PTEN expression, have reduced expression of the mitochondrial pro 
survival kinase, PINK1. We did not have time to further validate PINK1 as a cardioprotective 
protein. Further work may include investigating PINK1 in ischaemia-reperfusion injury.  
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8.2 Conclusions 
In this thesis, the hypothesis that PTEN inhibition would be cardioprotective against 
ischaemia-reperfusion injury, by reducing cell death, was investigated. A variety of 
experimental models were used (isolated hearts, isolated cardiomyocytes and cell lines) in 
which the PTEN level was reduced using different methods (using chemical inhibitors, PTEN 
haploinsufficient mouse and siRNA). Overall, in spite of AKT phosphorylation, PTEN 
reduction was not associated with an increased survival in any of our models. We attempted 
to investigate the reason for this but were unable to attain any conclusive explanations. 
Nonetheless, PTEN down regulation may favour a reduction in the threshold for 
cardioprotection (induced by other protective methods), which we demonstrated using 
ischaemic preconditioning. In conclusion, the data from the literature and this thesis indicate 
that PTEN inhibition may have implications for treating apoptotic related diseases such as 
ischaemia-reperfusion injury.  
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